

August 2015

Volume 3 Number 2

Editor: Kaye Wilson

email: hml@pharmac.govt.nz

Telephone +64 4 460 4990

Facsimile +64 4 460 4995

Level 9, 40 Mercer Street

PO Box 10 254 Wellington 6143

Freephone Information Line

0800 66 00 50 (9am – 5pm weekdays)

Circulation

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz.

Production

Typeset automatically from XML and T_EX.

XML version of the Schedule available from www.pharmac.govt.nz/pub/schedule/archive/

Programmers

Anrik Drenth & John Geering

email: texschedule@pharmac.govt.nz

©Pharmaceutical Management Agency



ISSN 1179-3708 pdf
ISSN 1172-9694 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Part I General Rules 5

Part II Alimentary Tract and Metabolism 13

Blood and Blood Forming Organs 27

Cardiovascular System 37

Dermatologicals 49

Genito-Urinary System 55

Hormone Preparations 59

Infections 69

Musculoskeletal System 92

Nervous System 102

Oncology Agents and Immunosuppressants 128

Respiratory System and Allergies 172

Sensory Organs 178

Various 184

Extemporaneous Compounds (ECPs) 192

Special Foods 195

Vaccines 209

Part III Optional Pharmaceuticals 215

Index 217

Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC's role:

"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at <http://www.pharmac.health.nz/about>.

Named Patient Pharmaceutical Assessment policy

Named Patient Pharmaceutical Assessment (NPPA) provides a mechanism for individual patients to receive funding for medicines not listed in the Pharmaceutical Schedule (either at all or for their clinical circumstances). PHARMAC will assess applications that meet the prerequisites according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions.

For more information on NPPA, or to apply, visit the PHARMAC website at <http://www.pharmac.health.nz/link/nppa> or call the Panel Coordinators at 0800 660 050 Option 2.

The Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The Schedule does not show the final cost to Government of subsidising each community pharmaceutical, nor to DHB hospitals in purchasing each hospital pharmaceutical or other pharmaceuticals, including medical devices. The final cost will depend on any rebate and other arrangements PHARMAC has with the supplier or on any logistics arrangements put in place.

Finding Information in Section H

This book contains Section H of the Pharmaceutical Schedule and lists pharmaceuticals that can be used in DHB hospitals:

- Part I lists the rules in relation to use of Pharmaceuticals by DHB hospitals.
- Part II lists hospital pharmaceuticals that are funded for use in DHB hospitals. These are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. It also provides information on any national contracts that exist, and indicates which products have Hospital Supply Status (HSS).
- Part III lists optional pharmaceuticals for which national contracts exist, and DHB hospitals may choose to fund. In addition to the products listed in this book, a number of additional Optional Pharmaceuticals are listed in an addendum to Part III available at <http://www.pharmac.govt.nz>.

The listings are displayed alphabetically under each heading. The index lists both chemical entities and product brand names.

Glossary

Units of Measure

gram	g	microgram.....	mcg	millimole.....	mmol
kilogram	kg	milligram	mg	unit.....	u
international unit	iu	millilitre.....	ml		

Abbreviations

application	app	enteric coated	EC	solution	soln
capsule	cap	granules	grans	suppository	suppos
cream.....	crm	injection	inj	tablet.....	tab
dispersible	disp	liquid	liq	tincture.....	tinc
effervescent	eff	lotion	lotn		
emulsion	emul	ointment.....	oint		

HSS Hospital Supply Status (Refer to Rule 20)

Guide to Section H listings

Example

ANATOMICAL HEADING				
	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer	
THERAPEUTIC HEADING				
Generic name listed by therapeutic group and subgroup	CHEMICAL A - Restricted see terms below ⬇️ Presentation A.....10.00 ➡️ Restricted Only for use in children under 12 years of age	100	Brand A	Brand or manufacturer's name
Indicates only presentation B1 is Restricted	CHEMICAL B - Some items restricted see terms below ⬇️ Presentation B1.....1,589.00 Presentation B2 ➡️ Restricted Oncologist or haematologist	1	Brand B1 e.g. Brand B2	
From 1 January 2012 to 30 June 2014, at least 99% of the total volume of this item purchased must be Brand C	CHEMICAL C Presentation C - 1% DV Limit Jan-12 to 201415.00	28	Brand C	Product with Hospital Supply Status (HSS)
Standard national price excluding GST	CHEMICAL D - Restricted see terms below ⬇️ Presentation D - 1% DV Limit Mar-13 to 201438.65 ➡️ Restricted <i>Limited to five weeks' treatment</i> Either: 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or 2 For the prophylaxis of venous thromboembolism following a total knee replacement.	500	Brand D	Quantity the Price applies to
Form and strength	CHEMICAL E Presentation E.....		e.g. Brand E	Not a contracted product
⬆️ Item restricted (see above); ⬇️ Item restricted (see below) Products with Hospital Supply Status (HSS) are in bold				

INTRODUCTION

Section H contains general rules that apply, and other information relating, to Hospital Pharmaceuticals and Optional Pharmaceuticals.

Where relevant, Section H shows the Price at which a Pharmaceutical can be purchased directly from the Pharmaceutical supplier by DHBs, providers of logistics services, wholesalers or other such distributors, or Contract Manufacturers.

The Price is determined via contractual arrangements between PHARMAC and the relevant Pharmaceutical supplier. Where a Pharmaceutical is listed in Part II of Section H, but no Price and/or brand of Pharmaceutical is indicated, each DHB may purchase any brand and/or pay the price that the DHB negotiates with the relevant Pharmaceutical supplier.

As required by section 23(7) of the Act, in performing any of its functions in relation to the supply of Pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule.

INTERPRETATION AND DEFINITIONS

1 Interpretation and Definitions

1.1 In this Schedule, unless the context otherwise requires:

“Act”, means the New Zealand Public Health and Disability Act 2000.

“Combined Pharmaceutical Budget”, means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

“Community”, means any setting outside of a DHB Hospital.

“Community Pharmaceutical”, means a Pharmaceutical listed in Sections A to G or I of the Pharmaceutical Schedule that is subsidised by the Funder from the Combined Pharmaceutical Budget and, for the purposes of this Section H, includes Pharmaceutical Cancer Treatments (PCTs).

“Contract Manufacturer”, means a manufacturer or a supplier that is a party to a contract with the relevant DHB Hospital to compound Pharmaceuticals, on request from that DHB Hospital.

“Designated Delivery Point”, means at a DHB Hospital’s discretion:

- a) a delivery point agreed between a Pharmaceutical supplier and the relevant DHB Hospital, to which delivery point that Pharmaceutical supplier must supply a National Contract Pharmaceutical directly at the Price; and/or
- b) any delivery point designated by the relevant DHB Hospital or PHARMAC, such delivery point being within 30 km of the relevant Pharmaceutical supplier’s national distribution centre.

“DHB”, means an organisation established as a District Health Board by or under Section 19 of the Act.

“DHB Hospital”, means a hospital (including community trust hospitals) and/or an associated health service that is funded by a DHB including (but not limited to) district nursing services and child dental services.

“DV Limit”, means, for a particular National Contract Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

“DV Pharmaceutical”, means a discretionary variance Pharmaceutical that does not have HSS but is used in place of one that does. Usually this means it is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant National Contract Pharmaceutical with HSS. Where this is not the case, a note will be included with the listing of the relevant Hospital Pharmaceutical.

“Extemporaneously Compounded Product”, means a Pharmaceutical that is compounded from two or more Pharmaceuticals, for the purposes of reconstitution, dilution or otherwise.

“First Transition Period”, means the period of time after notification that a Pharmaceutical has been awarded HSS and before HSS is implemented.

“Funder”, means the body or bodies responsible, pursuant to the Act, for the funding of Pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

“Give”, means to administer, provide or dispense (or, in the case of a Medical Device, use) a Pharmaceutical, or to arrange for the administration, provision or dispensing (or, in the case of a Medical Device, use) of a Pharmaceutical, and “Given” has a corresponding meaning.

“Hospital Pharmaceuticals”, means the list of Pharmaceuticals set out in Section H Part II of the Schedule which includes some National Contract Pharmaceuticals.

“HSS”, stands for hospital supply status, which means the status of being the brand of the relevant National Contract Pharmaceutical that DHBs are obliged to purchase, subject to any DV Limit, for the period of hospital supply,

as awarded under an agreement between PHARMAC and the relevant Pharmaceutical supplier. Pharmaceuticals with HSS are listed in Section H in bold text.

“Indication Restriction”, means a limitation placed by PHARMAC on the funding of a Hospital Pharmaceutical which restricts funding to treatment of particular clinical circumstances.

“Individual DV Limit”, means, for a particular National Contract Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

“Local Restriction”, means a restriction on the use of a Pharmaceutical in specific DHB Hospitals on the basis of prescriber type that is implemented by the relevant DHB in accordance with rule 7.

“Medical Device”, has the meaning set out in the Medicines Act 1981.

“Named Patient Pharmaceutical Assessment Advisory Panel”, means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising PHARMAC, in accordance with its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and any Exceptional Circumstances renewal applications submitted after 1 March 2012.

“National Contract”, means a contractual arrangement between PHARMAC and a Pharmaceutical supplier which sets out the basis on which any Pharmaceutical may be purchased for use in a DHB Hospital, including an agreement as to a national price.

“National Contract Pharmaceutical”, means a brand of Pharmaceutical listed in Section H, where PHARMAC has entered into contractual arrangements with the relevant Pharmaceutical supplier that specify the terms and conditions of listing, including the Price. Such Pharmaceuticals are recognisable in Section H because the relevant listing identifies the brand and Price.

“National DV Limit”, means, for a particular National Contract Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

“Optional Pharmaceuticals”, means the list of National Contract Pharmaceuticals set out in Section H Part III of the Schedule.

“PHARMAC”, means the Pharmaceutical Management Agency established by Section 46 of the Act.

“Pharmacode”, means the six or seven digit identifier assigned to a Pharmaceutical by the Pharmacy Guild following application from a Pharmaceutical supplier.

“Pharmaceutical”, means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

“Pharmaceutical Cancer Treatment”, means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must fund for use in their DHB hospitals, and/or in association with outpatient services provided by their DHB Hospitals, in relation to the treatment of cancers.

“Prescriber Restriction”, means a restriction placed by PHARMAC on the funding of a Pharmaceutical on the basis of prescriber type (and where relevant in these rules, includes a Local Restriction).

“Price”, means the standard national price for a National Contract Pharmaceutical, and, unless agreed otherwise between PHARMAC and the Pharmaceutical supplier, includes any costs associated with the supply of the National Contract Pharmaceutical to, at a DHB Hospital's discretion, any Designated Delivery Point, or to a Contract Manufacturer (expressly for the purpose of compounding), but does not include the effect of any rebates which may have been negotiated between PHARMAC and the Pharmaceutical supplier.

“Restriction”, means a limitation, put in place by PHARMAC or a DHB, restricting the funding of a Pharmaceutical and includes Indication Restrictions, Local Restrictions and Prescriber Restrictions (as defined in this Part I of Section H).

“Schedule”, means this Pharmaceutical Schedule and all its sections and appendices.

“Special Authority Approval”, means an approval for funding of a Community Pharmaceutical that is marked in Sections B-G of the Schedule as being subject to a Special Authority restriction.

“Total Market Volume”, means, for a particular Hospital Pharmaceutical with HSS in any given period, in accordance with the data available to PHARMAC, the sum of:

- a) the total number of Units of the relevant Hospital Pharmaceutical with HSS purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit; and
- b) the total number of Units of all the relevant DV Pharmaceuticals purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit.

“Unapproved Indication”, means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Clinicians prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in rule 23.

“Unit”, means an individual unit of a Pharmaceutical (e.g. a tablet, 1 ml of an oral liquid, an ampoule or a syringe).

“Unlisted Pharmaceutical”, means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical, but is not listed in Section H Part II.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
 - a) the singular includes the plural; and
 - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under, that legislation.

HOSPITAL SUPPLY OF PHARMACEUTICALS

2 Hospital Pharmaceuticals

- 2.1 Section H Part II contains the list of Hospital Pharmaceuticals that must be funded by DHB Hospitals. Section H Part II does not currently encompass the following categories of pharmaceuticals except for any items specifically listed in this Section H Part II:
 - a) Medical Devices;
 - b) whole or fractionated blood products;
 - c) diagnostic products which have an ex vivo use, such as pregnancy tests and reagents;
 - d) disinfectants and sterilising products, except those that are to be used in or on a patient;
 - e) foods and probiotics;
 - f) radioactive materials;
 - g) medical gases; and
 - h) parenteral nutrition.

Subject to rule 2.2, the funding of pharmaceuticals identified in a)–h) above is a decision for individual DHB Hospitals.

- 2.2 Section H Part III lists Optional Pharmaceuticals that PHARMAC and the relevant Pharmaceutical supplier have entered into contractual arrangements for the purchase of, including an agreement on a national price and other obligations such as HSS. DHB Hospitals may choose whether or not to fund the Optional Pharmaceuticals listed in Part III of Section H, but if they do, they must comply with any National Contract requirements.
- 2.3 Section H Part II does not encompass the provision of pharmaceutical treatments for DHB Hospital staff as part of an occupational health and safety programme. DHB Hospitals may choose whether or not to fund pharmaceutical treatments for such use, but if they do, they must comply with any National Contract requirements.

3 DHB Supply Obligations

- 3.1 In accordance with section 23(7) of the Act, in performing any of its functions in relation to the supply of pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule, which includes these General Rules.
- 3.2 DHB Hospitals are not required to hold stock of every Hospital Pharmaceutical listed in Section H Part II, but they must Give it within a reasonable time if it is prescribed.
- 3.3 DHB Hospitals are able to hold stock of an Unlisted Pharmaceutical if doing so is considered necessary for the DHB Hospital to be able to Give the Unlisted Pharmaceutical in a timely manner under rules 11–17 inclusive.
- 3.4 Except where permitted in accordance with rule 11, DHBs must not Give:
 - a) an Unlisted Pharmaceutical; or
 - b) a Hospital Pharmaceutical outside of any relevant Restrictions.

4 Funding

- 4.1 The purchase costs of Hospital Pharmaceuticals or Optional Pharmaceuticals administered, provided or dispensed by DHB Hospitals must be funded by the relevant DHB Hospital from its own budget, with the exception of:
 - a) Pharmaceutical Cancer Treatments;
 - b) Community Pharmaceuticals that have been brought to the DHB hospital by the patient who is being treated by outpatient Services or who is admitted as an inpatient;
 - c) Community Pharmaceuticals that have been dispensed to a mental health day clinic under a Practitioner's

- Supply Order; and
 - d) Unlisted Pharmaceutical that have been brought to the DHB Hospital by the patient who is admitted as an inpatient.
- 4.2 For the avoidance of doubt, Pharmaceutical Cancer Treatments and Community Pharmaceuticals are funded through the Combined Pharmaceutical Budget, and Unlisted Pharmaceuticals are funded by the patient.

LIMITS ON SUPPLY

5 Prescriber Restrictions

- 5.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has a Prescriber Restriction if it is prescribed:
- a) by a clinician of the type specified in the restriction for that Pharmaceutical or, subject to rule 5.2, pursuant to a recommendation from such a clinician;
 - b) in accordance with a protocol or guideline that has been endorsed by the DHB Hospital; or
 - c) in an emergency situation, provided that the prescriber has made reasonable attempts to comply with rule 5.1(a) above. If on-going treatment is required (i.e. beyond 24 hours) subsequent prescribing must comply with rule 5.1(a).
- 5.2 Where a Hospital Pharmaceutical is prescribed pursuant to a recommendation from a clinician of the type specified in the restriction for that Pharmaceutical:
- a) the prescriber must consult with a clinician of the type specified in the restriction for that Pharmaceutical; and
 - b) the consultation must relate to the patient for whom the prescription is written; and
 - c) the consultation may be in person, by telephone, letter, facsimile or email; and
 - d) appropriate records are kept of the consultation, including recording the name of the advising clinician on the prescription/chart.
- 5.3 Where a clinician is working under supervision of a consultant who is of the type specified in the restriction for that Pharmaceutical, the requirements of rule 5.2 can be deemed to have been met.

6 Indication Restrictions

- 6.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has an Indication Restriction, if it is prescribed for treatment of a patient with the particular clinical circumstances set out in the Indication Restriction.
- 6.2 If a patient has a current Special Authority Approval for the Hospital Pharmaceutical that the DHB Hospital wishes to Give, then the Indication Restriction is deemed to have been met.
- 6.3 If a Hospital Pharmaceutical has an Indication Restriction that is “for continuation only” then the DHB Hospital should only Give the Hospital Pharmaceutical where:
- a) the patient has been treated with the Pharmaceutical in the Community; or
 - b) the patient is unable to be treated with an alternative Hospital Pharmaceutical, and the prescriber has explained to the patient that the Pharmaceutical is not fully subsidised in the Community.

7 Local Restrictions

- 7.1 A DHB Hospital may implement a Local Restriction, provided that:
- a) in doing so, it ensures that the Local Restriction does not unreasonably limit funded access to the Hospital Pharmaceutical or undermine PHARMAC’s decision that the Hospital Pharmaceutical must be funded;
 - b) it provides PHARMAC with details of each Local Restriction that it implements; and
- 7.2 PHARMAC may, when it considers that a Local Restriction does not conform to rule 7.1 above, require a DHB to amend or remove that Local Restriction.

8 Community use of Hospital Pharmaceuticals

- 8.1 Except where otherwise specified in Section H, DHB Hospitals can Give any Hospital Pharmaceutical to a patient for use in the Community, provided that:
- a) the quantity does not exceed that sufficient for up to 30 days’ treatment, unless:
 - i) it would be inappropriate to provide less than the amount in an original pack; or
 - ii) the relevant DHB Hospital has a Dispensing for Discharge Policy and the quantity dispensed is in accordance with that policy; and
 - b) the Hospital Pharmaceutical is supplied consistent with any applicable Restrictions.

9 Community use of Medical Devices

- 9.1 Subject to rules 9.2 and 9.3, DHB Hospitals may Give a Medical Device for patients for use in the Community.
- 9.2 Where a Medical Device (or a similar Medical Device) is a Community Pharmaceutical, the DHB Hospital must supply:

- a) the brand of Medical Device that is listed in Sections A-G of the Schedule; and
 - b) only to patients who meet the funding eligibility criteria set out in Sections A-G of the Schedule.
- 9.3 Where a DHB Hospital has supplied a Medical Device to a patient; and
- a) that Medical Device (or a similar Medical Device) is subsequently listed in Sections A-G of the Schedule; and
 - b) the patient would not meet any funding eligibility criteria for the Medical Device set out in Sections A-G of the Schedule; and
 - c) the Medical Device has consumable components that need to be replaced throughout its usable life; then DHB Hospitals may continue to fund consumable products for that patient until the end of the usable life of the Medical Device. At the end of the usable life of the device, funding for a replacement device must be consistent with the Pharmaceutical Schedule and/or in accordance with the Named Patient Pharmaceutical Assessment policy.
- 9.4 DHB Hospitals may also continue to fund consumable products, as in rule 9.3 above, in situations where the DHB has been funding consumable products but where the Medical Device was funded by the patient.

10 Extemporaneous Compounding

- 10.1 A DHB Hospital may Give any Extemporaneously Compounded Product for a patient in its care, provided that:
- a) all of the component Pharmaceuticals of the Extemporaneously Compounded Product are Hospital Pharmaceuticals; and
 - b) the Extemporaneously Compounded Product is supplied consistent with any applicable rules or Restrictions for its component Hospital Pharmaceuticals.
- 10.2 For the avoidance of doubt, this rule 10.1 applies to any Extemporaneously Compounded Product, whether it is manufactured by the DHB Hospital or by a Contract Manufacturer.

EXCEPTIONS

11 Named Patient Pharmaceutical Assessment

- 11.1 A DHB Hospitals may only Give:
- a) an Unlisted Pharmaceutical; or
 - b) a Hospital Pharmaceutical outside of any relevant Restrictions,
- in accordance with the Named Patient Pharmaceutical Assessment Policy or rules 12–17 inclusive.

12 Continuation

- 12.1 Where a patient's clinical circumstances have been stabilised via treatment in the Community with a pharmaceutical that has not been funded by the Funder, and that patient is admitted to hospital as an inpatient, a DHB Hospital may fund that pharmaceutical for the duration of the patient's stay, where:
- a) the patient has not brought (or cannot arrange to bring) the pharmaceuticals to the DHB Hospital, or pharmacy staff consider that the pharmaceuticals brought to the DHB Hospital by the patient cannot be used; and
 - b) interrupted or delayed treatment would have significant adverse clinical consequences; and
 - c) it is not considered appropriate to switch treatment to a Hospital Pharmaceutical.

13 Pre-Existing Use

- 13.1 Subject to 13.2, where a DHB Hospital has Given a pharmaceutical for a patient prior to 1 July 2013, and the pharmaceutical:
- a) is an Unlisted Pharmaceutical; or
 - b) treatment of the patient would not comply with any relevant Restrictions;
- the DHB Hospital may continue to Give that pharmaceutical if it is considered that there would be significant adverse clinical consequences from ceasing or switching treatment.
- 13.2 Each DHB Hospital must, by no later than 1 October 2013, provide PHARMAC with a report on pharmaceuticals it has Given in accordance with this rule 13 where treatment has continued beyond 1 August 2013.

14 Clinical Trials and Free Stock

- 14.1 DHB Hospitals may Give any pharmaceutical that is funded by a third party and is being used:
- 14.1.1 as part of a clinical trial that has Ethics Committee approval; or
 - 14.1.2 for on-going treatment of patients following the end of such a clinical trial.
- 14.2 DHB Hospitals may Give any pharmaceutical that is provided free of charge by a supplier, provided that the pharmaceutical is provided as part of a programme of which the DHB, or supplier, has notified PHARMAC.

15 Pharmaceutical Cancer Treatments in Paediatrics

DHB Hospitals may Give any pharmaceutical for use within a paediatric oncology/haematology service for the treatment of

cancer.

16 Other Government Funding

DHB Hospitals may Give any pharmaceutical where funding for that pharmaceutical has been specifically provided by a Government entity other than PHARMAC or a DHB.

17 Other Exceptions

- 17.1 PHARMAC may also approve the funding of a pharmaceutical within a single DHB Hospital for information gathering purposes or otherwise related to PHARMAC's decision-making process for considering additions to or amendments to the Pharmaceutical Schedule.
- 17.2 Funding approvals granted under rule 17.1 will be subject to specific limitations on use as determined appropriate by PHARMAC in each circumstance, in consultation with the relevant DHB Hospital and/or DHB.

NATIONAL CONTRACTING

18 Hospital Pharmaceutical Contracts

- 18.1 A DHB Hospital may enter into a contract for the purchase of any Pharmaceutical, including any Medical Device, that it is entitled to fund in accordance with this Schedule H and that is not a National Contract Pharmaceutical, provided that such a contract:
 - a) does not oblige the relevant DHB Hospital to purchase a volume of that Pharmaceutical, if that Pharmaceutical is a DV Pharmaceutical, that is greater than the relevant DV Limit;
 - b) enables PHARMAC to access and use future price and volume data in respect of that Pharmaceutical; and
 - c) enables the relevant DHB Hospital to terminate the contract or relevant parts of the contract in order to give full effect to the National Contract on no more than 3 months' written notice to the Pharmaceutical supplier.
- 18.2 From 1 July 2013, where a DHB Hospital has a pre-existing supply contract for a particular brand of chemical entity for which there is a National Contract Pharmaceutical, the DHB may continue purchasing the chemical entity in accordance with its pre-existing supply contract however:
 - a) from the day its pre-existing supply contract expires, that DHB Hospital is to purchase the relevant National Contract Pharmaceutical listed in Section H at the Price, and is to comply with any DV Limits for the National Contract Pharmaceutical where it has HSS;
 - b) if purchase of the relevant National Contract Pharmaceutical listed in Section H at the Price, where it has HSS, would not cause the relevant DHB Hospital to be in breach of its pre-existing supply contract for a particular brand of chemical entity; the DHB Hospital must purchase the National Contract Pharmaceutical.
- 18.3 Following written notification from PHARMAC that a Pharmaceutical is a National Contract Pharmaceutical, either through Section H updates or otherwise, DHB Hospitals must, unless PHARMAC expressly notifies otherwise:
 - a) take any steps available to them to terminate pre-existing contracts or relevant parts of such a contract, and
 - b) not enter any new contracts or extend the period of any current contracts, for the supply of that National Contract Pharmaceutical or the relevant chemical entity or Medical Device.

19 National Contract Pharmaceuticals

- 19.1 DHB Hospitals must take all necessary steps to enable any contracts between PHARMAC and a Pharmaceutical supplier in relation to National Contract Pharmaceuticals to be given full effect.
- 19.2 The contractual arrangement between PHARMAC and the relevant supplier of a National Contract Pharmaceutical requires it to be made available for purchase at the relevant Price by any or all of the following:
 - a) DHB Hospitals at Designated Delivery Points; and/or
 - b) Contract Manufacturers (expressly for the purpose of compounding).

In the case of Medical Devices, a National Contract may require the Medical Device to be purchased by, and/or supplied to, a third party logistics provider.

20 Hospital Supply Status (HSS)

- 20.1 The DV Limit for any National Contract Pharmaceutical which has HSS is set out in the listing of the relevant National Contract Pharmaceutical in Section H, and may be amended from time to time.
- 20.2 If a National Contract Pharmaceutical is listed in Section H as having HSS, DHB Hospitals:
 - a) are expected to use up any existing stocks of DV Pharmaceuticals during the First Transition Period;
 - b) must not purchase DV Pharmaceuticals in volumes exceeding their usual requirements, or in volumes exceeding those which they reasonably expect to use, within the First Transition Period;
 - c) must ensure that Contract Manufacturers, when manufacturing an Extemporaneously Compounded Product on their behalf, use the National Contract Pharmaceutical with HSS; and

- d) must purchase the National Contract Pharmaceutical with HSS except:
 - i) to the extent that the DHB Hospital may use its discretion to purchase a DV Pharmaceutical within the DV Limit, provided that (subject to rule 20.2(d)(iii) below) the DV Limit has not been exceeded nationally;
 - ii) if the Pharmaceutical supplier fails to supply that National Contract Pharmaceutical, in which case the relevant DHB Hospital does not have to comply with the DV Limit for that National Contract Pharmaceutical during that period of non-supply (and any such month(s) included in a period of non-supply will be excluded in any review of the DV Limit in accordance with rule 20.3 below);
 - iii) that where the DV Limit has been exceeded nationally, the DHB Hospital may negotiate with the Pharmaceutical supplier that supplies the National Contract Pharmaceutical with HSS for written permission to vary the application of that DHB Hospital's Individual DV Limit for any patient whose exceptional needs require a DV Pharmaceutical.

20.3 PHARMAC may, in its discretion, for any period or part period:

- a) review usage by DHB Hospitals of the National Contract Pharmaceutical and DV Pharmaceuticals to determine whether the DV Limit has been exceeded; and
- b) audit compliance by DHB Hospitals with the DV Limits and related requirements.

20.4 PHARMAC will address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit by:

- a) obtaining the relevant DHB or DHB Hospital's assurance that it will comply with the DV Limit for that National Contract Pharmaceutical with HSS in the remainder of the applicable period and any subsequent periods; and
- b) informing the relevant supplier of the HSS Pharmaceutical of any individual DHB or DHB Hospital's non-compliance with the DV Limit for that HSS Pharmaceutical.

20.5 In addition to the steps taken by PHARMAC under rule 20.4 above to address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit, the relevant Pharmaceutical supplier may require, in its discretion, financial compensation from the relevant DHB or DHB Hospital:

- a) an amount representing that DHB or DHB Hospital's contribution towards exceeding the DV Limit (where PHARMAC is able to quantify this based on the information available to it); or
- b) the sum of \$1,000 or \$5,000 (depending on the terms of the applicable national contract applying to the HSS Pharmaceutical),

whichever is the greater as between sub-paragraphs (a) and (b) within the number of business days specified in the notice from the Pharmaceutical supplier requiring such payment to be made.

21 Collection of rebates and payment of financial compensation

21.1 Following the receipt of any rebates from a Pharmaceutical supplier in respect of a particular National Contract Pharmaceutical, PHARMAC will notify each relevant DHB and DHB Hospital of the amount of the rebate owing to it, being a portion of the total rebate determined by PHARMAC on the basis of that DHB Hospital's usage of that National Contract Pharmaceutical, where this is able to be determined. Where data to determine individual DHB Hospitals' usage is not available, PHARMAC will apportion rebates on the basis of an alternative method agreed between the relevant DHBs and PHARMAC.

21.2 PHARMAC will pay each DHB Hospital the rebate amounts (if any) owing to it, no less frequently than once each calendar quarter in respect of rebates received quarterly (or more often).

22 Price and Volume Data

22.1 DHB Hospitals must provide to PHARMAC, on a monthly basis in accordance with PHARMAC's requirements, any volume data and, unless it would result in a breach of a pre-existing contract, price data held by those DHB Hospitals in respect of any Pharmaceutical (including any Medical Device) listed in Section H.

22.2 All price and volume data provided to PHARMAC under rule 22.1 above should identify the relevant Hospital Pharmaceutical by using a Pharmacode or some other unique numerical identifier, and the date (month and year) on which the DHB Hospital incurred a cost for the purchase of that Hospital Pharmaceutical. Volume is to be measured in units (that being the smallest possible whole Unit – e.g. a capsule, a vial, a millilitre etc).

MISCELLANEOUS PROVISIONS

23 Unapproved Pharmaceuticals

Prescribers should, where possible, prescribe Hospital Pharmaceuticals that are approved under the Medicines Act 1981. However, the funding criteria (including Restrictions) under which a Hospital Pharmaceutical is listed in Section H of the

Schedule may:

23.1 in some cases, explicitly permit a DHB to fund a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or

23.2 not explicitly prohibit a DHB from funding a Pharmaceutical for use for an Unapproved Indication;

Accordingly, if clinicians are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, they should:

23.1 be aware of and comply with their obligations under sections 25 and/or 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;

23.2 be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that clinicians obtain written consent); and

23.3 exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Clinicians should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule, PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antacids and Antiflatulents			
Antacids and Reflux Barrier Agents			
ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE			
Tab 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg			<i>e.g. Mylanta</i>
Oral liq 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg per 5 ml			<i>e.g. Mylanta</i>
Oral liq 400 mg with magnesium hydroxide 400 mg and simethicone 30 mg per 5 ml			<i>e.g. Mylanta Double Strength</i>
SIMETHICONE			
Oral drops 100 mg per ml			
SODIUM ALGINATE WITH MAGNESIUM ALGINATE			
Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet			<i>e.g. Gaviscon Infant</i>
SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE			
Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg			<i>e.g. Gaviscon Double Strength</i>
Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml	4.95	500 ml	Acidex
SODIUM CITRATE			
Oral liq 8.8% (300 mmol/l)			
Phosphate Binding Agents			
ALUMINIUM HYDROXIDE			
Tab 600 mg			
CALCIUM CARBONATE – Restricted see terms below			
☿ Oral liq 250 mg per ml (100 mg elemental per ml)	39.00	500 ml	Roxane
☞ Restricted			
Only for use in children under 12 years of age for use as a phosphate binding agent			
Antidiarrhoeals and Intestinal Anti-Inflammatory Agents			
Antipropulsives			
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE			
Tab 2.5 mg with atropine sulphate 25 mcg			
LOPERAMIDE HYDROCHLORIDE			
Tab 2 mg			
Cap 2 mg – 1% DV Jul-14 to 2016	7.84	400	Diamide Relief
Rectal and Colonic Anti-Inflammatories			
BUDESONIDE – Restricted see terms on the next page			
☿ Cap 3 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Crohn's disease			
Both:			
1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and			
2 Any of the following:			
2.1 Diabetes; or			
2.2 Cushingoid habitus; or			
2.3 Osteoporosis where there is significant risk of fracture; or			
2.4 Severe acne following treatment with conventional corticosteroid therapy; or			
2.5 History of severe psychiatric problems associated with corticosteroid treatment; or			
2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or			
2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).			
Collagenous and lymphocytic colitis (microscopic colitis)			
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies			
Gut Graft versus Host disease			
Patient has a gut Graft versus Host disease following allogenic bone marrow transplantation			
HYDROCORTISONE ACETATE			
Rectal foam 10%, CFC free (14 applications) – 1% DV Oct-15 to 2018	26.55	21.1 g	Colifoam
MESALAZINE			
Tab EC 400 mg	49.50	100	Asacol
Tab EC 500 mg	49.50	100	Asamax
Tab long-acting 500 mg	59.05	100	Pentasa
Modified release granules 1 g	141.72	120 g	Pentasa
Suppos 500 mg	22.80	20	Asacol
Suppos 1 g – 1% DV Jun-15 to 2018	54.60	30	Pentasa
Enema 1 g per 100 ml – 1% DV Sep-15 to 2018	41.30	7	Pentasa
OLSALAZINE			
Tab 500 mg			
Cap 250 mg			
SODIUM CROMOGLYCATE			
Cap 100 mg			
SULPHASALAZINE			
Tab 500 mg – 1% DV Oct-13 to 2016	11.68	100	Salazopyrin
Tab EC 500 mg – 1% DV Oct-13 to 2016	12.89	100	Salazopyrin EN
Local Preparations for Anal and Rectal Disorders			
Antihaemorrhoidal Preparations			
CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE			
Oint 5 mg with hydrocortisone 5 mg per g	15.00	30 g	Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g	9.90	12	Proctosedyl
FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE			
Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g	6.35	30 g	Ultraproct
Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg	2.66	12	Ultraproct

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Management of Anal Fissures			
GLYCERYL TRINITRATE			
Oint 0.2%	22.00	30 g	Rectogesic
Rectal Sclerosants			
OILY PHENOL [PHENOL OILY]			
Inj 5%, 5 ml vial			
Antispasmodics and Other Agents Altering Gut Motility			
GLYCOPYRRONIUM BROMIDE			
Inj 200 mcg per ml, 1 ml ampoule – 1% DV Oct-13 to 2016	28.56	10	Max Health
HYOSCINE BUTYLBROMIDE			
Tab 10 mg	2.18	20	Gastrosoothe
Inj 20 mg, 1 ml ampoule	9.57	5	Buscopan
MEBEVERINE HYDROCHLORIDE			
Tab 135 mg – 1% DV Sep-14 to 2017	18.00	90	Colofac
Antulcerants			
Antisecretory and Cytoprotective			
MISOPROSTOL			
Tab 200 mcg			
H2 Antagonists			
CIMETIDINE			
Tab 200 mg			
Tab 400 mg			
RANITIDINE			
Tab 150 mg – 1% DV Nov-14 to 2017	10.30	500	Ranitidine Relief
Tab 300 mg – 1% DV Nov-14 to 2017	14.73	500	Ranitidine Relief
Oral liq 150 mg per 10 ml – 1% DV Sep-14 to 2017	4.92	300 ml	Peptisoothe
Inj 25 mg per ml, 2 ml ampoule	8.75	5	Zantac
Proton Pump Inhibitors			
LANSOPRAZOLE			
Cap 15 mg	2.00	28	Solox
Cap 30 mg	2.32	28	Solox
OMEPRAZOLE			
⚡ Tab dispersible 20 mg			
➡ Restricted			
Only for use in tube-fed patients			
Cap 10 mg – 1% DV Jan-15 to 2017	2.23	90	Omezol Relief
Cap 20 mg – 1% DV Jan-15 to 2017	2.91	90	Omezol Relief
Cap 40 mg – 1% DV Jan-15 to 2017	4.42	90	Omezol Relief
Powder for oral liq	42.50	5 g	Midwest
Inj 40 mg ampoule	19.00	5	Dr Reddy's Omeprazole
Inj 40 mg ampoule with diluent	28.65	5	Dr Reddy's Omeprazole

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PANTOPRAZOLE			
Tab EC 20 mg – 1% DV May-14 to 2016	2.68	100	Pantoprazole Actavis 20
Tab EC 40 mg – 1% DV May-14 to 2016	3.54	100	Pantoprazole Actavis 40
Inj 40 mg vial			

Site Protective Agents

BISMUTH TRIOXIDE			
Tab 120 mg	32.50	112	De-Nol
SUCRALFATE			
Tab 1 g			

Bile and Liver Therapy

L-ORNITHINE L-ASPARTATE – **Restricted** see terms below

⚡ Grans for oral liquid 3 g

➡ **Restricted**

For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

RIFAXIMIN – **Restricted** see terms below

⚡ Tab 550 mg – 1% DV Oct-14 to 2017 625.00 56 **Xifaxan**

➡ **Restricted**

For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

Diabetes

Alpha Glucosidase Inhibitors

ACARBOSE			
Tab 50 mg – 1% DV Oct-15 to 2018	4.28	90	Glucobay
	9.82		Accarb
Tab 100 mg – 1% DV Oct-15 to 2018	7.78	90	Glucobay
	15.83		Accarb

(Accarb Tab 50 mg to be delisted 1 October 2015)

(Accarb Tab 100 mg to be delisted 1 October 2015)

Hyperglycaemic Agents

DIAZOXIDE – **Restricted** see terms below

⚡ Cap 25 mg	110.00	100	Proglycem
⚡ Cap 100 mg	280.00	100	Proglycem
⚡ Oral liq 50 mg per ml	620.00	30 ml	Proglycem

➡ **Restricted**

For patients with confirmed hypoglycaemia caused by hyperinsulinism.

GLUCAGON HYDROCHLORIDE

Inj 1 mg syringe kit 32.00 1 Glucagen Hypokit

GLUCOSE [DEXTROSE]

Tab 1.5 g
Tab 3.1 g
Tab 4 g
Gel 40%

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GLUCOSE WITH SUCROSE AND FRUCTOSE			
Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet			
Insulin - Intermediate-Acting Preparations			
INSULIN ASPART WITH INSULIN ASPART PROTAMINE			
Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen	52.15	5	NovoMix 30 FlexPen
INSULIN ISOPHANE			
Inj insulin human 100 u per ml, 10 ml vial			
Inj insulin human 100 u per ml, 3 ml cartridge			
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge	42.66	5	Humalog Mix 25
Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge	42.66	5	Humalog Mix 50
INSULIN NEUTRAL WITH INSULIN ISOPHANE			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge			
Insulin - Long-Acting Preparations			
INSULIN GLARGINE			
Inj 100 u per ml, 3 ml disposable pen	94.50	5	Lantus SoloStar
Inj 100 u per ml, 3 ml cartridge	94.50	5	Lantus
Inj 100 u per ml, 10 ml vial	63.00	1	Lantus
Insulin - Rapid-Acting Preparations			
INSULIN ASPART			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Inj 100 u per ml, 3 ml syringe	51.19	5	NovoRapid FlexPen
INSULIN GLULISINE			
Inj 100 u per ml, 10 ml vial	27.03	1	Apidra
Inj 100 u per ml, 3 ml cartridge	46.07	5	Apidra
Inj 100 u per ml, 3 ml disposable pen	46.07	5	Apidra Solostar
INSULIN LISPRO			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Insulin - Short-Acting Preparations			
INSULIN NEUTRAL			
Inj human 100 u per ml, 10 ml vial			
Inj human 100 u per ml, 3 ml cartridge			

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Oral Hypoglycaemic Agents			
GLIBENCLAMIDE			
Tab 5 mg			
GLICLAZIDE			
Tab 80 mg – 1% DV Nov-14 to 2017	11.50	500	Glizide
GLIPIZIDE			
Tab 5 mg – 1% DV Sep-15 to 2018	2.85	100	Minidiab
METFORMIN			
Tab immediate-release 500 mg	12.30	1,000	Apotex
Tab immediate-release 850 mg	10.10	500	Apotex
PIOGLITAZONE			
Tab 15 mg	1.50	28	Pizaccord
Tab 30 mg	2.50	28	Pizaccord
Tab 45 mg	3.50	28	Pizaccord

Digestives Including Enzymes

PANCREATIC ENZYME

Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u pro- tease – 1% DV Oct-15 to 2018	34.93	100	Creon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease – 1% DV Oct-15 to 2018	94.38	100	Creon 25000
Cap EC 25,000 BP u lipase, 22,500 BP u amylase and 1,250 BP u protease			
Powder 25,000 u lipase with 30,000 u amylase and 1,400 u protease per g			

URSODEOXYCHOLIC ACID – Restricted see terms below

¶ Cap 250 mg – 1% DV Sep-14 to 2017	53.40	100	Ursosan
---	-------	-----	----------------

➡Restricted

Alagille syndrome or progressive familial intrahepatic cholestasis

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Chronic severe drug induced cholestatic liver injury

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Cirrhosis

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 µmol/l; decompensated cirrhosis).

Pregnancy

Patient diagnosed with cholestasis of pregnancy.

Haematological transplant

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogeneic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Total parenteral nutrition induced cholestasis

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
- 2 Liver function has not improved with modifying the TPN composition.

Laxatives

Bowel-Cleansing Preparations

CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE

Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet

e.g. PicoPrep

MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet

e.g. Glycoprep-C

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet

e.g. Glycoprep-C

MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE

Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet

14.31 4 Klean Prep

Bulk-Forming Agents

ISPAGHULA (PSYLLIUM) HUSK

Powder for oral soln – 1% DV Sep-13 to 2016.....5.51

500 g Konsyl-D

STERCULIA WITH FRANGULA – Restricted: For continuation only

➔ Powder for oral soln

Faecal Softeners

DOCUSATE SODIUM

Tab 50 mg – 1% DV Jan-15 to 20172.31

100 Coloxyl

Tab 120 mg – 1% DV Jan-15 to 20173.13

100 Coloxyl

DOCUSATE SODIUM WITH SENNOSIDES

Tab 50 mg with sennosides 8 mg4.40

200 Laxsol

PARAFFIN

Oral liquid 1 mg per ml
Enema 133 ml

POLOXAMER

Oral drops 10% – 1% DV Sep-14 to 20173.78

30 ml Coloxyl

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Osmotic Laxatives			
GLYCEROL			
Suppos 1.27 g			
Suppos 2.55 g			
Suppos 3.6 g – 1% DV Sep-15 to 2018	6.50	20	PSM
LACTULOSE			
Oral liq 10 g per 15 ml	3.84	500 ml	Laevolac
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE – Restricted see terms below			
☞ Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg			
☞ Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Oct-14 to 2017	7.65	30	Lax-Sachets
☞ Restricted			
Either:			
1 Both:			
1.1 The patient has problematic constipation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated; and			
1.2 The patient would otherwise require a per rectal preparation; or			
2 For short-term use for faecal disimpaction.			
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE			
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1% DV Sep-13 to 2016	19.95	50	Micolette
SODIUM PHOSPHATE WITH PHOSPHORIC ACID			
Oral liq 16.4% with phosphoric acid 25.14%			
Enema 10% with phosphoric acid 6.58%	2.50	1	Fleet Phosphate Enema

Stimulant Laxatives

BISACODYL			
Tab 5 mg – 1% DV Oct-15 to 2018	5.99	200	Lax-Tabs
Suppos 5 mg	3.00	6	Dulcolax
Suppos 10 mg	3.00	6	Dulcolax
SENNOSIDES			
Tab 7.5 mg			

Metabolic Disorder Agents

ARGININE			
Powder			
Inj 600 mg per ml, 25 ml vial			
BETAINE – Restricted see terms below			
☞ Powder			
☞ Restricted			
Metabolic disorders physician or metabolic disorders dietitian			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BIOTIN – Restricted see terms below			
☞ Cap 50 mg			
☞ Cap 100 mg			
☞ Inj 10 mg per ml, 5 ml vial			
➔ Restricted			
Metabolic disorders physician or metabolic disorders dietitian.			
HAEM ARGINATE			
Inj 25 mg per ml, 10 ml ampoule			
IMIGLUCERASE – Restricted see terms below			
☞ Inj 40 iu per ml, 5 ml vial			
☞ Inj 40 iu per ml, 10 ml vial			
➔ Restricted			
Only for use in patients with approval by the Gaucher's Treatment Panel			
LEVOCARNITINE – Restricted see terms below			
☞ Cap 500 mg			
☞ Oral soln 1,100 mg per 15 ml			
☞ Inj 200 mg per ml, 5 ml vial			
➔ Restricted			
Metabolic disorders physician, metabolic disorders dietitian or neurologist			
PYRIDOXAL-5-PHOSPHATE – Restricted see terms below			
☞ Tab 50 mg			
➔ Restricted			
Metabolic disorders physician, metabolic disorders dietitian or neurologist			
SODIUM BENZOATE			
Cap 500 mg			
Powder			
Soln 100 mg per ml			
Inj 20%, 10 ml ampoule			
SODIUM PHENYLBUTYRATE			
Tab 500 mg			
Oral liq 250 mg per ml			
Inj 200 mg per ml, 10 ml ampoule			
TRIENTINE DIHYDROCHLORIDE			
Cap 300 mg			

Minerals

Calcium

CALCIUM CARBONATE

Tab 1.25 g (500 mg elemental) – 1% DV Sep-14 to 2017	5.38	250	Arrow-Calcium
Tab eff 1.75 g (1 g elemental)	6.21	30	Calsource

Fluoride

SODIUM FLUORIDE

Tab 1.1 mg (0.5 mg elemental)			
-------------------------------	--	--	--

ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Iodine			
POTASSIUM IODATE			
Tab 253 mcg (150 mcg elemental iodine) – 1% DV Dec-14 to 2017	3.65	90	NeuroTabs
POTASSIUM IODATE WITH IODINE			
Oral liq 10% with iodine 5%			
Iron			
FERRIC CARBOXYMALTOSE – Restricted see terms below			
⚡ Inj 50 mg per ml, 10 ml vial	150.00	1	Ferinject
➡ Restricted			
Treatment with oral iron has proven ineffective or is clinically inappropriate.			
FERROUS FUMARATE			
Tab 200 mg (65 mg elemental) – 1% DV Jun-15 to 2018	2.89	100	Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID			
Tab 310 mg (100 mg elemental) with folic acid 350 mcg	4.75	60	Ferro-F-Tabs
FERROUS GLUCONATE WITH ASCORBIC ACID			
Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg			
FERROUS SULPHATE			
Tab long-acting 325 mg (105 mg elemental)	2.06	30	Ferrograd
Oral liq 30 mg (6 mg elemental) per ml – 1% DV Apr-14 to 2016	10.28	500 ml	Ferodan
FERROUS SULPHATE WITH ASCORBIC ACID			
Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg			
FERROUS SULPHATE WITH FOLIC ACID			
Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg			
IRON POLYMALTOSE			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017	15.22	5	Ferrum H
IRON SUCROSE			
Inj 20 mg per ml, 5 ml ampoule	100.00	5	Venofer
Magnesium			
MAGNESIUM HYDROXIDE			
Tab 311 mg (130 mg elemental)			
MAGNESIUM OXIDE			
Cap 663 mg (400 mg elemental)			
MAGNESIUM SULPHATE			
Inj 0.4 mmol per ml, 250 ml bag			
Inj 2 mmol per ml, 5 ml ampoule – 1% DV Oct-14 to 2017	12.65	10	DBL
Zinc			
ZINC			
Oral liq 5 mg per 5 drops			
ZINC CHLORIDE			
Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule			
ZINC SULPHATE			
Cap 137.4 mg (50 mg elemental) – 1% DV Mar-15 to 2017	11.00	100	Zincaps

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)
e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST)	Brand or Generic
\$ Per	Manufacturer

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE

Soln 0.15%
Spray 0.15%
Spray 0.3%

BENZYDAMINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHLORIDE

Lozenge 3 mg with cetylpyridinium chloride

CARBOXYMETHYLCELLULOSE

Oral spray

CHLORHEXIDINE GLUCONATE

Mouthwash 0.2% – 1% DV Sep-15 to 2018 2.57 200 ml **healthE**

CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE

Adhesive gel 8.7% with cetalkonium chloride 0.01%

DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL

Lozenge 1.2 mg with amylmetacresol 0.6 mg

SODIUM CARBOXYMETHYLCELLULOSE WITH PECTIN AND GELATINE

Paste
Powder

TRIAMCINOLONE ACETONIDE

Paste 0.1% – 1% DV Apr-15 to 2017 5.33 5 g **Kenalog in Orabase**

Oropharyngeal Anti-Infectives

AMPHOTERICIN B

Lozenge 10 mg 5.86 20 **Fungilin**

MICONAZOLE

Oral gel 20 mg per g – 1% DV Sep-15 to 2018 4.79 40 g **Decozol**

NYSTATIN

Oral liquid 100,000 u per ml 3.35 24 ml **Nilstat**

Other Oral Agents

SODIUM HYALURONATE [HYALURONIC ACID] – **Restricted** see terms below

💉 Inj 20 mg per ml, 1 ml syringe

➡ **Restricted**

Otolaryngologist

THYMOL GLYCERIN

Compound, BPC

Vitamins

Multivitamin Preparations

MULTIVITAMIN AND MINERAL SUPPLEMENT – **Restricted** see terms on the next page

💉 Cap

*e.g. Clinicians Multivit &
Mineral Boost*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➡Restricted			
<i>Limited to 3 months' treatment</i>			
Both:			
1 Patient was admitted to hospital with burns; and			
2 Any of the following:			
2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or			
2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or			
2.3 Nutritional status prior to admission or dietary intake is poor.			
Note: Multivitamin and mineral supplement capsule composition includes vitamin A 250 IU, thiamine 2.5 mg, riboflavin 2.5 mg, nicotinamide 12.5 mg, vitamin B5 10 mg, pyridoxine 5 mg, vitamin B12 6.2 mcg, vitamin C 125 mg, cholecalciferol 2.5 mcg, vitamin E 25 mg, betaine 12.5 mg, biotin 12.5 mcg, boron 250 mcg, calcium 25 mg, choline 6.2 mg, chromium 25 mcg, citric acid 50mg, citrus bioflavonoid complex 50mg, co-enzyme Q10 1.2 mg, copper 125 mcg, folic acid 37.5 mcg, inositol 6.2 mg, iodine 25 mcg, iron 250 mcg, L-Glutamine 6.2 mg, magnesium 12.5 mg, molybdenum 12.5 mcg, manganese 0.5 mg, potassium 5 mg, selenium 18.7 mcg, zinc 1.9 mg.			
MULTIVITAMINS			
Tab (BPC cap strength)			<i>e.g. Mvite</i>
⚡ Cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg			<i>e.g. Vitabdeck</i>
➡Restricted			
Either:			
1 Patient has cystic fibrosis with pancreatic insufficiency; or			
2 Patient is an infant or child with liver disease or short gut syndrome.			
⚡ Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg			<i>e.g. Paediatric Seravit</i>
➡Restricted			
Patient has inborn errors of metabolism.			
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)			<i>e.g. Pabrinex IV</i>
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1)			<i>e.g. Pabrinex IM</i>
Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)			<i>e.g. Pabrinex IV</i>
VITAMIN A WITH VITAMINS D AND C			
Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops			<i>e.g. Vitadol C</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Vitamin A			
RETINOL			
Tab 10,000 iu			
Cap 25,000 iu			
Oral liq 150,000 iu per ml			
Vitamin B			
HYDROXOCOBALAMIN			
Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-15 to 2018	2.31	3	Neo-B12
	5.10		ABM Hydroxocobalamin
<i>(ABM Hydroxocobalamin Inj 1 mg per ml, 1 ml ampoule to be delisted 1 September 2015)</i>			
PYRIDOXINE HYDROCHLORIDE			
Tab 25 mg – 1% DV Apr-15 to 2017	2.15	90	Vitamin B6 25
Tab 50 mg – 1% DV Oct-14 to 2017	11.55	500	Apo-Pyridoxine
Inj 100 mg per ml, 1 ml ampoule			
THIAMINE HYDROCHLORIDE			
Tab 50 mg			
Tab 100 mg			
Inj 100 mg per ml, 2 ml vial			
VITAMIN B COMPLEX			
Tab strong, BPC			
Vitamin C			
ASCORBIC ACID			
Tab 100 mg – 1% DV Nov-13 to 2016	7.00	500	Cvite
Tab chewable 250 mg			
Vitamin D			
ALFACALCIDOL			
Cap 0.25 mcg	26.32	100	One-Alpha
Cap 1 mcg	87.98	100	One-Alpha
Oral drops 2 mcg per ml			
CALCITRIOL			
Cap 0.25 mcg	3.03	30	Airflow
	10.10	100	Calcitriol-AFT
Cap 0.5 mcg	5.62	30	Airflow
	18.73	100	Calcitriol-AFT
Oral liq 1 mcg per ml			
Inj 1 mcg per ml, 1 ml ampoule			
CHOLECALCIFEROL			
Tab 1.25 mg (50,000 iu)	7.76	12	Cal-d-Forte
Vitamin E			
ALPHA TOCOPHERYL ACETATE – Restricted see terms on the next page			
⚡ Cap 100 u			
⚡ Cap 500 u			
⚡ Oral liq 156 u per ml			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➡Restricted

Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
 - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
 - 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Osteoradionecrosis

For the treatment of osteoradionecrosis

Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
 - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
 - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

Price (ex man. excl. GST)	Brand or Generic
\$	Per Manufacturer

Antianaemics

Hypoplastic and Haemolytic

EPOETIN ALFA [ERYTHROPOIETIN ALFA] – **Restricted** see terms below

⚡ Inj 1,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018	48.68	6	Eprex
⚡ Inj 2,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018	120.18	6	Eprex
⚡ Inj 3,000 iu in 0.3 ml syringe – 5% DV Mar-15 to 28 Feb 2018	166.87	6	Eprex
⚡ Inj 4,000 iu in 0.4 ml syringe – 5% DV Mar-15 to 28 Feb 2018	193.13	6	Eprex
⚡ Inj 5,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018	243.26	6	Eprex
⚡ Inj 6,000 iu in 0.6 ml syringe – 5% DV Mar-15 to 28 Feb 2018	291.92	6	Eprex
⚡ Inj 8,000 iu in 0.8 ml syringe – 5% DV May-15 to 28 Feb 2018	352.69	6	Eprex
⚡ Inj 10,000 iu in 1 ml syringe – 5% DV Mar-15 to 28 Feb 2018	395.18	6	Eprex
⚡ Inj 40,000 iu in 1 ml syringe – 5% DV May-15 to 28 Feb 2018	263.45	1	Eprex

→ Restricted

Initiation - chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin \leq 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate \leq 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate \leq 45ml/min; or
- 4 Patient is on haemodialysis or peritoneal dialysis.

Initiation - myelodysplasia*

Re-assessment required after 2 months

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin $<$ 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum erythropoietin level of $<$ 500 IU/L; and
- 6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Continuation - myelodysplasia*

Re-assessment required after 12 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Initiation - all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

*Note: Indications marked with * are Unapproved Indications.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Megaloblastic			
FOLIC ACID			
Tab 0.8 mg – 1% DV Oct-15 to 2018	20.60	1,000	Apo-Folic Acid
Tab 5 mg – 1% DV Oct-15 to 2018	10.92	500	Apo-Folic Acid
Oral liq 50 mcg per ml	24.00	25 ml	Biomed
Inj 5 mg per ml, 10 ml vial			

Antifibrinolytics, Haemostatics and Local Sclerosants

APROTININ – **Restricted** see terms below

☞ Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial

☞ **Restricted**

Cardiac anaesthetist

Either:

- 1 Paediatric patient undergoing cardiopulmonary bypass procedure; or
- 2 Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

ELTROMBOPAG – **Restricted** see terms below

☞ Tab 25 mg 1,771.00 28 Revolade

☞ Tab 50 mg 3,542.00 28 Revolade

☞ **Restricted**

Haematologist

Initiation (idiopathic thrombocytopenic purpura - post-splenectomy)

Re-assessment required after 6 weeks

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialed and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of \leq 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of \leq 10,000 platelets per microlitre.

Initiation - (idiopathic thrombocytopenic purpura - preparation for splenectomy)

Re-assessment required after 6 weeks

The patient requires eltrombopag treatment as preparation for splenectomy.

Continuation - (idiopathic thrombocytopenic purpura - post-splenectomy)

Re-assessment required after 12 months

The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of $>$ 30,000 platelets per microlitre.

FERRIC SUBSULFATE

Gel 25.9%

Soln 500 ml

POLIDOCANOL

Inj 0.5%, 30 ml vial

SODIUM TETRADECYL SULPHATE

Inj 3%, 2 ml ampoule

THROMBIN

Powder

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TRANEXAMIC ACID			
Tab 500 mg – 1% DV Oct-14 to 2016	23.00	100	Cyklokapron
Inj 100 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	55.00	10	Cyklokapron

Blood Factors

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – **Restricted** see terms below

⚡ Inj 1 mg syringe	1,163.75	1	NovoSeven RT
⚡ Inj 2 mg syringe	2,327.50	1	NovoSeven RT
⚡ Inj 5 mg syringe	5,818.75	1	NovoSeven RT
⚡ Inj 8 mg syringe	9,310.00	1	NovoSeven RT

➔Restricted

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

FACTOR EIGHT INHIBITORS BYPASSING AGENT – **Restricted** see terms below

⚡ Inj 500 U	1,640.00	1	FEIBA
⚡ Inj 1,000 U	3,280.00	1	FEIBA

➔Restricted

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – **Restricted** see terms below

⚡ Inj 250 iu vial	225.00	1	Xyntha
⚡ Inj 500 iu vial	450.00	1	Xyntha
⚡ Inj 1,000 iu vial	900.00	1	Xyntha
⚡ Inj 2,000 iu vial	1,800.00	1	Xyntha
⚡ Inj 3,000 iu vial	2,700.00	1	Xyntha

➔Restricted

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

NONACOG ALFA [RECOMBINANT FACTOR IX] – **Restricted** see terms below

⚡ Inj 250 iu vial	310.00	1	BeneFIX
⚡ Inj 500 iu vial	620.00	1	BeneFIX
⚡ Inj 1,000 iu vial	1,240.00	1	BeneFIX
⚡ Inj 2,000 iu vial	2,480.00	1	BeneFIX

➔Restricted

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] – **Restricted** see terms on the next page

⚡ Inj 250 iu vial	237.50	1	Advate
	250.00		Kogenate FS
⚡ Inj 500 iu vial	475.00	1	Advate
	500.00		Kogenate FS
⚡ Inj 1,000 iu vial	950.00	1	Advate
	1,000.00		Kogenate FS
⚡ Inj 1,500 iu vial	1,425.00	1	Advate
⚡ Inj 2,000 iu vial	1,900.00	1	Advate
	2,000.00		Kogenate FS
⚡ Inj 3,000 iu vial	2,850.00	1	Advate
	3,000.00		Kogenate FS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➡Restricted

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Vitamin K

PHYTOMENADIONE

Inj 2 mg in 0.2 ml ampoule	8.00	5	Konaktion MM
Inj 10 mg per ml, 1 ml ampoule	9.21	5	Konaktion MM

Anti-thrombotics

Anticoagulants

BIVALIRUDIN – **Restricted** see terms below

⚡ Inj 250 mg vial

➡Restricted

Either:

- 1 For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance; or
- 2 For use in patients undergoing endovascular procedures.

DABIGATRAN

Cap 75 mg	148.00	60	Pradaxa
Cap 110 mg	148.00	60	Pradaxa
Cap 150 mg	148.00	60	Pradaxa

DALTEPARIN

Inj 2,500 iu in 0.2 ml syringe	19.97	10	Fragmin
Inj 5,000 iu in 0.2 ml syringe	39.94	10	Fragmin
Inj 7,500 iu in 0.75 ml syringe	60.03	10	Fragmin
Inj 10,000 iu in 1 ml syringe	77.55	10	Fragmin
Inj 12,500 iu in 0.5 ml syringe	99.96	10	Fragmin
Inj 15,000 iu in 0.6 ml syringe	120.05	10	Fragmin
Inj 18,000 iu in 0.72 ml syringe	158.47	10	Fragmin

DANAPAROID – **Restricted** see terms below

⚡ Inj 750 u in 0.6 ml ampoule

➡Restricted

For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance

DEFIBROTIDE – **Restricted** see terms below

⚡ Inj 80 mg per ml, 2.5 ml ampoule

➡Restricted

Haematologist

Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities

DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]

Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml,
100 ml bag

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ENOXAPARIN			
Inj 20 mg in 0.2 ml syringe	37.24	10	Clexane
Inj 40 mg in 0.4 ml ampoule			
Inj 40 mg in 0.4 ml syringe	49.69	10	Clexane
Inj 60 mg in 0.6 ml syringe	74.91	10	Clexane
Inj 80 mg in 0.8 ml syringe	99.86	10	Clexane
Inj 100 mg in 1 ml syringe	125.06	10	Clexane
Inj 120 mg in 0.8 ml syringe	155.40	10	Clexane
Inj 150 mg in 1 ml syringe	177.60	10	Clexane
FONDAPARINUX SODIUM – Restricted see terms below			
⚡ Inj 2.5 mg in 0.5 ml syringe			
⚡ Inj 7.5 mg in 0.6 ml syringe			
➡ Restricted			
For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance			
HEPARIN SODIUM			
Inj 100 iu per ml, 250 ml bag			
Inj 1,000 iu per ml, 1 ml ampoule	66.80	50	Hospira
Inj 1,000 iu per ml, 35 ml ampoule			
Inj 1,000 iu per ml, 5 ml ampoule	61.04	50	Pfizer
Inj 5,000 iu in 0.2 ml ampoule			
Inj 5,000 iu per ml, 1 ml ampoule	14.20	5	Hospira
Inj 5,000 iu per ml, 5 ml ampoule	236.60	50	Pfizer
HEPARINISED SALINE			
Inj 10 iu per ml, 5 ml ampoule	39.00	50	Pfizer
Inj 100 iu per ml, 2 ml ampoule			
Inj 100 iu per ml, 5 ml ampoule			
PHENINDIONE			
Tab 10 mg			
Tab 25 mg			
Tab 50 mg			
PROTAMINE SULPHATE			
Inj 10 mg per ml, 5 ml ampoule			
RIVAROXABAN – Restricted see terms below			
⚡ Tab 10 mg	153.00	15	Xarelto
➡ Restricted			
Either:			
1 Limited to five weeks' treatment for the prophylaxis of venous thromboembolism following a total hip replacement; or			
2 Limited to two weeks' treatment for the prophylaxis of venous thromboembolism following a total knee replacement.			
SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE			
Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride			
74.6 mcg per ml, 5,000 ml bag			
TRISODIUM CITRATE			
Inj 4%, 5 ml ampoule			
Inj 46.7%, 3 ml syringe			
Inj 46.7%, 5 ml ampoule			

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
WARFARIN SODIUM			
Tab 1 mg	6.86	100	Marevan
Tab 2 mg			
Tab 3 mg	9.70	100	Marevan
Tab 5 mg	11.75	100	Marevan
Antiplatelets			
ASPIRIN			
Tab 100 mg – 1% DV Mar-14 to 2016	1.60	90	Ethics Aspirin EC
	10.50	990	Ethics Aspirin EC
Suppos 300 mg			
CLOPIDOGREL			
Tab 75 mg – 1% DV Dec-13 to 2016	5.48	84	Arrow - Clopid
DIPYRIDAMOLE			
Tab 25 mg			
Tab long-acting 150 mg	11.52	60	Pytazen SR
Inj 5 mg per ml, 2 ml ampoule			
EPTIFIBATIDE – Restricted see terms below			
⚡ Inj 2 mg per ml, 10 ml vial	111.00	1	Integrilin
⚡ Inj 750 mcg per ml, 100 ml vial	324.00	1	Integrilin
➡Restricted			
Either:			
1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or			
2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography.			
PRASUGREL – Restricted see terms below			
⚡ Tab 5 mg	108.00	28	Effient
⚡ Tab 10 mg	120.00	28	Effient
➡Restricted			
Bare metal stents			
Limited to 6 months' treatment			
Patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic.			
Drug-eluting stents			
Limited to 12 months' treatment			
Patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic.			
Stent thrombosis			
Patient has experienced cardiac stent thrombosis whilst on clopidogrel.			
Myocardial infarction			
Limited to 7 days' treatment			
For short term use while in hospital following ST-elevated myocardial infarction.			
Note: Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.			
TICAGRELOR – Restricted see terms below			
⚡ Tab 90 mg	90.00	56	Brilinta
➡Restricted			
Restricted to treatment of acute coronary syndromes specifically for patients who have recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.			
TICLOPIDINE			
Tab 250 mg			

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)
e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Fibrinolytic Agents			
ALTEPLASE			
Inj 2 mg vial			
Inj 10 mg vial			
Inj 50 mg vial			
TENECTEPLASE			
Inj 50 mg vial			
UROKINASE			
Inj 10,000 iu vial			
Inj 50,000 iu vial			
Inj 100,000 iu vial			
Inj 500,000 iu vial			
Colony-Stimulating Factors			
Granulocyte Colony-Stimulating Factors			
FILGRASTIM – Restricted see terms below			
⚡ Inj 300 mcg in 0.5 ml syringe – 1% DV Jan-13 to 31 Dec 2015	540.00	5	Zarzio
⚡ Inj 300 mcg in 1 ml vial	650.00	5	Neupogen
⚡ Inj 480 mcg in 0.5 ml syringe – 1% DV Jan-13 to 31 Dec 2015	864.00	5	Zarzio
➡Restricted			
Oncologist or haematologist			
PEGFILGRASTIM – Restricted see terms below			
⚡ Inj 6 mg per 0.6 ml syringe	1,080.00	1	Neulastim
➡Restricted			
For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk ≥ 20%*).			
*Febrile neutropenia risk ≥ 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.			
Fluids and Electrolytes			
Intravenous Administration			
CALCIUM CHLORIDE			
Inj 100 mg per ml, 10 ml vial			
CALCIUM GLUCONATE			
Inj 10%, 10 ml ampoule	34.24	10	Hospira
COMPOUND ELECTROLYTES			
Inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, bag	5.00	500 ml	Baxter
	3.10	1,000 ml	Baxter
COMPOUND ELECTROLYTES WITH GLUCOSE			
Inj glucose 50 g with 140 mmol/l sodium, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, bag	7.00	1,000 ml	Baxter
Products with Hospital Supply Status (HSS) are in bold			
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.			

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bi-carbonate 29 mmol/l, chloride 111 mmol/l, bag	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
COMPOUND SODIUM LACTATE WITH GLUCOSE			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bi-carbonate 29 mmol/l, chloride 111 mmol/l and glucose 5%, bag	5.38	1,000 ml	Baxter
GLUCOSE [DEXTROSE]			
Inj 5%, bag	2.87	50 ml	Baxter
	2.84	100 ml	Baxter
	3.87	250 ml	Baxter
	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
Inj 10%, bag	3.70	500 ml	Baxter
	5.29	1,000 ml	Baxter
Inj 50%, bag	6.84	500 ml	Baxter
Inj 50%, 10 ml ampoule – 1% DV Oct-14 to 2017	27.50	5	Biomed
Inj 50%, 90 ml bottle – 1% DV Oct-14 to 2017	14.50	1	Biomed
Inj 70%, 1,000 ml bag			
Inj 70%, 500 ml bag			
GLUCOSE WITH POTASSIUM CHLORIDE			
Inj 5% glucose with 20 mmol/l potassium chloride, bag	7.36	1,000 ml	Baxter
Inj 5% glucose with 30 mmol/l potassium chloride, 1,000 ml bag			
Inj 10% glucose with 10 mmol/l potassium chloride, 500 ml bag			
GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE			
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, bag	3.45	500 ml	Baxter
	4.30	1,000 ml	Baxter
Inj 4% glucose with potassium chloride 30 mmol/l and sodium chloride 0.18%, bag	3.62	1,000 ml	Baxter
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag			
Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag			
GLUCOSE WITH SODIUM CHLORIDE			
Inj glucose 2.5% with sodium chloride 0.45%, bag	4.95	500 ml	Baxter
Inj glucose 5% with sodium chloride 0.45%, bag	9.87	500 ml	Baxter
	5.80	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.9%, bag	4.54	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.2%, 500 ml bag			
POTASSIUM CHLORIDE			
Inj 75 mg (1 mmol) per ml, 10 ml ampoule			
Inj 225 mg (3 mmol) per ml, 20 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
POTASSIUM CHLORIDE WITH SODIUM CHLORIDE			
Inj 20 mmol/l potassium chloride with 0.9% sodium chloride, bag	3.85	1,000 ml	Baxter
Inj 30 mmol/l potassium chloride with 0.9% sodium chloride, bag	2.59	1,000 ml	Baxter
Inj 40 mmol/l potassium chloride with 0.9% sodium chloride, bag	6.62	1,000 ml	Baxter
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag			
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag			
POTASSIUM DIHYDROGEN PHOSPHATE			
Inj 1 mmol per ml, 10 ml ampoule – 1% DV Oct-15 to 2018	151.80	10	Hospira
RINGER'S SOLUTION			
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, bag	5.13	1,000 ml	Baxter
SODIUM ACETATE			
Inj 4 mmol per ml, 20 ml ampoule			
SODIUM BICARBONATE			
Inj 8.4%, 10 ml vial			
Inj 8.4%, 50 ml vial	19.95	1	Biomed
Inj 8.4%, 100 ml vial	20.50	1	Biomed
SODIUM CHLORIDE			
Inj 0.45%, bag	5.50	500 ml	Baxter
Inj 0.9%, bag	1.70	500 ml	Freeflex
	1.71	1,000 ml	Freeflex
	3.01	50 ml	Baxter
	2.28	100 ml	Baxter
	3.60	250 ml	Baxter
	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
Inj 3%, bag	5.69	1,000 ml	Baxter
Inj 0.9%, 5 ml ampoule	10.85	50	Multichem
	15.50		Pfizer
Inj 0.9%, 10 ml ampoule	11.50	50	Multichem
	15.50		Pfizer
⚡ Inj 0.9%, 3 ml syringe, non-sterile pack – 1% DV Jun-15 to 2018	10.65	30	BD PosiFlush
➡ Restricted			
For use in flushing of in-situ vascular access devices only.			
⚡ Inj 0.9%, 5 ml syringe, non-sterile pack – 1% DV Jun-15 to 2018	10.80	30	BD PosiFlush
➡ Restricted			
For use in flushing of in-situ vascular access devices only.			
⚡ Inj 0.9%, 10 ml syringe, non-sterile pack – 1% DV Jun-15 to 2018	11.25	30	BD PosiFlush
➡ Restricted			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, 20 ml ampoule	8.41	20	Multichem
Inj 23.4% (4 mmol/ml), 20 ml – 1% DV Sep-13 to 2016	31.25	5	Biomed
Inj 1.8%, 500 ml bottle			
SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]			
Inj 1 mmol per ml, 20 ml ampoule – 1% DV Oct-15 to 2018	47.50	5	Biomed

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
WATER			
Inj, bag	2.75	1,000 ml	Baxter
Inj 5 ml ampoule	10.25	50	Multichem
Inj 10 ml ampoule	11.25	50	Multichem
Inj 20 ml ampoule	6.50	20	Multichem
Inj 250 ml bag			
Inj 500 ml bag			
Oral Administration			
CALCIUM POLYSTYRENE SULPHONATE			
Powder	169.85	300 g	Calcium Resonium
COMPOUND ELECTROLYTES			
Powder for oral soln			
COMPOUND ELECTROLYTES WITH GLUCOSE			
Soln with electrolytes			
PHOSPHORUS			
Tab eff 500 mg (16 mmol)			
POTASSIUM CHLORIDE			
Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)			
Tab long-acting 600 mg (8 mmol) – 1% DV Sep-15 to 2018	7.42	200	Span-K
Oral liq 2 mmol per ml			
SODIUM BICARBONATE			
Cap 840 mg	8.52	100	Sodibic
SODIUM CHLORIDE			
Tab 600 mg			
Oral liq 2 mmol/ml			
SODIUM POLYSTYRENE SULPHONATE			
Powder – 1% DV Sep-15 to 2018	84.65	454 g	Resonium A
Plasma Volume Expanders			
GELATINE, SUCCINYLATED			
Inj 4%, 500 ml bag	108.00	10	Gelofusine
HYDROXYETHYL STARCH 130/0.4 WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE AND SODIUM CHLORIDE			
Inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag	198.00	20	Volulyte 6%
HYDROXYETHYL STARCH 130/0.4 WITH SODIUM CHLORIDE			
Inj 6% with sodium chloride 0.9%, 500 ml bag	198.00	20	Voluven

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Agents Affecting the Renin-Angiotensin System

ACE Inhibitors

CAPTOPRIL

☞ Oral liq 5 mg per ml	94.99	95 ml	Capoten
------------------------------	-------	-------	---------

☞ Restricted

Any of the following:

- 1 For use in children under 12 years of age; or
- 2 For use in tube-fed patients; or
- 3 For management of rebound transient hypertension following cardiac surgery.

CILAZAPRIL

Tab 0.5 mg – 1% DV Sep-13 to 2016	2.00	90	Zapril
Tab 2.5 mg – 1% DV Sep-13 to 2016	4.31	90	Zapril
Tab 5 mg – 1% DV Sep-13 to 2016	6.98	90	Zapril

ENALAPRIL MALEATE

Tab 5 mg – 1% DV Sep-15 to 2018	0.96	100	Ethics Enalapril
Tab 10 mg – 1% DV Sep-15 to 2018	1.24	100	Ethics Enalapril
Tab 20 mg – 1% DV Sep-15 to 2018	1.78	100	Ethics Enalapril

LISINOPRIL

Tab 5 mg	3.58	90	Arrow-Lisinopril
Tab 10 mg	4.08	90	Arrow-Lisinopril
Tab 20 mg	4.88	90	Arrow-Lisinopril

PERINDOPRIL

Tab 2 mg – 1% DV Oct-14 to 2017	3.75	30	Apo-Perindopril
Tab 4 mg – 1% DV Oct-14 to 2017	4.80	30	Apo-Perindopril

QUINAPRIL

Tab 5 mg – 1% DV Sep-15 to 2018	4.31	90	Arrow-Quinapril 5
Tab 10 mg – 1% DV Sep-15 to 2018	3.15	90	Arrow-Quinapril 10
Tab 20 mg – 1% DV Sep-15 to 2018	5.97	90	Arrow-Quinapril 20

TRANDOLAPRIL – **Restricted**: For continuation only

☞ Cap 1 mg

☞ Cap 2 mg

ACE Inhibitors with Diuretics

CILAZAPRIL WITH HYDROCHLOROTHIAZIDE

Tab 5 mg with hydrochlorothiazide 12.5 mg – 1% DV Mar-14 to 2016	10.72	100	Apo-Cilazapril/ Hydrochlorothiazide
--	-------	-----	--

ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE – **Restricted**: For continuation only

☞ Tab 20 mg with hydrochlorothiazide 12.5 mg

QUINAPRIL WITH HYDROCHLOROTHIAZIDE

Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-15 to 2018	3.65	30	Accuretic 10
Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-15 to 2018	4.78	30	Accuretic 20

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Angiotensin II Antagonists			
CANDESARTAN CILEXETIL – Restricted see terms below			
⚡ Tab 4 mg – 1% DV Sep-15 to 2018	2.50	90	Candestar
⚡ Tab 8 mg – 1% DV Sep-15 to 2018	3.68	90	Candestar
⚡ Tab 16 mg – 1% DV Sep-15 to 2018	6.12	90	Candestar
⚡ Tab 32 mg – 1% DV Sep-15 to 2018	10.66	90	Candestar
➡ Restricted			
ACE inhibitor intolerance			
Either:			
1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or			
2 Patient has a history of angioedema.			
Unsatisfactory response to ACE inhibitor			
Patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.			
LOSARTAN POTASSIUM			
Tab 12.5 mg – 1% DV Jan-15 to 2017	1.55	84	Losartan Actavis
Tab 25 mg – 1% DV Jan-15 to 2017	1.90	84	Losartan Actavis
Tab 50 mg – 1% DV Jan-15 to 2017	2.25	84	Losartan Actavis
Tab 100 mg – 1% DV Jan-15 to 2017	2.60	84	Losartan Actavis
Angiotensin II Antagonists with Diuretics			
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE			
Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-14 to 2017	2.18	30	Arrow-Losartan & Hydrochlorothiazide
Alpha-Adrenoceptor Blockers			
DOXAZOSIN			
Tab 2 mg – 1% DV Sep-14 to 2017	6.75	500	Apo-Doxazosin
Tab 4 mg – 1% DV Sep-14 to 2017	9.67	500	Apo-Doxazosin
PHENOXYBENZAMINE HYDROCHLORIDE			
Cap 10 mg			
Inj 50 mg per ml, 2 ml ampoule			
PHENTOLAMINE MESYLATE			
Inj 10 mg per ml, 1 ml ampoule			
PRAZOSIN			
Tab 1 mg	5.53	100	Apo-Prazosin
Tab 2 mg	7.00	100	Apo-Prazosin
Tab 5 mg	11.70	100	Apo-Prazosin
TERAZOSIN			
Tab 1 mg – 1% DV Sep-13 to 2016	0.50	28	Arrow
Tab 2 mg – 1% DV Sep-13 to 2016	0.45	28	Arrow
Tab 5 mg – 1% DV Sep-13 to 2016	0.68	28	Arrow
Antiarrhythmics			
ADENOSINE			
Inj 3 mg per ml, 2 ml vial			
⚡ Inj 3 mg per ml, 10 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
For use in cardiac catheterisation, electrophysiology and MRI.			
AJMALINE – Restricted see terms below			
⚡ Inj 5 mg per ml, 10 ml ampoule			
➔Restricted			
Cardiologist			
AMIODARONE HYDROCHLORIDE			
Tab 100 mg			
Tab 200 mg			
Inj 50 mg per ml, 3 ml ampoule – 1% DV Aug-13 to 2016	22.80	6	Cordarone-X
ATROPINE SULPHATE			
Inj 600 mcg per ml, 1 ml ampoule	71.00	50	AstraZeneca
DIGOXIN			
Tab 62.5 mcg			
Tab 250 mcg			
Oral liq 50 mcg per ml			
Inj 250 mcg per ml, 2 ml vial			
DISOPYRAMIDE PHOSPHATE			
Cap 100 mg			
Cap 150 mg			
FLECAINIDE ACETATE			
Tab 50 mg	38.95	60	Tambocor
Tab 100 mg	68.78	60	Tambocor
Cap long-acting 100 mg	38.95	30	Tambocor CR
Cap long-acting 200 mg	68.78	30	Tambocor CR
Inj 10 mg per ml, 15 ml ampoule	52.45	5	Tambocor
MEXILETINE HYDROCHLORIDE			
Cap 150 mg	162.00	100	Mexiletine Hydrochloride USP
Cap 250 mg	202.00	100	Mexiletine Hydrochloride USP
PROPAFENONE HYDROCHLORIDE			
Tab 150 mg			

Antihypotensives

MIDODRINE – **Restricted** see terms below

⚡ Tab 2.5 mg

⚡ Tab 5 mg

➔Restricted

Patient has disabling orthostatic hypotension not due to drugs.

Beta-Adrenoceptor Blockers

ATENOLOL

Tab 50 mg – 1% DV Sep-15 to 2018	4.61	500	Mylan Atenolol
Tab 100 mg – 1% DV Sep-15 to 2018	7.67	500	Mylan Atenolol
Oral liq 5 mg per ml	21.25	300 ml	Atenolol-AFT

CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BISOPROLOL FUMARATE			
Tab 2.5 mg – 1% DV Mar-15 to 2017	2.40	30	Bosvate
Tab 5 mg – 1% DV Mar-15 to 2017	3.50	30	Bosvate
Tab 10 mg – 1% DV Mar-15 to 2017	6.40	30	Bosvate
CARVEDILOL			
Tab 6.25 mg – 1% DV Jun-15 to 2017	3.90	60	Dicarz
Tab 12.5 mg – 1% DV Jun-15 to 2017	5.10	60	Dicarz
Tab 25 mg – 1% DV Jun-15 to 2017	6.30	60	Dicarz
CELIPROLOL			
Tab 200 mg	21.40	180	Celol
ESMOLOL HYDROCHLORIDE			
Inj 10 mg per ml, 10 ml vial			
LABETALOL			
Tab 50 mg	8.23	100	Hybloc
Tab 100 mg	10.06	100	Hybloc
Tab 200 mg	17.55	100	Hybloc
Tab 400 mg			
Inj 5 mg per ml, 20 ml ampoule			
METOPROLOL SUCCINATE			
Tab long-acting 23.75 mg	0.96	30	Metoprolol - AFT CR
Tab long-acting 47.5 mg	1.41	30	Metoprolol - AFT CR
Tab long-acting 95 mg	2.42	30	Metoprolol - AFT CR
Tab long-acting 190 mg	4.66	30	Metoprolol - AFT CR
METOPROLOL TARTRATE			
Tab 50 mg	16.00	100	Lopresor
Tab 100 mg	21.00	60	Lopresor
Tab long-acting 200 mg	18.00	28	Slow-Lopresor
Inj 1 mg per ml, 5 ml vial	24.00	5	Lopresor
NADOLOL			
Tab 40 mg – 1% DV Oct-15 to 2018	16.05	100	Apo-Nadolol
Tab 80 mg – 1% DV Oct-15 to 2018	24.70	100	Apo-Nadolol
PINDOLOL			
Tab 5 mg – 1% DV Nov-13 to 2016	9.72	100	Apo-Pindolol
Tab 10 mg – 1% DV Nov-13 to 2016	15.62	100	Apo-Pindolol
Tab 15 mg – 1% DV Nov-13 to 2016	23.46	100	Apo-Pindolol
PROPRANOLOL			
Tab 10 mg	3.65	100	Apo-Propranolol
Tab 40 mg	4.65	100	Apo-Propranolol
Cap long-acting 160 mg	18.17	100	Cardinol LA
Oral liq 4 mg per ml			
Inj 1 mg per ml, 1 ml ampoule			
SOTALOL			
Tab 80 mg	27.50	500	Mylan
Tab 160 mg	10.50	100	Mylan
Inj 10 mg per ml, 4 ml ampoule	65.39	5	Sotacor
TIMOLOL MALEATE			
Tab 10 mg			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST)	Brand or Generic
\$	Per Manufacturer

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

AMLODIPINE

Tab 2.5 mg – 1% DV Feb-15 to 2017	2.21	100	Apo-Amlodipine
Tab 5 mg – 1% DV May-15 to 2017	5.04	250	Apo-Amlodipine
Tab 10 mg – 1% DV May-15 to 2017	7.21	250	Apo-Amlodipine

FELODIPINE

Tab long-acting 2.5 mg – 1% DV Sep-15 to 2018	1.45	30	Plendil ER
Tab long-acting 5 mg – 1% DV Sep-15 to 2018	1.55	30	Plendil ER
Tab long-acting 10 mg – 1% DV Sep-15 to 2018	2.30	30	Plendil ER

ISRADIPINE

Tab 2.5 mg
Cap 2.5 mg
Cap long-acting 2.5 mg
Cap long-acting 5 mg

NICARDIPINE HYDROCHLORIDE – **Restricted** see terms below

☞ Inj 2.5 mg per ml, 10 ml vial

☞ **Restricted**

Anaesthetist, intensivist or paediatric cardiologist

Both:

- 1 Patient is a paediatric patient; and
- 2 Any of the following:
 - 2.1 Patient has hypertension requiring urgent treatment with an intravenous agent; or
 - 2.2 Patient has excessive ventricular afterload; or
 - 2.3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.

NIFEDIPINE

Tab long-acting 10 mg			
Tab long-acting 20 mg	9.59	100	Nyefax Retard
Tab long-acting 30 mg – 1% DV Sep-14 to 2017	3.75	30	Adefin XL
Tab long-acting 60 mg – 1% DV Sep-14 to 2017	5.75	30	Adefin XL
Cap 5 mg			

NIMODIPINE

Tab 30 mg
Inj 200 mcg per ml, 50 ml vial

Other Calcium Channel Blockers

DILTIAZEM HYDROCHLORIDE

Tab 30 mg	4.60	100	Dilzem
Tab 60 mg	8.50	100	Dilzem
Cap long-acting 120 mg	1.91	30	Cardizem CD
	31.83	500	Apo-Diltiazem CD
Cap long-acting 180 mg	7.56	30	Cardizem CD
	47.67	500	Apo-Diltiazem CD
Cap long-acting 240 mg	10.22	30	Cardizem CD
	63.58	500	Apo-Diltiazem CD
Inj 5 mg per ml, 5 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PERHEXILINE MALEATE			
Tab 100 mg	62.90	100	Pexsig
VERAPAMIL HYDROCHLORIDE			
Tab 40 mg	7.01	100	Isoptin
Tab 80 mg – 1% DV Sep-14 to 2017	11.74	100	Isoptin
Tab long-acting 120 mg	15.20	250	Verpamil SR
Tab long-acting 240 mg	25.00	250	Verpamil SR
Inj 2.5 mg per ml, 2 ml ampoule	7.54	5	Isoptin

Centrally-Acting Agents

CLONIDINE			
Patch 2.5 mg, 100 mcg per day – 1% DV Jul-14 to 2017	12.80	4	Catapres-TTS-1
Patch 5 mg, 200 mcg per day – 1% DV Jul-14 to 2017	18.04	4	Catapres-TTS-2
Patch 7.5 mg, 300 mcg per day – 1% DV Jul-14 to 2017	22.68	4	Catapres-TTS-3
CLONIDINE HYDROCHLORIDE			
Tab 25 mcg – 1% DV Sep-15 to 2018	10.53	112	Clonidine BNM
Tab 150 mcg	34.32	100	Catapres
Inj 150 mcg per ml, 1 ml ampoule	16.07	5	Catapres
METHYLDOPA			
Tab 125 mg	14.25	100	Prodopa
Tab 250 mg	15.10	100	Prodopa
Tab 500 mg	23.15	100	Prodopa

Diuretics

Loop Diuretics

BUMETANIDE			
Tab 1 mg	16.36	100	Burinex
Inj 500 mcg per ml, 4 ml vial			
FUROSEMIDE (FRUSEMIDE)			
Tab 40 mg – 1% DV Sep-15 to 2018	8.00	1,000	Diurin 40
Tab 500 mg – 1% DV Sep-15 to 2018	25.00	50	Urex Forte
Oral liq 10 mg per ml			
Inj 10 mg per ml, 2 ml ampoule	1.30	5	Frusemide-Claris
Inj 10 mg per ml, 25 ml ampoule			

Osmotic Diuretics

MANNITOL			
Inj 10%, 1,000 ml bag	14.21	1,000 ml	Baxter
Inj 15%, 500 ml bag	9.84	500 ml	Baxter
Inj 20%, 500 ml bag	10.80	500 ml	Baxter

Potassium Sparing Combination Diuretics

AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE			
Tab 5 mg with furosemide 40 mg			
AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE			
Tab 5 mg with hydrochlorothiazide 50 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Potassium Sparing Diuretics			
AMILORIDE HYDROCHLORIDE			
Tab 5 mg	17.50	100	Apo-Amiloride
Oral liq 1 mg per ml	30.00	25 ml	Biomed
SPIRONOLACTONE			
Tab 25 mg – 1% DV Sep-13 to 2016	3.65	100	Spiractin
Tab 100 mg – 1% DV Sep-13 to 2016	11.80	100	Spiractin
Oral liq 5 mg per ml	30.00	25 ml	Biomed
Thiazide and Related Diuretics			
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]			
Tab 2.5 mg – 1% DV Sep-14 to 2017	5.48	500	Arrow-Bendrofluazide
Tab 5 mg – 1% DV Sep-14 to 2017	8.95	500	Arrow-Bendrofluazide
CHLOROTHIAZIDE			
Oral liq 50 mg per ml	26.00	25 ml	Biomed
CHLORTALIDONE [CHLORTHALIDONE]			
Tab 25 mg	8.00	50	Hygroton
INDAPAMIDE			
Tab 2.5 mg – 1% DV Oct-13 to 2016	2.25	90	Dapa-Tabs
METOLAZONE – Restricted see terms below			
⬇ Tab 5 mg			
➡ Restricted			
Either:			
1 Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide combination therapy; or			
2 Patient has severe refractory nephrotic oedema unresponsive to high dose loop diuretics and concentrated albumin infusions			
Lipid-Modifying Agents			
Fibrates			
BEZAFIBRATE			
Tab 200 mg – 1% DV Oct-15 to 2018	9.05	90	Bezalip
Tab long-acting 400 mg – 1% DV Oct-15 to 2018	6.78	30	Bezalip Retard
GEMFIBROZIL			
Tab 600 mg – 1% DV Nov-13 to 2016	17.60	60	Lipazil
HMG CoA Reductase Inhibitors (Statins)			
ATORVASTATIN			
Tab 10 mg	2.52	90	Zarator
Tab 20 mg	4.17	90	Zarator
Tab 40 mg	7.32	90	Zarator
Tab 80 mg	16.23	90	Zarator
PRAVASTATIN			
Tab 10 mg			
Tab 20 mg – 1% DV Oct-14 to 2017	3.45	30	Cholvastin
Tab 40 mg – 1% DV Oct-14 to 2017	6.36	30	Cholvastin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SIMVASTATIN			
Tab 10 mg – 1% DV Sep-14 to 2017	0.95	90	Arrow-Simva
Tab 20 mg – 1% DV Sep-14 to 2017	1.61	90	Arrow-Simva
Tab 40 mg – 1% DV Sep-14 to 2017	2.83	90	Arrow-Simva
Tab 80 mg – 1% DV Sep-14 to 2017	7.91	90	Arrow-Simva

Resins

CHOLESTYRAMINE

Powder for oral liq 4 g

COLESTIPOL HYDROCHLORIDE

Grans for oral liq 5 g

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – **Restricted** see terms below

⚡ Tab 10 mg – 1% DV Aug-15 to 2017 3.35 30 **Ezemibe**

➡ **Restricted**

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

EZETIMIBE WITH SIMVASTATIN – **Restricted** see terms below

⚡ Tab 10 mg with simvastatin 10 mg – 1% DV Aug-15 to 2017 5.15 30 **Zimybe**

⚡ Tab 10 mg with simvastatin 20 mg – 1% DV Aug-15 to 2017 6.15 30 **Zimybe**

⚡ Tab 10 mg with simvastatin 40 mg – 1% DV Aug-15 to 2017 7.15 30 **Zimybe**

⚡ Tab 10 mg with simvastatin 80 mg – 1% DV Aug-15 to 2017 8.15 30 **Zimybe**

➡ **Restricted**

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Other Lipid-Modifying Agents

ACIPIMOX

Cap 250 mg

NICOTINIC ACID

Tab 50 mg – 1% DV Oct-14 to 2017 3.96 100 **Apo-Nicotinic Acid**

Tab 500 mg – 1% DV Oct-14 to 2017 17.37 100 **Apo-Nicotinic Acid**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Nitrates			
GLYCERYL TRINITRATE			
Tab 600 mcg	8.00	100	Lycinate
Inj 1 mg per ml, 5 ml ampoule	22.70	10	Nitronal
Inj 1 mg per ml, 50 ml vial	86.60	10	Nitronal
Inj 5 mg per ml, 10 ml ampoule	100.00	5	Hospira
Oral pump spray, 400 mcg per dose	4.45	250 dose	Nitrolingual Pump Spray
Oral spray, 400 mcg per dose	4.45	250 dose	Glytrin
Patch 25 mg, 5 mg per day – 1% DV Sep-14 to 2017	15.73	30	Nitroderm TTS 5
Patch 50 mg, 10 mg per day – 1% DV Sep-14 to 2017	18.62	30	Nitroderm TTS 10
ISOSORBIDE MONONITRATE			
Tab 20 mg – 1% DV Sep-14 to 2017	17.10	100	Ismo-20
Tab long-acting 40 mg	7.50	30	Ismo 40 Retard
Tab long-acting 60 mg	3.94	90	Duride
Other Cardiac Agents			
LEVOSIMENDAN – Restricted see terms below			
⚡ Inj 2.5 mg per ml, 5 ml vial			
⚡ Inj 2.5 mg per ml, 10 ml vial			
➡ Restricted			
Heart transplant			
Either:			
1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or			
2 For the treatment of heart failure following heart transplant.			
Heart failure			
cardiologist or intensivist			
For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.			
Sympathomimetics			
ADRENALINE			
Inj 1 in 1,000, 1 ml ampoule	4.98	5	Aspen Adrenaline
	5.25		Hospira
Inj 1 in 1,000, 30 ml vial			
Inj 1 in 10,000, 10 ml ampoule	27.00	5	Hospira
	49.00	10	Aspen Adrenaline
Inj 1 in 10,000, 10 ml syringe			
DOBUTAMINE HYDROCHLORIDE			
Inj 12.5 mg per ml, 20 ml vial			
DOPAMINE HYDROCHLORIDE			
Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	16.89	5	DBL Sterile Dopamine Concentrate
	69.77	10	Martindale
<i>(Martindale Inj 40 mg per ml, 5 ml ampoule to be delisted 1 September 2015)</i>			
EPHEDRINE			
Inj 3 mg per ml, 10 ml syringe			
Inj 30 mg per ml, 1 ml ampoule – 1% DV Mar-15 to 2017	51.48	10	Max Health

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ISOPRENALINE			
Inj 200 mcg per ml, 1 ml ampoule			
Inj 200 mcg per ml, 5 ml ampoule			
METARAMINOL			
Inj 0.5 mg per ml, 20 ml syringe			
Inj 1 mg per ml, 1 ml ampoule			
Inj 1 mg per ml, 10 ml syringe			
Inj 10 mg per ml, 1 ml ampoule			
NORADRENALINE			
Inj 0.06 mg per ml, 100 ml bag			
Inj 0.06 mg per ml, 50 ml syringe			
Inj 0.1 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 50 ml syringe			
Inj 0.16 mg per ml, 50 ml syringe			
Inj 1 mg per ml, 100 ml bag			
Inj 1 mg per ml, 4 ml ampoule			
PHENYLEPHRINE HYDROCHLORIDE			
Inj 10 mg per ml, 1 ml vial	115.50	25	Neosynephrine HCL
Vasodilators			
ALPROSTADIL HYDROCHLORIDE			
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Oct-15 to 2018	1,650.00	5	Prostin VR
AMYL NITRITE			
Liq 98% in 3 ml capsule			
DIAZOXIDE			
Inj 15 mg per ml, 20 ml ampoule			
HYDRALAZINE HYDROCHLORIDE			
⚡ Tab 25 mg			
➡ Restricted			
Either:			
1 For the treatment of refractory hypertension; or			
2 For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.			
Inj 20 mg ampoule	25.90	5	Apresoline
MILRINONE			
Inj 1 mg per ml, 10 ml ampoule			
MINOXIDIL – Restricted see terms below			
⚡ Tab 10 mg	70.00	100	Loniten
➡ Restricted			
For patients with severe refractory hypertension who have failed to respond to extensive multiple therapies.			
NICORANDIL			
Tab 10 mg	27.95	60	Ikorel
Tab 20 mg	33.28	60	Ikorel
PAPAVERINE HYDROCHLORIDE			
Inj 30 mg per ml, 1 ml vial			
Inj 12 mg per ml, 10 ml ampoule	217.90	5	Hospira

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PENTOXIFYLLINE [OXPENTIFYLLINE]			
Tab 400 mg			
SODIUM NITROPRUSSIDE			
Inj 50 mg vial			

Endothelin Receptor Antagonists

AMBRISSENTAN – **Restricted** see terms below

⚡ Tab 5 mg	4,585.00	30	Volibris
⚡ Tab 10 mg	4,585.00	30	Volibris

➡ **Restricted**

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 In hospital stabilisations in emergency situations.

BOSENTAN – **Restricted** see terms below

⚡ Tab 62.5 mg – 1% DV Jan-16 to 2018	375.00	56	Mylan-Bosentan
	1,500.00	60	pms-Bosentan
	4,585.00		Tracleer
⚡ Tab 125 mg – 1% DV Jan-16 to 2018	375.00	56	Mylan-Bosentan
	1,500.00	60	pms-Bosentan
	4,585.00		Tracleer

(pms-Bosentan Tab 62.5 mg to be delisted 1 January 2016)

(Tracleer Tab 62.5 mg to be delisted 1 January 2016)

(pms-Bosentan Tab 125 mg to be delisted 1 January 2016)

(Tracleer Tab 125 mg to be delisted 1 January 2016)

➡ **Restricted**

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 In hospital stabilisation in emergency situations.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – **Restricted** see terms below

⚡ Tab 25 mg – 1% DV Sep-15 to 2018	0.75	4	Vedafil
	1.85		Silagra
⚡ Tab 50 mg – 1% DV Sep-15 to 2018	0.75	4	Vedafil
	1.85		Silagra
⚡ Tab 100 mg – 1% DV Sep-15 to 2018	2.75	4	Vedafil
	7.45		Silagra

(Silagra Tab 25 mg to be delisted 1 September 2015)

(Silagra Tab 50 mg to be delisted 1 September 2015)

(Silagra Tab 100 mg to be delisted 1 September 2015)

➡ **Restricted**

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
- 3 For use in weaning patients from inhaled nitric oxide; or
- 4 For perioperative use in cardiac surgery patients; or
- 5 For use in intensive care as an alternative to nitric oxide; or
- 6 In-hospital stabilisation in emergency situations; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

7 All of the following:

- 7.1 Patient has Raynaud's phenomenon; and
- 7.2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 7.3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
- 7.4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

Prostacyclin Analogues

ILOPROST

Inj 50 mcg in 0.5 ml ampoule – 1% DV Sep-15 to 2016	89.50	1	Arrow-Iloprost
¶ Nebuliser soln 10 mcg per ml, 2 ml	1,185.00	30	Ventavis

➡**Restricted**

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For diagnostic use in catheter laboratories; or
- 3 For use following mitral or tricuspid valve surgery; or
- 4 In hospital stabilisation in emergency situations.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
FUSIDIC ACID			
Crm 2% – 1% DV Jan-15 to 2016	2.52	15 g	DP Fusidic Acid Cream
Oint 2% – 1% DV Sep-13 to 2016	3.45	15 g	Foban
HYDROGEN PEROXIDE			
Crm 1%	8.56	15 g	Crystaderm
Soln 3% (10 vol)			
MAFENIDE ACETATE – Restricted see terms below			
↓ Powder 50 g sachet			
➔ Restricted			
For the treatment of burns patients.			
MUPIROCIN			
Oint 2%			
SULPHADIAZINE SILVER			
Crm 1%	12.30	50 g	Flamazine
Antifungals			
AMOROLFINE			
Nail soln 5% – 1% DV Jan-15 to 2017	19.95	5 ml	Myc Nail
CICLOPIROX OLAMINE			
Nail soln 8% – 1% DV Sep-15 to 2018	6.50	7 ml	Apo-Ciclopirox
➔ Soln 1% – Restricted: For continuation only			
CLOTTRIMAZOLE			
Crm 1% – 1% DV Sep-14 to 2017	0.52	20 g	Clomazol
➔ Soln 1% – Restricted: For continuation only			
ECONAZOLE NITRATE			
➔ Crm 1% – Restricted: For continuation only			
Foaming soln 1%			
KETOCONAZOLE			
Shampoo 2% – 1% DV Dec-14 to 2017	2.99	100 ml	Sebizole
METRONIDAZOLE			
Gel 0.75%			
MICONAZOLE NITRATE			
Crm 2% – 1% DV Mar-15 to 2017	0.55	15 g	Multichem
➔ Lotn 2% – Restricted: For continuation only			
Tinc 2%			
NYSTATIN			
Crm 100,000 u per g			
Antiparasitics			
LINDANE [GAMMA BENZENE HEXACHLORIDE]			
Crm 1%			
(Any Crm 1% to be delisted 1 January 2016)			

DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MALATHION [MALDISON] Lotn 0.5% Shampoo 1%			
MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2% Note: Temporary listing to cover out-of-stock.			
PERMETHRIN Crm 5% – 1% DV Apr-15 to 2017	4.20	30 g	Lyderm
Lotn 5% – 1% DV Sep-14 to 2017	3.19	30 ml	A-Scabies

Antiacne Preparations

ADAPALENE Crm 0.1% Gel 0.1%			
BENZOYL PEROXIDE Soln 5%			
ISOTRETINOIN Cap 10 mg	18.71	120	Oratane
Cap 20 mg	28.91	120	Oratane
TRETINOIN Crm 0.05%			

Antipruritic Preparations

CALAMINE Crm, aqueous, BP	1.77	100 g	Pharmacy Health
Lotn, BP	13.45	2,000 ml	PSM
CROTAMITON Crm 10% – 1% DV Sep-15 to 2018	3.37	20 g	Itch-Soothe

Barrier Creams and Emollients

Barrier Creams

DIMETHICONE Crm 5% tube – 1% DV Apr-14 to 2016	1.65	100 g	healthE Dimethicone 5%
Crm 5% pump bottle – 1% DV Apr-14 to 2016	4.73	500 ml	healthE Dimethicone 5%
ZINC Crm			e.g. Zinc Cream (Orion); Zinc Cream (PSM)
Oint Paste			e.g. Zinc oxide (PSM)
ZINC AND CASTOR OIL Crm	1.63	20 g	Orion
Oint, BP – 1% DV Jul-15 to 2017	1.39	20 g	healthE

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ZINC WITH WOOL FAT			
Crm zinc 15.25% with wool fat 4%			<i>e.g. Sudocrem</i>
Emollients			
AQUEOUS CREAM			
Crm 100 g	1.23	100 g	AFT
Crm 500 g	1.96	500 g	AFT
CETOMACROGOL			
Crm BP, 500 g	3.50	500 g	Pharmacy Health
Crm BP, 100 g	1.65	1	healthE
CETOMACROGOL WITH GLYCEROL			
Crm 90% with glycerol 10%,	2.10	100 g	Pharmacy Health
	2.00		Pharmacy Health
	3.20		healthE
Crm 90% with glycerol 10%	4.50	500 ml	Pharmacy Health
			Sorbolene with Glycerin
	6.50	1,000 ml	Pharmacy Health
			Sorbolene with Glycerin
Crm 90% with glycerol 10%, 500 ml, 1 bottle	5.46	1	healthE
EMULSIFYING OINTMENT			
Oint BP – 1% DV Apr-15 to 2017	1.84	100 g	Jaychem
Note: DV limit applies to pack sizes of less than 200 g.			
Oint BP, 500 g – 1% DV Jul-15 to 2017	2.73	500 g	AFT
Note: DV limit applies to pack sizes of greater than 200 g.			
GLYCEROL WITH PARAFFIN			
Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%			<i>e.g. QV cream</i>
OIL IN WATER EMULSION			
Crm	2.63	500 g	healthE Fatty Cream
Crm, 100 g	1.60	1	healthE Fatty Cream
PARAFFIN			
Oint liquid paraffin 50% with white soft paraffin 50%	3.10	100 g	healthE
White soft – 1% DV Sep-15 to 2018	0.85	10 g	healthE
Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.			
Yellow soft			
PARAFFIN WITH WOOL FAT			
Lotn liquid paraffin 15.9% with wool fat 0.6%			<i>e.g. AlphaKeri;BK ;DP; Hydroderm Lotn</i>
Lotn liquid paraffin 91.7% with wool fat 3%			<i>e.g. Alpha Keri Bath Oil</i>
UREA			
Crm 10%			
WOOL FAT			
Crm			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Corticosteroids			
BETAMETHASONE DIPROPIONATE			
Crm 0.05%			
Oint 0.05%			
BETAMETHASONE VALERATE			
Crm 0.1% – 1% DV Jun-15 to 2018	3.15	50 g	Beta Cream
Oint 0.1% – 1% DV Jun-15 to 2018	3.15	50 g	Beta Ointment
Lotn 0.1%			
CLOBETASOL PROPIONATE			
Crm 0.05% – 1% DV Jul-15 to 2016	3.20	30 g	Clobetasol BNM
Oint 0.05% – 1% DV Jul-15 to 2016	3.20	30 g	Clobetasol BNM
CLOBETASONE BUTYRATE			
Crm 0.05%			
DIFLUCORTOLONE VALERATE – Restricted: For continuation only			
➡ Crm 0.1%			
➡ Fatty oint 0.1%			
HYDROCORTISONE			
Crm 1%, 100 g	3.75	100 g	Pharmacy Health
Crm 1%, 500 g	14.00	500 g	Pharmacy Health
HYDROCORTISONE ACETATE			
Crm 1%	2.48	14.2 g	AFT
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN			
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – 1% DV Dec-14 to 2017	10.57	250 ml	DP Lotn HC
HYDROCORTISONE BUTYRATE			
Crm 0.1%	2.30	30 g	Locoid Lipocream
	6.85	100 g	Locoid Lipocream
Oint 0.1%	6.85	100 g	Locoid
Milky emul 0.1%	6.85	100 ml	Locoid Crelo
HYDROCORTISONE WITH PARAFFIN AND WOOL FAT			
Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%			
METHYLPREDNISOLONE ACEPONATE			
Crm 0.1%	4.95	15 g	Advantan
Oint 0.1%	4.95	15 g	Advantan
MOMETASONE FUROATE			
Crm 0.1%	1.78	15 g	m-Mometasone
	3.42	45 g	m-Mometasone
Oint 0.1%	1.78	15 g	m-Mometasone
	3.42	45 g	m-Mometasone
Lotn 0.1% – 1% DV Sep-15 to 2018	7.35	30 ml	Elocon
TRIAMCINOLONE ACETONIDE			
Crm 0.02% – 1% DV Apr-15 to 2017	6.30	100 g	Aristocort
Oint 0.02% – 1% DV Apr-15 to 2017	6.35	100 g	Aristocort

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Corticosteroids with Anti-Infective Agents			
BETAMETHASONE VALERATE WITH CLIOQUINOL – Restricted see terms below			
☞ Crm 0.1% with clioquinol 3%			
☞ Restricted			
Either:			
1 For the treatment of intertrigo; or			
2 For continuation use			
BETAMETHASONE VALERATE WITH FUSIDIC ACID			
Crm 0.1% with fusidic acid 2%			
HYDROCORTISONE WITH MICONAZOLE			
Crm 1% with miconazole nitrate 2% – 1% DV Sep-15 to 2018	2.00	15 g	Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN			
Crm 1% with natamycin 1% and neomycin sulphate 0.5%	2.79	15 g	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	2.79	15 g	Pimafucort
TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN			
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g			

Psoriasis and Eczema Preparations

ACITRETIN			
Cap 10 mg – 1% DV Nov-14 to 2017	17.86	60	Novatretin
Cap 25 mg – 1% DV Nov-14 to 2017	41.36	60	Novatretin
BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL			
Gel 500 mcg with calcipotriol 50 mcg per g – 1% DV Sep-15 to 2018	26.12	30 g	Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g – 1% DV Sep-15 to 2018	26.12	30 g	Daivobet
CALCIPOTRIOL			
Crm 50 mcg per g	45.00	100 g	Daivonex
Oint 50 mcg per g	45.00	100 g	Daivonex
Soln 50 mcg per ml	16.00	30 ml	Daivonex
COAL TAR WITH SALICYLIC ACID AND SULPHUR			
Oint 12% with salicylic acid 2% and sulphur 4%			
COAL TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN			
Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium	3.36	500 ml	Pinetarsol
	5.82	1,000 ml	Pinetarsol
METHOXSALEN [8-METHOXYPSORALEN]			
Tab 10 mg			
Lotn 1.2%			
POTASSIUM PERMANGANATE			
Tab 400 mg			
Crystals			

Scalp Preparations

BETAMETHASONE VALERATE			
Scalp app 0.1%	7.75	100 ml	Beta Scalp

DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CLOBETASOL PROPIONATE			
Scalp app 0.05%	6.96	30 ml	Dermol
HYDROCORTISONE BUTYRATE			
Scalp lotn 0.1%	3.65	100 ml	Locoid

Wart Preparations

IMIQUIMOD			
Crm 5%, 250 mg sachet – 1% DV Feb-15 to 2017	17.98	12	Apo-Imiquimod Cream 5%
PODOPHYLLOTOXIN			
Soln 0.5%	33.60	3.5 ml	Condyline
SILVER NITRATE			
Sticks with applicator			

Other Skin Preparations

DIPHEMANIL METILSULFATE			
Powder 2%			
SUNSCREEN, PROPRIETARY			
Crm			
Lotn	3.30	100 g	Marine Blue Lotion SPF 50+
	5.10	200 g	Marine Blue Lotion SPF 50+

Antineoplastics

FLUOROURACIL SODIUM			
Crm 5% – 1% DV Sep-15 to 2018	8.95	20 g	Efudix
METHYL AMINOLEVULINATE HYDROCHLORIDE – Restricted see terms below			
☞ Crm 16%			
☞ Restricted			
Dermatologist or plastic surgeon			

Wound Management Products

CALCIUM GLUCONATE			
Gel 2.5%	21.00	1	healthE

Price (ex man. excl. GST)	Brand or Generic
\$	Per Manufacturer

Anti-Infective Agents

ACETIC ACID

- Soln 3%
- Soln 5%

ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID

- Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator

CHLORHEXIDINE GLUCONATE

- | | | | |
|---|------|------|----------------|
| Crm 1% – 1% DV Sep-15 to 2018 | 1.21 | 50 g | healthE |
| Lotn 1%, 200 ml – 1% DV Sep-15 to 2018 | 2.98 | 1 | healthE |

CLOTRIMAZOLE

- | | | | |
|--|------|------|-----------------|
| Vaginal crm 1% with applicator – 1% DV Dec-13 to 2016 | 1.45 | 35 g | Clomazol |
| Vaginal crm 2% with applicator – 1% DV Dec-13 to 2016 | 2.20 | 20 g | Clomazol |

MICONAZOLE NITRATE

- | | | | |
|--|------|------|----------------|
| Vaginal crm 2% with applicator – 1% DV Oct-14 to 2017 | 3.95 | 40 g | Micreme |
|--|------|------|----------------|

NYSTATIN

- Vaginal crm 100,000 u per 5 g with applicator(s)

Contraceptives

Antiandrogen Oral Contraceptives

CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

- | | | | |
|--|------|-----|--------------|
| Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets – 1% DV Dec-14 to 2017 | 5.36 | 168 | Ginet |
|--|------|-----|--------------|

Combined Oral Contraceptives

ETHINYLOESTRADIOL WITH DESOGESTREL

- Tab 20 mcg with desogestrel 150 mcg
- Tab 30 mcg with desogestrel 150 mcg

ETHINYLOESTRADIOL WITH LEVONORGESTREL

- | | | | |
|--|------|----|------------------|
| Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets | 2.65 | 84 | Ava 20 ED |
| Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets | 2.30 | 84 | Ava 30 ED |
| Tab 20 mcg with levonorgestrel 100 mcg | | | |
| Tab 30 mcg with levonorgestrel 150 mcg | | | |
| Tab 50 mcg with levonorgestrel 125 mcg | 9.45 | 84 | Microgynon 50 ED |

ETHINYLOESTRADIOL WITH NORETHISTERONE

- Tab 35 mcg with norethisterone 1 mg
- Tab 35 mcg with norethisterone 500 mcg

NORETHISTERONE WITH MESTRANOL

- Tab 1 mg with mestranol 50 mcg

Contraceptive Devices

INTRA-UTERINE DEVICE

- | | | | |
|--|-------|---|-----------------------|
| IUD 29.1 mm length × 23.2 mm width | 31.60 | 1 | Choice TT380 Short |
| IUD 33.6 mm length × 29.9 mm width | 31.60 | 1 | Choice TT380 Standard |

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Emergency Contraception			
LEVONORGESTREL			
Tab 1.5 mg – 1% DV Jul-13 to 2016	3.50	1	Postinor-1
Progestogen-Only Contraceptives			
LEVONORGESTREL			
Tab 30 mcg			
Subdermal implant (2 × 75 mg rods) – 5% DV Oct-14 to 31 Dec 2017	133.65	1	Jadelle
⚡ Intra-uterine system, 20 mcg per day			<i>e.g. Mirena</i>
➡ Restricted			
Obstetrician or gynaecologist			
Initiation – heavy menstrual bleeding			
All of the following:			
1 The patient has a clinical diagnosis of heavy menstrual bleeding; and			
2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and			
3 Any of the following:			
3.1 Serum ferritin level < 16 mcg/l (within the last 12 months); or			
3.2 Haemoglobin level < 120 g/l; or			
3.3 The patient has had a uterine ultrasound and either a hysteroscopy or endometrial biopsy.			
Continuation – heavy menstrual bleeding			
Either:			
1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or			
2 Previous insertion was removed or expelled within 3 months of insertion.			
Initiation – endometriosis			
The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy.			
Continuation – endometriosis			
Either:			
1 Patient demonstrated satisfactory management of endometriosis; or			
2 Previous insertion was removed or expelled within 3 months of insertion.			
Note: endometriosis is an unregistered indication.			
MEDROXYPROGESTERONE ACETATE			
Inj 150 mg per ml, 1 ml syringe – 1% DV Sep-13 to 2016	7.00	1	Depo-Provera
NORETHISTERONE			
Tab 350 mcg – 1% DV Oct-15 to 2018	6.25	84	Noriday 28
Obstetric Preparations			
Antiprogestogens			
MIFEPRISTONE			
Tab 200 mg			
Oxytocics			
CARBOPROST TROMETAMOL			
Inj 250 mcg per ml, 1 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DINOPROSTONE			
Pessaries 10 mg			
Gel 1 mg in 2.5 ml	52.65	1	Prostin E2
Gel 2 mg in 2.5 ml	64.60	1	Prostin E2
ERGOMETRINE MALEATE			
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	94.70	5	DBL Ergometrine
OXYTOCIN			
Inj 5 iu per ml, 1 ml ampoule	4.75	5	Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule	5.98	5	BNM
OXYTOCIN WITH ERGOMETRINE MALEATE			
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1% DV Sep-15 to 2018	11.13	5	Syntometrine

Tocolytics

PROGESTERONE – Restricted see terms below

☛ Cap 100 mg 16.50 30 Utrogestan

☛ **Restricted**

Obstetrician or gynaecologist

Both:

- 1 For the prevention of pre-term labour*; and
- 2 Either:
 - 2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks) or
 - 2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 23.1).

TERBUTALINE – Restricted see terms below

☛ Inj 500 mcg ampoule

☛ **Restricted**

Obstetrician

Oestrogens

OESTRIOL

Crm 1 mg per g with applicator

Pessaries 500 mcg

Urologicals

5-Alpha Reductase Inhibitors

FINASTERIDE – Restricted see terms below

☛ Tab 5 mg – 1% DV Dec-14 to 2017 1.95 28 **Finpro**

☛ **Restricted**

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
 - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
 - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Alpha-1A Adrenoceptor Blockers			
TAMSULOSIN – Restricted see terms below			
☞ Cap 400 mcg – 1% DV Dec-13 to 2016	13.51	100	Tamsulosin-Rex
☞ Restricted			
Both:			
1 Patient has symptomatic benign prostatic hyperplasia; and			
2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.			
Urinary Alkalisers			
POTASSIUM CITRATE – Restricted see terms below			
☞ Oral liq 3 mmol per ml	30.00	200 ml	Biomed
☞ Restricted			
Both:			
1 The patient has recurrent calcium oxalate urolithiasis; and			
2 The patient has had more than two renal calculi in the two years prior to the application.			
SODIUM CITRO-TARTRATE			
Grans eff 4 g sachets – 1% DV Feb-15 to 2017	2.93	28	Ural
Urinary Antispasmodics			
OXYBUTYNIN			
Tab 5 mg – 1% DV Jun-13 to 2016	11.20	500	Apo-Oxybutynin
Oral liq 5 mg per 5 ml – 1% DV Jun-13 to 2016	56.45	473 ml	Apo-Oxybutynin
SOLIFENACIN SUCCINATE – Restricted see terms below			
☞ Tab 5 mg	37.50	30	Vesicare
☞ Tab 10 mg	37.50	30	Vesicare
☞ Restricted			
Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.			
TOLTERODINE TARTRATE – Restricted see terms below			
☞ Tab 1 mg	14.56	56	Arrow-Tolterodine
☞ Tab 2 mg	14.56	56	Arrow-Tolterodine
☞ Restricted			
Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.			

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Anabolic Agents

OXANDROLINE

⚡ Tab 2.5 mg

➡ **Restricted**

For the treatment of burns patients.

Androgen Agonists and Antagonists

CYPROTERONE ACETATE

Tab 50 mg – 1% DV Oct-15 to 2018	15.87	50	Procur
	18.80		Siterone
Tab 100 mg – 1% DV Oct-15 to 2018	30.40	50	Procur
	34.25		Siterone

(Siterone Tab 50 mg to be delisted 1 October 2015)

(Siterone Tab 100 mg to be delisted 1 October 2015)

TESTOSTERONE

Patch 2.5 mg per day	80.00	60	Androderm
----------------------------	-------	----	-----------

TESTOSTERONE CYPIONATE

Inj 100 mg per ml, 10 ml vial – 1% DV Sep-14 to 2017	76.50	1	Depo-Testosterone
--	-------	---	--------------------------

TESTOSTERONE ESTERS

Inj testosterone decanoate 100 mg, testosterone isocaproate 60 mg,
testosterone phenylpropionate 60 mg and testosterone propionate
30 mg per ml, 1 ml ampoule

TESTOSTERONE UNDECANOATE

Cap 40 mg – 1% DV Sep-15 to 2018	16.80	60	Andriol Testocaps
Inj 250 mg per ml, 4 ml vial	86.00	1	Reandron 1000

Calcium Homeostasis

CALCITONIN

Inj 100 iu per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	121.00	5	Miacalcic
--	--------	---	------------------

ZOLEDRONIC ACID

⚡ Inj 4 mg per 5 ml, vial	550.00	1	Zometa
---------------------------------	--------	---	--------

➡ **Restricted**

Oncologist, haematologist or palliative care specialist

Any of the following:

- 1 Patient has hypercalcaemia of malignancy; or
- 2 Both:
 - 2.1 Patient has bone metastases or involvement; and
 - 2.2 Patient has severe bone pain resistant to standard first-line treatments; or
- 3 Both:
 - 3.1 Patient has bone metastases or involvement; and
 - 3.2 Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

Corticosteroids

BETAMETHASONE

Tab 500 mcg
Inj 4 mg per ml, 1 ml ampoule

HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE			
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule			
DEXAMETHASONE			
Tab 1 mg	5.87	100	Douglas
Tab 4 mg	8.16	100	Douglas
Oral liq 1 mg per ml	45.00	25 ml	Biomed
DEXAMETHASONE PHOSPHATE			
Inj 4 mg per ml, 1 ml ampoule – 1% DV Apr-14 to 2016	25.80	10	Dexamethasone- hameln
Inj 4 mg per ml, 2 ml ampoule – 1% DV Apr-14 to 2016	17.98	5	Dexamethasone- hameln
FLUDROCORTISONE ACETATE			
Tab 100 mcg	14.32	100	Florinef
HYDROCORTISONE			
Tab 5 mg – 1% DV Sep-15 to 2018	8.10	100	Douglas
Tab 20 mg – 1% DV Sep-15 to 2018	20.32	100	Douglas
Inj 100 mg vial – 1% DV Oct-13 to 2016	4.99	1	Solu-Cortef
METHYLPREDNISOLONE (AS SODIUM SUCCINATE)			
Tab 4 mg – 1% DV Oct-15 to 2018	80.00	100	Medrol
Tab 100 mg – 1% DV Oct-15 to 2018	180.00	20	Medrol
Inj 40 mg vial – 1% DV Oct-15 to 2018	10.50	1	Solu-Medrol
Inj 125 mg vial – 1% DV Oct-15 to 2018	22.25	1	Solu-Medrol
Inj 500 mg vial – 1% DV Oct-15 to 2018	9.00	1	Solu-Medrol
Inj 1 g vial – 1% DV Oct-15 to 2018	16.00	1	Solu-Medrol
METHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml vial – 1% DV Oct-15 to 2018	40.00	5	Depo-Medrol
METHYLPREDNISOLONE ACETATE WITH LIDOCAINE [LIGNOCAINE]			
Inj 40 mg with lidocaine [lignocaine], 1 ml vial – 1% DV Oct-15 to 2018	9.25	1	Depo-Medrol with Lidocaine
PREDNISOLONE			
Oral liq 5 mg per ml	7.50	30 ml	Redipred
Enema 200 mcg per ml, 100 ml			
PREDNISONE			
Tab 1 mg	2.13	100	Apo-Prednisone S29
Tab 1 mg	10.68	500	Apo-Prednisone
Tab 2.5 mg	12.09	500	Apo-Prednisone
Tab 5 mg	11.09	500	Apo-Prednisone
Tab 20 mg	29.03	500	Apo-Prednisone
TRIAMCINOLONE ACETONIDE			
Inj 10 mg per ml, 1 ml ampoule – 1% DV Apr-15 to 2017	20.80	5	Kenacort-A 10
Inj 40 mg per ml, 1 ml ampoule – 1% DV Apr-15 to 2017	51.70	5	Kenacort-A 40
TRIAMCINOLONE HEXACETONIDE			
Inj 20 mg per ml, 1 ml vial			

Price (ex man. excl. GST)		Brand or Generic
\$	Per	Manufacturer

Hormone Replacement Therapy

Oestrogens

OESTRADIOL

- Tab 1 mg
- Tab 2 mg
- Patch 25 mcg per day
- Patch 50 mcg per day
- Patch 100 mcg per day

OESTRADIOL VALERATE

Tab 1 mg – 1% DV Jun-15 to 2018	12.36	84	Progynova
Tab 2 mg – 1% DV Jun-15 to 2018	12.36	84	Progynova

OESTROGENS (CONJUGATED EQUINE)

- Tab 300 mcg
- Tab 625 mcg

Progestogen and Oestrogen Combined Preparations

OESTRADIOL WITH NORETHISTERONE ACETATE

- Tab 1 mg with 0.5 mg norethisterone acetate
- Tab 2 mg with 1 mg norethisterone acetate
- Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)

OESTROGENS WITH MEDROXYPROGESTERONE ACETATE

- Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate
- Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate

Progestogens

MEDROXYPROGESTERONE ACETATE

Tab 2.5 mg – 1% DV Sep-13 to 2016	3.09	30	Provera
Tab 5 mg – 1% DV Sep-13 to 2016	13.06	100	Provera
Tab 10 mg – 1% DV Sep-13 to 2016	6.85	30	Provera

Other Endocrine Agents

CABERGOLINE – **Restricted** see terms below

⚡ Tab 0.5 mg – 1% DV Sep-15 to 2018	4.75	2	Dostinex
	19.00	8	Dostinex

↪ **Restricted**

Any of the following:

- 1 Inhibition of lactation; or
- 2 Patient has pathological hyperprolactinemia; or
- 3 Patient has acromegaly.

CLOMIPHENE CITRATE

Tab 50 mg – 1% DV Sep-13 to 2016	29.84	10	Serophene
--	-------	----	------------------

HORMONE PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DANAZOL			
Cap 100 mg	68.33	100	Azol
Cap 200 mg	97.83	100	Azol
GESTRINONE			
Cap 2.5 mg			
METYRAPONE			
Cap 250 mg			
PENTAGASTRIN			
Inj 250 mcg per ml, 2 ml ampoule			

Other Oestrogen Preparations

ETHINYLOESTRADIOL			
Tab 10 mcg – 1% DV Sep-15 to 2018	17.60	100	NZ Medical & Scientific
OESTRADIOL			
Implant 50 mg			
OESTRIOL			
Tab 2 mg			

Other Progestogen Preparations

MEDROXYPROGESTERONE			
Tab 100 mg – 1% DV Sep-13 to 2016	96.50	100	Provera
NORETHISTERONE			
Tab 5 mg – 1% DV Jun-15 to 2018	18.29	100	Primolut N

Pituitary and Hypothalamic Hormones and Analogues

CORTICOTRORELIN (OVINE)			
Inj 100 mcg vial			
THYROTROPIN ALFA			
Inj 900 mcg vial			

Adrenocorticotrophic Hormones

TETRACOSACTIDE [TETRACOSACTRIN]			
Inj 250 mcg per ml, 1 ml ampoule	177.18	10	Synacthen
Inj 1 mg per ml, 1 ml ampoule	29.56	1	Synacthen Depot

GnRH Agonists and Antagonists

BUSERELIN			
Inj 1 mg per ml, 5.5 ml vial			
GONADORELIN			
Inj 100 mcg vial			
GOSERELIN			
Implant 3.6 mg	166.20	1	Zoladex
Implant 10.8 mg	443.76	1	Zoladex

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LEUPRORELIN ACETATE			
Inj 3.75 mg syringe	221.60	1	Lucrin Depot PDS
Inj 7.5 mg syringe	166.20	1	Eligard
Inj 11.25 mg syringe	591.68	1	Lucrin Depot PDS
Inj 22.5 mg syringe	443.76	1	Eligard
Inj 30 mg syringe	1,109.40	1	Lucrin Depot PDS
Inj 30 mg vial	591.68	1	Eligard
Inj 45 mg syringe	832.05	1	Eligard

Gonadotrophins

CHORIOGONADOTROPIN ALFA

Inj 250 mcg in 0.5 ml syringe

Growth Hormone

SOMATROPIN – Restricted see terms below

⚡ Inj 5 mg cartridge – 1% DV Jan-15 to 31 Dec 2017	109.50	1	Omnitrope
⚡ Inj 10 mg cartridge – 1% DV Jan-15 to 31 Dec 2017	219.00	1	Omnitrope
⚡ Inj 15 mg cartridge – 1% DV Jan-15 to 31 Dec 2017	328.50	1	Omnitrope

➡ Restricted

Initiation - growth hormone deficiency in children

Endocrinologist

Paediatric Endocrinologist

Either:

- Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
- All of the following:
 - Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
 - A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
 - If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - Appropriate imaging of the pituitary gland has been obtained.

Continuation - growth hormone deficiency in children

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

All of the following:

- A current bone age is ≤ 14 years (female patients) or ≤ 16 years (male patients); and
- Height velocity is ≥ 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- Height velocity is ≥ 2.0 cm per year, as calculated over 6 months; and
- No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- No malignancy has developed since starting growth hormone.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Initiation - Turner syndrome

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Continuation - Turner syndrome

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity \geq 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is \geq 2 cm per year, calculated over six months; and
- 3 A current bone age is \leq 14 years; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initiation - short stature without growth hormone deficiency

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Continuation - short stature without growth hormone deficiency

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is \geq 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is \geq 2 cm per year as calculated over six months; and
- 3 Current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initiation - short stature due to chronic renal insufficiency

Endocrinologist

Paediatric Endocrinologist

Renal Physician on the recommendation of a Paediatric Endocrinologist or Endocrinologist

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is \leq to 14 years (female patients) or \leq to 16 years (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
 - 6.1 The patient has a $GFR \leq 30 \text{ ml/min/1.73 m}^2$ as measured by the Schwartz method ($\text{Height(cm)/plasma creatinine (umol/l)} \times 40 = \text{corrected GFR (ml/min/1.73 m}^2)$) in a child who may or may not be receiving dialysis; or
 - 6.2 The patient has received a renal transplant and has received < 5mg/ m^2 /day of prednisone or equivalent for at least 6 months.

Continuation - short stature due to chronic renal insufficiency

Endocrinologist

Paediatric Endocrinologist

Renal Physician on the recommendation of a Paediatric Endocrinologist or Endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is \geq 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is \geq 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initiation - Prader-Willi syndrome

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient's height velocity is < 25th percentile for bone age adjusted for bone age/pubertal status if appropriate as calculated over 6 to 12 months using the standards of Tanner and Davies (1985) or pubertal status over 6 to 12 months; and
- 3 Either:
 - 3.1 The patient is under two years of age and height velocity has been assessed over a minimum six month period from the age of 12 months, with at least three supine length measurements over this period demonstrating clear and consistent evidence of linear growth failure (with height velocity < 25th percentile); or
 - 3.2 The patient is aged two years or older; and
- 4 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 5 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 6 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by ≥ 0.5 standard deviations in the preceding 12 months.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Continuation - Prader-Willi syndrome

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is \geq 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is \geq 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by \geq 0.5 standard deviations in the preceding 12 months.

Initiation - adults and adolescents

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA[®]).

Notes:

For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of \leq 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of \leq 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Continuation - adults and adolescents

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

Either:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA[®]) score from baseline; and
 - 1.3 Serum IGF-I levels have increased to within \pm 1SD of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

2 All of the following:

- 2.1 The patient has been treated with somatropin for more than 12 months; and
- 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA[®] score on treatment (other than due to obvious external factors such as external stressors); and
- 2.3 Serum IGF-I levels have continued to be maintained within ± 1 SD of the mean of the normal range for age and sex (other than for obvious external factors); and
- 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

Thyroid and Antithyroid Preparations

CARBIMAZOLE

Tab 5 mg

IODINE

Soln BP 50 mg per ml

LEVOTHYROXINE

Tab 25 mcg

Tab 50 mcg

Tab 100 mcg

LIOTHYRONINE SODIUM

☯ Tab 20 mcg

☛ Restricted

For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy

Inj 20 mcg vial

POTASSIUM IODATE

Tab 170 mg

POTASSIUM PERCHLORATE

Cap 200 mg

PROPYLTHIOURACIL – **Restricted** see terms below

☯ Tab 50 mg	35.00	100	PTU
-------------------	-------	-----	-----

☛ Restricted

Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

PROTIRELIN

Inj 100 mcg per ml, 2 ml ampoule

Vasopressin Agents

ARGIPRESSIN [VASOPRESSIN]

Inj 20 u per ml, 1 ml ampoule

DESMOPRESSIN ACETATE – **Some items restricted** see terms on the next page

☯ Tab 100 mcg	36.40	30	Minirin
☯ Tab 200 mcg	93.60	30	Minirin
Nasal spray 10 mcg per dose – 1% DV Sep-14 to 2017	22.95	6 ml	Desmopressin-PH&T
Inj 4 mcg per ml, 1 ml ampoule			
Inj 15 mcg per ml, 1 ml ampoule			
Nasal drops 100 mcg per ml			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➡Restricted			
Nocturnal enuresis			
Either:			
1 The nasal forms of desmopressin are contraindicated; or			
2 An enuresis alarm is contraindicated.			
Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated			
TERLIPRESSIN			
Inj 0.1 mg per ml, 8.5 ml ampoule	450.00	5	Glypressin
Inj 1 mg per 8.5 ml ampoule – 1% DV Jun-15 to 2018	215.00	5	Glypressin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antibacterials			
Aminoglycosides			
AMIKACIN – Restricted see terms below			
⌚ Inj 5 mg per ml, 10 ml syringe			
⌚ Inj 5 mg per ml, 5 ml syringe	176.00	10	Biomed
⌚ Inj 15 mg per ml, 5 ml syringe			
⌚ Inj 250 mg per ml, 2 ml vial – 1% DV Oct-14 to 2017	431.20	5	DBL Amikacin
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
GENTAMICIN SULPHATE			
Inj 10 mg per ml, 1 ml ampoule	8.56	5	Hospira
Inj 10 mg per ml, 2 ml ampoule	175.10	25	APP Pharmaceuticals
Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018	6.00	10	Pfizer
PAROMOMYCIN – Restricted see terms below			
⌚ Cap 250 mg	126.00	16	Humatin
➔ Restricted			
Infectious disease physician or clinical microbiologist			
STREPTOMYCIN SULPHATE – Restricted see terms below			
⌚ Inj 400 mg per ml, 2.5 ml ampoule			
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
TOBRAMYCIN			
⌚ Powder			
➔ Restricted			
For addition to orthopaedic bone cement.			
⌚ Inj 40 mg per ml, 2 ml vial	29.32	5	DBL Tobramycin
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
⌚ Inj 100 mg per ml, 5 ml vial			
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
⌚ Solution for inhalation 60 mg per ml, 5 ml	2,200.00	56 dose	TOBI
➔ Restricted			
Patient has cystic fibrosis			
Carbapenems			
ERTAPENEM – Restricted see terms below			
⌚ Inj 1 g vial	73.50	1	Invanz
➔ Restricted			
Infectious disease physician or clinical microbiologist			
IMIPENEM WITH CILASTATIN – Restricted see terms below			
⌚ Inj 500 mg with 500 mg cilastatin vial – 1% DV Jun-15 to 2017	13.79	1	Imipenem+Cilastatin RBX
➔ Restricted			
Infectious disease physician or clinical microbiologist			
MEROPENEM – Restricted see terms on the next page			
⌚ Inj 500 mg vial – 1% DV Oct-14 to 2017	35.22	10	DBL Meropenem
⌚ Inj 1 g vial – 1% DV Oct-14 to 2017	65.21	10	DBL Meropenem

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Infectious disease physician or clinical microbiologist			
Cephalosporins and Cephamycins - 1st Generation			
CEFALEXIN			
Cap 500 mg – 1% DV Oct-13 to 2016	5.70	20	Cephalexin ABM
Grans for oral liq 25 mg per ml – 1% DV Sep-15 to 2018	8.00	100 ml	Cefalexin Sandoz
Grans for oral liq 50 mg per ml – 1% DV Sep-15 to 2018	11.00	100 ml	Cefalexin Sandoz
CEFAZOLIN			
Inj 500 mg vial – 1% DV Sep-14 to 2017	3.99	5	AFT
Inj 1 g vial – 1% DV Sep-14 to 2017	3.38	5	AFT
Cephalosporins and Cephamycins - 2nd Generation			
CEFACLOR			
Cap 250 mg – 1% DV Dec-13 to 2016	26.00	100	Ranbaxy-Cefaclor
Grans for oral liq 25 mg per ml – 1% DV Dec-13 to 2016	3.53	100 ml	Ranbaxy-Cefaclor
CEFOXITIN			
Inj 1 g vial	74.25	5	Hospira
CEFUROXIME			
Tab 250 mg	29.40	50	Zinnat
Inj 750 mg vial	3.70	5	Zinacef
Inj 1.5 g vial	1.30	1	Zinacef
Cephalosporins and Cephamycins - 3rd Generation			
CEFOTAXIME			
Inj 500 mg vial	1.90	1	Cefotaxime Sandoz
Inj 1 g vial – 1% DV Oct-14 to 2017	17.10	10	DBL Cefotaxime
CEFTAZIDIME – Restricted see terms below			
⚡ Inj 500 mg vial – 1% DV Jan-15 to 2017	5.30	1	Fortum
⚡ Inj 1 g vial – 1% DV Jan-15 to 2017	1.55	1	Fortum
⚡ Inj 2 g vial – 1% DV Jan-15 to 2017	3.34	1	Fortum
➔Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
CEFTRIAXONE			
Inj 500 mg vial – 1% DV Mar-14 to 2016	1.50	1	Ceftriaxone-AFT
Inj 1 g vial – 1% DV Mar-14 to 2016	5.22	5	Ceftriaxone-AFT
Inj 2 g vial – 1% DV Mar-14 to 2016	2.75	1	Ceftriaxone-AFT
Cephalosporins and Cephamycins - 4th Generation			
CEFEPIME – Restricted see terms below			
⚡ Inj 1 g vial – 1% DV Oct-15 to 2018	3.95	1	Cefepime-AFT
	8.80		DBL Cefepime
⚡ Inj 2 g vial – 1% DV Oct-15 to 2018	6.92	1	Cefepime-AFT
	17.60		DBL Cefepime
<i>(DBL Cefepime Inj 1 g vial to be delisted 1 October 2015)</i>			
<i>(DBL Cefepime Inj 2 g vial to be delisted 1 October 2015)</i>			
➔Restricted			
Infectious disease physician or clinical microbiologist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Cephalosporins and Cephamycins - 5th Generation			
CEFTAROLINE FOSAMIL – Restricted see terms below			
⚡ Inj 600 mg vial	1,450.00	10	Zinforo
➡ Restricted			
Infectious disease physician or clinical microbiologist			
Multi-resistant organism salvage therapy			
Either:			
1 for patients where alternative therapies have failed; or			
2 for patients who have a contraindication or hypersensitivity to standard current therapies.			
Macrolides			
AZITHROMYCIN – Restricted see terms below			
⚡ Tab 250 mg – 1% DV Sep-15 to 2018	9.00	30	Apo-Azithromycin
⚡ Tab 500 mg – 1% DV Sep-15 to 2018	1.05	2	Apo-Azithromycin
⚡ Grans for oral liq 200 mg per 5 ml (40 mg per ml) – 1% DV Oct-15 to 2018	12.50	15 ml	Zithromax
➡ Restricted			
Any of the following:			
1 Patient has received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome; or			
2 Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms; or			
3 For any other condition for five days' treatment, with review after five days.			
CLARITHROMYCIN – Restricted see terms below			
⚡ Tab 250 mg – 1% DV Sep-14 to 2017	3.98	14	Apo-Clarithromycin
⚡ Tab 500 mg – 1% DV Sep-14 to 2017	10.40	14	Apo-Clarithromycin
⚡ Grans for oral liq 25 mg per ml	23.12	70 ml	Klacid
⚡ Inj 500 mg vial – 1% DV Mar-15 to 2017	20.40	1	Martindale
➡ Restricted			
Tab 250 mg and oral liquid			
Tab 250 mg and oral liquid			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents.			
Tab 500 mg			
Helicobacter pylori eradication.			
Infusion			
Infusion			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or			
3 Community-acquired pneumonia.			
ERYTHROMYCIN (AS ETHYLSUCCINATE)			
Tab 400 mg	16.95	100	E-Mycin
Grans for oral liq 200 mg per 5 ml	5.00	100 ml	E-Mycin
Grans for oral liq 400 mg per 5 ml	6.77	100 ml	E-Mycin
ERYTHROMYCIN (AS LACTOBIONATE)			
Inj 1 g vial	16.00	1	Erythrocin IV
ERYTHROMYCIN (AS STEARATE) – Restricted : For continuation only			
➡ Tab 250 mg			
➡ Tab 500 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ROXITHROMYCIN			
Tab 150 mg	7.48	50	Arrow-Roxithromycin
Tab 300 mg	14.40	50	Arrow-Roxithromycin
Penicillins			
AMOXICILLIN			
Cap 250 mg – 1% DV Mar-14 to 2016	16.18	500	Apo-Amoxi
Cap 500 mg – 1% DV Jul-14 to 2016	20.94	500	Apo-Amoxi
Grans for oral liq 125 mg per 5 ml	0.88	100 ml	Amoxicillin Actavis
Grans for oral liq 250 mg per 5 ml	0.97	100 ml	Amoxicillin Actavis
Inj 250 mg vial – 1% DV Oct-14 to 2017	10.67	10	Ibiamox
Inj 500 mg vial – 1% DV Oct-14 to 2017	12.41	10	Ibiamox
Inj 1 g vial – 1% DV Oct-14 to 2017	17.29	10	Ibiamox
AMOXICILLIN WITH CLAVULANIC ACID			
Tab 500 mg with clavulanic acid 125 mg	1.95	20	Augmentin
.....	9.75	100	Curam Duo
Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml	1.61	100 ml	Augmentin
Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml	2.19	100 ml	Augmentin
Inj 500 mg with clavulanic acid 100 mg vial – 1% DV Sep-15 to 2018	10.14	10	m-Amoxiclav
Inj 1,000 mg with clavulanic acid 200 mg vial – 1% DV Sep-15 to 2018	12.80	10	m-Amoxiclav
BENZATHINE BENZYL PENICILLIN			
Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Sep-15 to 2018	315.00	10	Bicillin LA
BENZYL PENICILLIN SODIUM [PENICILLIN G]			
Inj 600 mg (1 million units) vial – 1% DV Sep-14 to 2017	10.35	10	Sandoz
FLUCLOXACILLIN			
Cap 250 mg – 1% DV Sep-15 to 2018	18.70	250	Staphlex
Cap 500 mg – 1% DV Sep-15 to 2018	62.90	500	Staphlex
Grans for oral liq 25 mg per ml – 1% DV Sep-15 to 2018	2.29	100 ml	AFT
Grans for oral liq 50 mg per ml – 1% DV Sep-15 to 2018	3.08	100 ml	AFT
Inj 250 mg vial – 1% DV Sep-14 to 2017	8.80	10	Flucloxin
Inj 500 mg vial – 1% DV Sep-14 to 2017	9.20	10	Flucloxin
Inj 1 g vial	5.80	5	DBL Flucloxacillin
.....	11.60	10	Flucloxin
PHENOXYMETHYL PENICILLIN [PENICILLIN V]			
Cap 250 mg – 1% DV Jun-15 to 2018	2.88	50	Cilicaine VK
Cap 500 mg – 1% DV Jun-15 to 2018	4.73	50	Cilicaine VK
Grans for oral liq 125 mg per 5 ml – 1% DV Apr-14 to 2016	1.64	100 ml	AFT
Grans for oral liq 250 mg per 5 ml – 1% DV Apr-14 to 2016	1.74	100 ml	AFT
PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below			
⚡ Inj 4 g with tazobactam 0.5 g vial – 1% DV Oct-13 to 2016	5.84	1	Tazocin EF
➡Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
PROCAINE PENICILLIN			
Inj 1.5 g in 3.4 ml syringe – 1% DV Sep-14 to 2017	123.50	5	Cilicaine
TICARCILLIN WITH CLAVULANIC ACID – Restricted see terms on the next page			
⚡ Inj 3 g with clavulanic acid 0.1 mg vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Infectious disease physician, clinical microbiologist or respiratory physician

QuinolonesCIPROFLOXACIN – **Restricted** see terms below

⚡ Tab 250 mg – 1% DV Sep-14 to 2017	1.75	28	Cipflox
⚡ Tab 500 mg – 1% DV Sep-14 to 2017	2.00	28	Cipflox
⚡ Tab 750 mg – 1% DV Sep-14 to 2017	3.75	28	Cipflox
⚡ Oral liq 50 mg per ml			
⚡ Oral liq 100 mg per ml			
⚡ Inj 2 mg per ml, 100 ml bag	41.00	10	Aspen Ciprofloxacin

➔ **Restricted**

Infectious disease physician or clinical microbiologist

MOXIFLOXACIN – **Restricted** see terms below

⚡ Tab 400 mg	52.00	5	Avelox
⚡ Inj 1.6 mg per ml, 250 ml bag	70.00	1	Avelox IV 400

➔ **Restricted****Mycobacterium infection**

Infectious disease physician, clinical microbiologist or respiratory physician

Either:

- 1 Active tuberculosis, with any of the following:
 - 1.1 Documented resistance to one or more first-line medications; or
 - 1.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
 - 1.3 Impaired visual acuity (considered to preclude ethambutol use); or
 - 1.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
 - 1.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated

Pneumonia

Infectious disease physician or clinical microbiologist

- 1 Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
- 2 Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

Penetrating eye injury

Ophthalmologist

Five days treatment for patients requiring prophylaxis following a penetrating eye injury

Mycoplasma genitalium

All of the following:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium; and
- 2 Has tried and failed to clear infection using azithromycin; and
- 3 Treatment is only for 7 days.

NORFLOXACIN

Tab 400 mg – 1% DV Sep-14 to 2017	13.50	100	Arrow-Norfloxacin
---	-------	-----	--------------------------

Tetracyclines

DEMECLOCYCLINE HYDROCHLORIDE

- Cap 150 mg
- Cap 300 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DOXYCYCLINE			
➔ Tab 50 mg – Restricted: For continuation only			
Tab 100 mg – 1% DV Sep-14 to 2017	6.75	250	Doxine
Inj 5 mg per ml, 20 ml vial			
MINOCYCLINE			
Tab 50 mg			
➔ Cap 100 mg – Restricted: For continuation only			
TETRACYCLINE			
Tab 250 mg			
Cap 500 mg	46.00	30	Tetracyclin Wolff
TIGECYCLINE – Restricted see terms below			
☞ Inj 50 mg vial			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
Other Antibacterials			
AZTREONAM – Restricted see terms below			
☞ Inj 1 g vial	131.00	5	Azactam
➔ Restricted			
Infectious disease physician or clinical microbiologist			
CHLORAMPHENICOL – Restricted see terms below			
☞ Inj 1 g vial			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
CLINDAMYCIN – Restricted see terms below			
☞ Cap 150 mg – 1% DV Oct-13 to 2016	5.80	16	Clindamycin ABM
☞ Oral liq 15 mg per ml			
☞ Inj 150 mg per ml, 4 ml ampoule – 1% DV Sep-13 to 2016	100.00	10	Dalacin C
➔ Restricted			
Infectious disease physician or clinical microbiologist			
COLISTIN SULPHOMETHATE [COLESTIMETHATE] – Restricted see terms below			
☞ Inj 150 mg per ml, 1 ml vial	65.00	1	Colistin-Link
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
DAPTOMYCIN – Restricted see terms below			
☞ Inj 350 mg vial – 1% DV Sep-15 to 2018	175.16	1	Cubicin
☞ Inj 500 mg vial – 1% DV Sep-15 to 2018	243.52	1	Cubicin
➔ Restricted			
Infectious disease physician or clinical microbiologist			
FOSFOMYCIN – Restricted see terms below			
☞ Powder for oral solution, 3 g sachet			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
FUSIDIC ACID – Restricted see terms below			
☞ Tab 250 mg	34.50	12	Fucidin
➔ Restricted			
Infectious disease physician or clinical microbiologist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
HEXAMINE HIPPURATE			
Tab 1 g			
LINCOMYCIN – Restricted see terms below			
⚡ Inj 300 mg per ml, 2 ml vial			
➡ Restricted			
Infectious disease physician or clinical microbiologist			
LINEZOLID – Restricted see terms below			
⚡ Tab 600 mg – 1% DV Sep-15 to 2018	800.00	10	Zyvox
⚡ Oral liq 20 mg per ml – 1% DV Sep-15 to 2018	775.00	150 ml	Zyvox
⚡ Inj 2 mg per ml, 300 ml bag – 1% DV Sep-15 to 2018	1,650.00	10	Zyvox
➡ Restricted			
Infectious disease physician or clinical microbiologist			
NITROFURANTOIN			
Tab 50 mg			
Tab 100 mg			
PIVMECILLINAM – Restricted see terms below			
⚡ Tab 200 mg			
➡ Restricted			
Infectious disease physician or clinical microbiologist			
SULPHADIAZINE – Restricted see terms below			
⚡ Tab 500 mg			
➡ Restricted			
Infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist			
TEICOPLANIN – Restricted see terms below			
⚡ Inj 400 mg vial			
➡ Restricted			
Infectious disease physician or clinical microbiologist			
TRIMETHOPRIM			
Tab 100 mg			
Tab 300 mg – 1% DV Oct-15 to 2018	15.00	50	TMP
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]			
Tab 80 mg with sulphamethoxazole 400 mg			
Oral liq 8 mg with sulphamethoxazole 40 mg per ml	2.15	100 ml	Deprim
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule			
VANCOMYCIN – Restricted see terms below			
⚡ Inj 500 mg vial – 1% DV Oct-14 to 2017	2.64	1	Mylan
➡ Restricted			
Infectious disease physician or clinical microbiologist			

Antifungals

Imidazoles

KETOCONAZOLE

⚡ Tab 200 mg

➡ **Restricted**

Oncologist

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Polyene Antimycotics			
AMPHOTERICIN B			
☞ Inj (liposomal) 50 mg vial – 1% DV Sep-15 to 2018	3,450.00	10	AmBisome
☞ Restricted			
Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician			
Either:			
1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or			
2 Both:			
2.1 Possible invasive fungal infection; and			
2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.			
☞ Inj 50 mg vial			
☞ Restricted			
Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician			
NYSTATIN			
Tab 500,000 u	17.09	50	Nilstat
Cap 500,000 u	15.47	50	Nilstat
Triazoles			
FLUCONAZOLE – Restricted see terms below			
☞ Cap 50 mg – 1% DV Nov-14 to 2017	3.49	28	Ozole
☞ Cap 150 mg – 1% DV Nov-14 to 2017	0.71	1	Ozole
☞ Cap 200 mg – 1% DV Nov-14 to 2017	9.69	28	Ozole
☞ Oral liquid 50 mg per 5 ml	98.50	35 ml	Diflucan
☞ Inj 2 mg per ml, 50 ml vial – 1% DV Oct-13 to 2016	4.95	1	Fluconazole-Claris
☞ Inj 2 mg per ml, 100 ml vial – 1% DV Oct-13 to 2016	6.47	1	Fluconazole-Claris
☞ Restricted			
Consultant			
ITRACONAZOLE – Restricted see terms below			
☞ Cap 100 mg – 1% DV Oct-13 to 2016	2.99	15	Itrazole
☞ Oral liquid 10 mg per ml			
☞ Restricted			
Infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist			
POSACONAZOLE – Restricted see terms below			
☞ Oral liq 40 mg per ml	761.13	105 ml	Noxafil
☞ Restricted			
Infectious disease physician or haematologist			
Initiation			
<i>Re-assessment required after 6 weeks</i>			
Both:			
1 Either:			
1.1 Patient has acute myeloid leukaemia; or			
1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and			
2 Patient is to be treated with high dose remission induction therapy or re-induction therapy			
Continuation			
<i>Re-assessment required after 6 weeks</i>			
Both:			

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
<ol style="list-style-type: none"> Patient has previously received posaconazole prophylaxis during remission induction therapy; and Any of the following: <ol style="list-style-type: none"> Patient is to be treated with high dose remission re-induction therapy; or Patient is to be treated with high dose consolidation therapy; or Patient is receiving a high risk stem cell transplant. 			
VORICONAZOLE – Restricted see terms below			
⚡ Tab 50 mg	730.00	56	Vfend
⚡ Tab 200 mg	2,930.00	56	Vfend
⚡ Oral liq 40 mg per ml	730.00	70 ml	Vfend
⚡ Inj 200 mg vial	185.00	1	Vfend
➡ Restricted			
Infectious disease physician, clinical microbiologist or haematologist			
Proven or probable aspergillus infection			
Both:			
<ol style="list-style-type: none"> Patient is immunocompromised; and Patient has proven or probable invasive aspergillus infection. 			
Possible aspergillus infection			
All of the following:			
<ol style="list-style-type: none"> Patient is immunocompromised; and Patient has possible invasive aspergillus infection; and A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate. 			
Resistant candidiasis infections and other moulds			
All of the following:			
<ol style="list-style-type: none"> Patient is immunocompromised, and Either: <ol style="list-style-type: none"> Patient has fluconazole resistant candidiasis; or Patient has mould strain such as <i>Fusarium</i> spp. and <i>Scedosporium</i> spp; and A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate. 			
Other Antifungals			
CASPOFUNGIN – Restricted see terms below			
⚡ Inj 50 mg vial	667.50	1	Candidas
⚡ Inj 70 mg vial	862.50	1	Candidas
➡ Restricted			
Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician			
Either:			
<ol style="list-style-type: none"> Proven or probable invasive fungal infection, to be prescribed under an established protocol; or Both: <ol style="list-style-type: none"> Possible invasive fungal infection; and A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate. 			
FLUCYTOSINE – Restricted see terms below			
⚡ Cap 500 mg			
➡ Restricted			
Infectious disease physician or clinical microbiologist.			
TERBINAFINE			
Tab 250 mg – 1% DV Sep-14 to 2017	1.50	14	Dr Reddy's Terbinafine

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antimycobacterials			
Antileprotics			
CLOFAZIMINE – Restricted see terms below			
☞ Cap 50 mg			
☞ Restricted			
Infectious disease physician, clinical microbiologist or dermatologist			
DAPSONE – Restricted see terms below			
☞ Tab 25 mg – 1% DV Sep-14 to 2017	95.00	100	Dapsone
☞ Tab 100 mg – 1% DV Sep-14 to 2017	110.00	100	Dapsone
☞ Restricted			
Infectious disease physician, clinical microbiologist or dermatologist			
Antituberculotics			
CYCLOSERINE – Restricted see terms below			
☞ Cap 250 mg			
☞ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
ETHAMBUTOL HYDROCHLORIDE – Restricted see terms below			
☞ Tab 100 mg	48.01	56	Myambutol
☞ Tab 400 mg	49.34	56	Myambutol
☞ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
ISONIAZID – Restricted see terms below			
☞ Tab 100 mg – 1% DV Sep-15 to 2018	20.00	100	PSM
☞ Restricted			
Internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician			
ISONIAZID WITH RIFAMPICIN – Restricted see terms below			
☞ Tab 100 mg with rifampicin 150 mg – 1% DV Sep-15 to 2018	85.54	100	Rifinah
☞ Tab 150 mg with rifampicin 300 mg – 1% DV Sep-15 to 2018	170.60	100	Rifinah
☞ Restricted			
Internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician			
PARA-AMINOSALICYLIC ACID – Restricted see terms below			
☞ Grans for oral liq 4 g	280.00	30	Paser
☞ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
PROTIONAMIDE – Restricted see terms below			
☞ Tab 250 mg	305.00	100	Peteha
☞ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
PYRAZINAMIDE – Restricted see terms below			
☞ Tab 500 mg			
☞ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
RIFABUTIN – Restricted see terms on the next page			
☞ Cap 150 mg – 1% DV Sep-13 to 2016	213.19	30	Mycobutin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Infectious disease physician, clinical microbiologist, respiratory physician or gastroenterologist			
RIFAMPICIN – Restricted see terms below			
⚡ Tab 600 mg – 1% DV Nov-14 to 2017	108.70	30	Rifadin
⚡ Cap 150 mg – 1% DV Nov-14 to 2017	55.75	100	Rifadin
⚡ Cap 300 mg – 1% DV Nov-14 to 2017	116.25	100	Rifadin
⚡ Oral liq 100 mg per 5 ml – 1% DV Nov-14 to 2017	12.00	60 ml	Rifadin
⚡ Inj 600 mg vial – 1% DV Nov-14 to 2017	128.85	1	Rifadin
➔Restricted			
Internal medicine physician, clinical microbiologist, dermatologist, paediatrician or public health physician			
Antiparasitics			
Anthelmintics			
ALBENDAZOLE – Restricted see terms below			
⚡ Tab 200 mg			
⚡ Tab 400 mg			
➔Restricted			
Infectious disease physician or clinical microbiologist			
IVERMECTIN – Restricted see terms below			
⚡ Tab 3 mg	17.20	4	Stromectol
➔Restricted			
Infectious disease physician, clinical microbiologist or dermatologist.			
MEBENDAZOLE			
Tab 100 mg	24.19	24	De-Worm
Oral liq 100 mg per 5 ml			
PRAZIQUANTEL			
Tab 600 mg			
Antiprotozoals			
ARTEMETHER WITH LUMEFANTRINE – Restricted see terms below			
⚡ Tab 20 mg with lumefantrine 120 mg			
➔Restricted			
Infectious disease physician or clinical microbiologist			
ARTESUNATE – Restricted see terms below			
⚡ Inj 60 mg vial			
➔Restricted			
Infectious disease physician or clinical microbiologist			
ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – Restricted see terms below			
⚡ Tab 62.5 mg with proguanil hydrochloride 25 mg – 1% DV Nov-14 to 2017	25.00	12	Malarone Junior
⚡ Tab 250 mg with proguanil hydrochloride 100 mg – 1% DV Nov-14 to 2017	64.00	12	Malarone
➔Restricted			
Infectious disease physician or clinical microbiologist			
CHLOROQUINE PHOSPHATE – Restricted see terms below			
⚡ Tab 250 mg			
➔Restricted			
Infectious disease physician, clinical microbiologist, dermatologist or rheumatologist			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MEFLOQUINE – Restricted see terms below			
☞ Tab 250 mg – 1% DV Dec-14 to 2017	33.48	8	Lariam
☞ Restricted			
Infectious disease physician, clinical microbiologist, dermatologist or rheumatologist			
METRONIDAZOLE			
Tab 200 mg	10.45	100	Trichazole
Tab 400 mg	18.15	100	Trichazole
Oral liq benzoate 200 mg per 5 ml	25.00	100 ml	Flagyl-S
Inj 5 mg per ml, 100 ml bag – 1% DV Apr-15 to 2017	6.94	5	AFT
Suppos 500 mg	24.48	10	Flagyl
NITAZOXANIDE – Restricted see terms below			
☞ Tab 500 mg	1,680.00	30	Alinia
☞ Oral liq 100 mg per 5 ml			
☞ Restricted			
Infectious disease physician or clinical microbiologist			
ORNIDAZOLE			
Tab 500 mg	16.50	10	Arrow-Ornidazole
PENTAMIDINE ISETHIONATE – Restricted see terms below			
☞ Inj 300 mg vial – 1% DV Mar-15 to 2017	180.00	5	Pentacarinat
☞ Restricted			
Infectious disease physician or clinical microbiologist			
PRIMAQUINE PHOSPHATE – Restricted see terms below			
☞ Tab 7.5 mg			
☞ Restricted			
Infectious disease physician or clinical microbiologist			
PYRIMETHAMINE – Restricted see terms below			
☞ Tab 25 mg			
☞ Restricted			
Infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist			
QUININE DIHYDROCHLORIDE – Restricted see terms below			
☞ Inj 60 mg per ml, 10 ml ampoule			
☞ Inj 300 mg per ml, 2 ml vial			
☞ Restricted			
Infectious disease physician or clinical microbiologist			
QUININE SULPHATE			
Tab 300 mg	54.06	500	Q 300
SODIUM STIBOGLUCONATE – Restricted see terms below			
☞ Inj 100 mg per ml, 1 ml vial			
☞ Restricted			
Infectious disease physician or clinical microbiologist			
SPIRAMYCIN – Restricted see terms below			
☞ Tab 500 mg			
☞ Restricted			
Maternal-foetal medicine specialist			

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Antiretrovirals

HIV Fusion Inhibitors

ENFUVIRTIDE – **Restricted** see terms below

¶ Inj 108 mg vial × 602,380.00 1 Fuzeon

➡ Restricted

Initiation

Re-assessment required after 12 months

All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
 - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
 - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
 - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
 - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
 - 5.3 Previous treatment with a protease inhibitor has failed.

Continuation

Patient has had at least a 10-fold reduction in viral load at 12 months

Non-Nucleoside Reverse Transcriptase Inhibitors

➡ Restricted

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:

continued...

continued...

- 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
- 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

EFAVIRENZ – Restricted see terms on the preceding page

† Tab 50 mg – 1% DV Sep-15 to 2018	63.38	30	Stocrin
† Tab 200 mg – 1% DV Sep-15 to 2018	190.15	90	Stocrin
† Tab 600 mg – 1% DV Sep-15 to 2018	63.38	30	Stocrin
† Oral liq 30 mg per ml			

ETRAVIRINE – Restricted see terms on the preceding page

† Tab 200 mg	770.00	60	Intelence
--------------------	--------	----	------------------

NEVIRAPINE – Restricted see terms on the preceding page

† Tab 200 mg	95.94	60	Nevirapine Alphapharm
† Oral suspension 10 mg per ml	134.55	240 ml	Viramune Suspension

Nucleoside Reverse Transcriptase Inhibitors

➡ Restricted

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ABACAVIR SULPHATE – Restricted see terms on the preceding page			
⬆ Tab 300 mg – 1% DV Oct-14 to 2017	229.00	60	Ziagen
⬆ Oral liq 20 mg per ml – 1% DV Oct-14 to 2017	256.31	240 ml	Ziagen
ABACAVIR SULPHATE WITH LAMIVUDINE – Restricted see terms on the preceding page			
⬆ Tab 600 mg with lamivudine 300 mg	630.00	30	Kivexa
DIDANOSINE [DDI] – Restricted see terms on the preceding page			
⬆ Cap 125 mg			
⬆ Cap 200 mg			
⬆ Cap 250 mg			
⬆ Cap 400 mg			
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE – Restricted see terms on the preceding page			
⬆ Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg	1,313.19	30	Atripla
EMTRICITABINE – Restricted see terms on the preceding page			
⬆ Cap 200 mg	307.20	30	Emtriva
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE – Restricted see terms on the preceding page			
⬆ Tab 200 mg with tenofovir disoproxil fumarate 300 mg	838.20	30	Truvada
LAMIVUDINE – Restricted see terms on the preceding page			
⬆ Oral liq 10 mg per ml			
STAVUDINE – Restricted see terms on the preceding page			
⬆ Cap 30 mg			
⬆ Cap 40 mg			
⬆ Powder for oral soln 1 mg per ml			
ZIDOVUDINE [AZT] – Restricted see terms on the preceding page			
⬆ Cap 100 mg – 1% DV Oct-13 to 2016	152.25	100	Retrovir
⬆ Oral liq 10 mg per ml – 1% DV Oct-13 to 2016	30.45	200 ml	Retrovir
⬆ Inj 10 mg per ml, 20 ml vial – 1% DV Oct-14 to 2017	750.00	5	Retrovir IV
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Restricted see terms on the preceding page			
⬆ Tab 300 mg with lamivudine 150 mg – 1% DV Sep-14 to 2017	44.00	60	Alphapharm

Protease Inhibitors

➡ Restricted

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and

continued...

continued...

2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

ATAZANAVIR SULPHATE – **Restricted** see terms on the preceding page

† Cap 150 mg	568.34	60	Reyataz
† Cap 200 mg	757.79	60	Reyataz

DARUNAVIR – **Restricted** see terms on the preceding page

† Tab 400 mg	837.50	60	Prezista
† Tab 600 mg	1,190.00	60	Prezista

INDINAVIR – **Restricted** see terms on the preceding page

- † Cap 200 mg
- † Cap 400 mg

LOPINAVIR WITH RITONAVIR – **Restricted** see terms on the preceding page

† Tab 100 mg with ritonavir 25 mg	183.75	60	Kaletra
† Tab 200 mg with ritonavir 50 mg	735.00	120	Kaletra
† Oral liq 80 mg with ritonavir 20 mg per ml	735.00	300 ml	Kaletra

RITONAVIR – **Restricted** see terms on the preceding page

† Tab 100 mg	43.31	30	Norvir
† Oral liq 80 mg per ml			

Strand Transfer Inhibitors

➡ **Restricted**

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.4.1 Patient aged 6 years and over; and
- 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

RALTEGRAVIR POTASSIUM – **Restricted** see terms on the preceding page

⬇ Tab 400 mg 1,090.00 60 Isentress

Antivirals

Hepatitis B

ADEFOVIR DIPIVOXIL – **Restricted** see terms below

⬇ Tab 10 mg 670.00 30 Hepsera

➡ **Restricted**

Gastroenterologist or infectious disease physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and

Documented resistance to lamivudine, defined as:

- 1 Patient has raised serum ALT ($> 1 \times \text{ULN}$); and
- 2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 -fold over nadir; and
- 3 Detection of M204I or M204V mutation; and
- 4 Either:

4.1 Both:

- 4.1.1 Patient is cirrhotic; and
- 4.1.2 Adefovir dipivoxil to be used in combination with lamivudine; or

4.2 Both:

- 4.2.1 Patient is not cirrhotic; and
- 4.2.2 Adefovir dipivoxil to be used as monotherapy.

ENTECAVIR – **Restricted** see terms below

⬇ Tab 0.5 mg 400.00 30 Baraclude

➡ **Restricted**

Gastroenterologist or infectious disease physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naïve; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
4.1 ALT greater than upper limit of normal; or			
4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater or moderate fibrosis) on liver histology; and			
5 Either:			
5.1 HBeAg positive; or			
5.2 Patient has $\geq 2,000$ IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and			
6 No continuing alcohol abuse or intravenous drug use; and			
7 Not co-infected with HCV, HIV or HDV; and			
8 Neither ALT nor AST greater than 10 times upper limit of normal; and			
9 No history of hypersensitivity to entecavir; and			
10 No previous documented lamivudine resistance (either clinical or genotypic).			
LAMIVUDINE – Restricted see terms below			
⚡ Tab 100 mg – 1% DV Nov-14 to 2017	6.00	28	Zeffix
⚡ Oral liq 5 mg per ml – 1% DV Nov-14 to 2017	270.00	240 ml	Zeffix
➡Restricted			
Gastroenterologist, infectious disease specialist, paediatrician or general physician			
Initiation			
<i>Re-assessment required after 12 months</i>			
Any of the following:			
1 HBV DNA positive cirrhosis prior to liver transplantation; or			
2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or			
3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or			
4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and			
5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or			
6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).			
Continuation - patients who have maintained continuous treatment and response to lamivudine			
<i>Re-assessment required after 2 years</i>			
All of the following:			
1 Have maintained continuous treatment with lamivudine; and			
2 Most recent test result shows continuing biochemical response (normal ALT); and			
3 HBV DNA $<100,000$ copies per ml by quantitative PCR at a reference laboratory; or			
Continuation - when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine			
<i>Re-assessment required after 2 years</i>			
All of the following:			
1 Lamivudine to be used in combination with adefovir dipivoxil; and			
2 Patient is cirrhotic; and			
Documented resistance to lamivudine, defined as:			
1 Patient has raised serum ALT ($> 1 \times$ ULN); and			
2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 -fold over nadir; and			
3 Detection of M204I or M204V mutation			
Continuation - when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil			
<i>Re-assessment required after 2 years</i>			
All of the following:			
1 Lamivudine to be used in combination with adefovir dipivoxil; and			
Documented resistance to adefovir, defined as:			
1 Patient has raised serum ALT ($> 1 \times$ ULN); and			
2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10 -fold over nadir; and			
3 Detection of N236T or A181T/V mutation.			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TENOFIVIR DISOPROXIL FUMARATE – Restricted see terms below			
⚡ Tab 300 mg	531.00	30	Viread

➡ **Restricted**

Confirmed hepatitis B

Any of the following:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \leq 10-fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has a decompensated cirrhosis with a Mayo score > 20.

Pregnant or Breastfeeding, Active hepatitis B

Limited to twelve months' treatment

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Pregnant, prevention of vertical transmission

Limited to six months' treatment

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 \times total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
- 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

Hepatitis C

BOCEPREVIR – **Restricted** see terms below

☞ Cap 200 mg5,015.00 336 Victrelis

☞Restricted

Chronic hepatitis C - genotype 1, first-line

Gastroenterologist, infectious disease physician or general physician

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has not received prior pegylated interferon treatment; and
- 3 Patient has IL-28B genotype CT or TT; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Patient is hepatitis C protease inhibitor treatment-naïve; and
- 6 Maximum of 44 weeks therapy.

Chronic hepatitis C - genotype 1, second-line

Gastroenterologist, infectious disease physician or general physician.

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has received pegylated interferon treatment; and
- 3 Any one of:
 - 3.1 Patient was a responder relapser; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received pegylated interferon prior to 2004; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Maximum of 44 weeks therapy.

Note: Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count $<100 \times 10^9 /l$ or Albumin $<35 g/l$.

Herpesviridae

ACICLOVIR

Tab dispersible 200 mg – 1% DV Sep-13 to 2016	1.78	25	Lovir
Tab dispersible 400 mg – 1% DV Sep-13 to 2016	5.98	56	Lovir
Tab dispersible 800 mg – 1% DV Sep-13 to 2016	6.64	35	Lovir
Inj 250 mg vial	14.09	5	Zovirax IV

CIDOFOVIR – **Restricted** see terms below

☞ Inj 75 mg per ml, 5 ml vial

☞Restricted

Infectious disease physician, clinical microbiologist, otolaryngologist or oral surgeon

FOSCARNET SODIUM – **Restricted** see terms below

☞ Inj 24 mg per ml, 250 ml bottle

☞Restricted

Infectious disease physician or clinical microbiologist

GANCICLOVIR – **Restricted** see terms on the next page

☞ Inj 500 mg vial380.00 5 Cymevene

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Infectious disease physician or clinical microbiologist			
VALACICLOVIR – Restricted see terms below			
⚡ Tab 500 mg	102.72	30	Valtrex
➔Restricted			
Any of the following:			
1 Patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.			
2 Patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.			
3 Patient has undergone organ transplantation.			
Immunocompromised patients			
Limited to 7 days treatment			
Both:			
1 Patient is immunocompromised; and			
2 Patient has herpes zoster.			
VALGANCICLOVIR – Restricted see terms below			
⚡ Tab 450 mg – 1% DV Jun-15 to 2018	1,050.00	60	Valcyte
➔Restricted			
Transplant cytomegalovirus prophylaxis			
Limited to three months' treatment			
Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.			
Lung transplant cytomegalovirus prophylaxis			
Limited to six months' treatment			
Both:			
1 Patient has undergone a lung transplant; and			
2 Either:			
2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or			
2.2 The recipient is cytomegalovirus positive.			
Cytomegalovirus in immunocompromised patients			
Both:			
1 Patient is immunocompromised; and			
2 Any of the following:			
2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or			
2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or			
2.3 Patient has cytomegalovirus retinitis.			
Influenza			
OSELTAMIVIR – Restricted see terms below			
⚡ Tab 75 mg			
⚡ Powder for oral suspension 6 mg per ml			
➔Restricted			
Either:			
1 Only for hospitalised patient with known or suspected influenza; or			
2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.			
ZANAMIVIR			
⚡ Powder for inhalation 5 mg	37.38	20 dose	Relenza Rotadisk
➔Restricted			
Either:			
1 Only for hospitalised patient with known or suspected influenza; or			
2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.			

Immune Modulators

INTERFERON ALFA-2A

- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe

INTERFERON ALFA-2B

- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

INTERFERON GAMMA – **Restricted** see terms below

- ⚡ Inj 100 mcg in 0.5 ml vial

➡ **Restricted**

Patient has chronic granulomatous disease and requires interferon gamma.

PEGYLATED INTERFERON ALFA-2A – **Restricted** see terms below

⚡ Inj 135 mcg prefilled syringe			
⚡ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)			
⚡ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)			
⚡ Inj 180 mcg prefilled syringe	900.00	4	Pegasys
⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)	1,159.84	1	Pegasus RBV Combination Pack
⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)	1,290.00	1	Pegasus RBV Combination Pack

➡ **Restricted**

Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant

Both:

- Any of the following:
 - Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - Patient has chronic hepatitis C and is co-infected with HIV; or
 - Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.
- Maximum of 48 weeks therapy.

Notes:

Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation – (Chronic hepatitis C - genotype 1 infection)

Gastroenterologist, infectious disease physician or general physician

All of the following:

- Patient has chronic hepatitis C, genotype 1; and
- Patient has had previous treatment with pegylated interferon and ribavirin; and
- Either:
 - Patient has responder relapsed; or
 - Patient was a partial responder; and
- Patient is to be treated in combination with boceprevir; and
- Maximum of 48 weeks therapy.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

Initiation (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior)

Gastroenterologist, infectious disease physician or general physician

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initiation – Hepatitis B

Gastroenterologist, infectious disease specialist or general physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naïve; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log₁₀ IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 Serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

Approved dose is 180 mcg once weekly.

The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.

In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.

In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.

Pegylated Interferon alfa-2a is not approved for use in children.

MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Anticholinesterases

EDROPHONIUM CHLORIDE – **Restricted** see terms below

⚡ Inj 10 mg per ml, 15 ml vial

⚡ Inj 10 mg per ml, 1 ml ampoule

➡ **Restricted**

For the diagnosis of myasthenia gravis

NEOSTIGMINE METILSULFATE

Inj 2.5 mg per ml, 1 ml ampoule – **1% DV Sep-14 to 2017** 98.00 50 **AstraZeneca**

NEOSTIGMINE METILSULFATE WITH GLYCOPYRROLONIUM BROMIDE

Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule
– **1% DV Nov-13 to 2016** 27.86 10 **Max Health**

PYRIDOSTIGMINE BROMIDE

Tab 60 mg 38.90 100 Mestinon

Antirheumatoid Agents

AURANOFIN

Tab 3 mg

HYDROXYCHLOROQUINE

Tab 200 mg – **1% DV Sep-15 to 2018** 10.50 100 **Plaquenil**

LEFLUNOMIDE

Tab 10 mg 55.00 30 Arava

Tab 20 mg 76.00 30 Arava

Tab 100 mg 54.44 3 Arava

PENICILLAMINE

Tab 125 mg 61.93 100 D-Penamine

Tab 250 mg 98.98 100 D-Penamine

SODIUM AUROTHIOMALATE

Inj 10 mg in 0.5 ml ampoule

Inj 20 mg in 0.5 ml ampoule

Inj 50 mg in 0.5 ml ampoule

Drugs Affecting Bone Metabolism

Bisphosphonates

ALENDRONATE SODIUM

⚡ Tab 40 mg 133.00 30 Fosamax

➡ **Restricted**

Both:

1 Paget's disease; and

2 Any of the following:

2.1 Bone or articular pain; or

2.2 Bone deformity; or

2.3 Bone, articular or neurological complications; or

2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or

2.5 Preparation for orthopaedic surgery.

⚡ Tab 70 mg 12.90 4 Fosamax

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➡Restricted

Osteoporosis

Any of the following:

- History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
- History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- History of two significant osteoporotic fractures demonstrated radiologically; or
- Documented T-Score ≤ -3.0 (see Note); or
- A 10-year risk of hip fracture $\geq 3\%$, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- Patient has had a Special Authority approval for zoledronic acid (osteoporosis) or raloxifene.

Initiation - glucocorticosteroid therapy

Re-assessment required after 12 months

- Both:
- The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
 - Any of the following:
 - The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or
 - The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

Continuation - glucocorticosteroid therapy

Re-assessment required after 12 months

The patient is continuing systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents)

- Notes:
- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
 - Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
 - Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
 - A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – **Restricted** see terms below

⚡ Tab 70 mg with cholecalciferol 5,600 iu	12.90	4	Fosamax Plus
---	-------	---	--------------

➡Restricted

Osteoporosis

Any of the following:

- History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
<ol style="list-style-type: none"> History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or History of two significant osteoporotic fractures demonstrated radiologically; or Documented T-Score ≤ -3.0 (see Note); or A 10-year risk of hip fracture $\geq 3\%$, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or Patient has had a Special Authority approval for zoledronic acid (osteoporosis) or raloxifene. 			
Initiation - glucocorticosteroid therapy			
<i>Re-assessment required after 12 months</i>			
Both:			
<ol style="list-style-type: none"> The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and Any of the following: <ol style="list-style-type: none"> The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene. 			
Continuation - glucocorticosteroid therapy			
<i>Re-assessment required after 12 months</i>			
The patient is continuing systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents)			
Notes:			
<ol style="list-style-type: none"> BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable. Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≥ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates. Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. 			
ETIDRONATE DISODIUM			
Tab 200 mg – 1% DV Sep-15 to 2018	13.50	100	Arrow-Etidronate
PAMIDRONATE DISODIUM			
Inj 3 mg per ml, 10 ml vial	6.80	1	Pamisol
Inj 6 mg per ml, 10 ml vial	13.20	1	Pamisol
Inj 9 mg per ml, 10 ml vial	19.20	1	Pamisol
RISEDRONATE SODIUM			
Tab 35 mg	4.00	4	Risedronate Sandoz
ZOLEDRONIC ACID			
☯ Inj 5 mg per 100 ml, vial	600.00	100 ml	Aclasta

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

➔ **Restricted**

Inherited bone fragility disorders

Patient has been diagnosed with an inherited bone fragility disorder (e.g. osteogenesis imperfecta).

Osteoporosis

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \geq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initiation - glucocorticosteroid therapy

Re-assessment required after 12 months

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation - glucocorticosteroid therapy

Re-assessment required after 12 months

Both:

- 1 The patient is continuing systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initiation - Paget's disease

Re-assessment required after 12 months

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation - Paget's disease

Re-assessment required after 12 months

Both:

- 1 Any of the following:

continued...

continued...

- 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
- 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
- 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

RALOXIFENE – **Restricted** see terms below

☞ Tab 60 mg53.76 28 Evista

☞ **Restricted**

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score ≥ -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture $\geq 3\%$, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or alendronate (Underlying cause - Osteoporosis).

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TERIPARATIDE – Restricted see terms below			
☒ Inj 250 mcg per ml, 2.4 ml cartridge	490.00	1	Forteo

☛ **Restricted**

Limited to 18 months' treatment

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- 1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- 2 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialed so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- 3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINOL

Tab 100 mg – 1% DV Mar-15 to 2017	15.11	1,000	Apo-Allopurinol
Tab 300 mg – 1% DV Mar-15 to 2017	15.91	500	Apo-Allopurinol

BENZBROMARONE – **Restricted** see terms below

☒ Tab 100 mg	45.00	100	Benzbromaron AL 100
--------------------	-------	-----	---------------------

☛ **Restricted**

All of the following:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 Both:
 - 2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
 - 2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - 2.4 All of the following:
 - 2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
 - 2.4.2 Allopurinol is contraindicated; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and

3 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/downloads/Benzbromarone-prescriber-information-NZRA-V2.pdf

COLCHICINE

Tab 500 mcg – **1% DV Oct-13 to 2016** 10.08 100 **Colgout**

FEBUXOSTAT – **Restricted** see terms below

☞ Tab 80 mg 39.50 28 Adenuric

☞ Tab 120 mg 39.50 28 Adenuric

☞ **Restricted**

Both:

1 Patient has been diagnosed with gout; and

2 Any of the following:

2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or

2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note)

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

Tab 500 mg

RASBURICASE – **Restricted** see terms below

☞ Inj 1.5 mg vial

☞ **Restricted**

Haematologist

Muscle Relaxants and Related Agents

ATRACURIUM BESYLATE

Inj 10 mg per ml, 2.5 ml ampoule 6.13 5 Tracrium

Inj 10 mg per ml, 5 ml ampoule 9.19 5 Tracrium

BACLOFEN

Tab 10 mg – **1% DV Jun-13 to 2016** 3.85 100 **Pacifen**

Oral liq 1 mg per ml

Inj 0.05 mg per ml, 1 ml ampoule – **1% DV Sep-15 to 2018** 11.55 1 **Lioresal Intrathecal**

Inj 2 mg per ml, 5 ml ampoule 209.29 1 Lioresal Intrathecal

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CLOSTRIDIUM BOTULINUM TYPE A TOXIN			
Inj 100 u vial	467.50	1	Botox
Inj 500 u vial	1,295.00	2	Dysport
DANTROLENE			
Cap 25 mg	65.00	100	Dantrium
Cap 50 mg	77.00	100	Dantrium
Inj 20 mg vial			<i>e.g. Dantrium IV</i>
MIVACURIUM CHLORIDE			
Inj 2 mg per ml, 5 ml ampoule	33.92	5	Mivacron
Inj 2 mg per ml, 10 ml ampoule	67.17	5	Mivacron
ORPHENADRINE CITRATE			
Tab 100 mg			
PANCURONIUM BROMIDE			
Inj 2 mg per ml, 2 ml ampoule	260.00	50	AstraZeneca
ROCURONIUM BROMIDE			
Inj 10 mg per ml, 5 ml vial	38.25	10	DBL Rocuronium Bromide
SUXAMETHONIUM CHLORIDE			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Jun-14 to 2017	78.00	50	AstraZeneca
VECURONIUM BROMIDE			
Inj 4 mg ampoule			
Inj 10 mg vial			

Reversers of Neuromuscular Blockade

SUGAMMADEX – Restricted see terms below

⚡ Inj 100 mg per ml, 2 ml vial	1,200.00	10	Bridion
⚡ Inj 100 mg per ml, 5 ml vial	3,000.00	10	Bridion

➡Restricted

Any of the following:

- 1 Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
- 2 Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required; or
- 3 Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
- 4 The duration of the patient's surgery is unexpectedly short; or
- 5 Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
- 6 Patient has a partial residual block after conventional reversal.

Non-Steroidal Anti-Inflammatory Drugs

CELECOXIB – Restricted see terms below

⚡ Cap 100 mg	
⚡ Cap 200 mg	
⚡ Cap 400 mg	

➡Restricted

For preoperative and/or postoperative use for a total of up to 8 days' use.

MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DICLOFENAC SODIUM			
Tab EC 25 mg	4.00	100	Apo-Diclo
Tab 50 mg dispersible	1.50	20	Voltaren D
Tab EC 50 mg	16.00	500	Apo-Diclo
Tab long-acting 75 mg	3.10	30	Diclax SR
	24.52	500	Diclax SR
Tab long-acting 100 mg	42.25	500	Diclax SR
Inj 25 mg per ml, 3 ml ampoule – 1% DV Oct-14 to 2017	13.20	5	Voltaren
Suppos 12.5 mg – 1% DV Oct-14 to 2017	2.04	10	Voltaren
Suppos 25 mg – 1% DV Oct-14 to 2017	2.44	10	Voltaren
Suppos 50 mg – 1% DV Oct-14 to 2017	4.22	10	Voltaren
Suppos 100 mg – 1% DV Oct-14 to 2017	7.00	10	Voltaren
ETORICOXIB – Restricted see terms below			
⚡ Tab 30 mg			
⚡ Tab 60 mg			
⚡ Tab 90 mg			
⚡ Tab 120 mg			
➡ Restricted			
For preoperative and/or postoperative use for a total of up to 8 days' use.			
IBUPROFEN			
Tab 200 mg			
➡ Tab 400 mg – Restricted: For continuation only			
➡ Tab 600 mg – Restricted: For continuation only			
Tab long-acting 800 mg – 1% DV Jul-15 to 2018	7.99	30	Brufen SR
Oral liq 20 mg per ml – 1% DV Mar-14 to 2016	1.89	200 ml	Fenpaed
Inj 5 mg per ml, 2 ml ampoule			
Inj 10 mg per ml, 2 ml vial			
INDOMETHACIN			
Cap 25 mg			
Cap 50 mg			
Cap long-acting 75 mg			
Inj 1 mg vial			
Suppos 100 mg			
KETOPROFEN			
Cap long-acting 200 mg	12.07	28	Oruvail SR
MEFENAMIC ACID – Restricted: For continuation only			
➡ Cap 250 mg			
MELOXICAM – Restricted see terms below			
⚡ Tab 7.5 mg			
➡ Restricted			
Either:			
1 Haemophilic arthropathy, with both of the following:			
1.1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and			
1.2 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated; or			
2 For preoperative and/or postoperative use for a total of up to 8 days' use.			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NAPROXEN			
Tab 250 mg – 1% DV Sep-15 to 2018	18.06	500	Noflam 250
Tab 500 mg – 1% DV Sep-15 to 2018	18.91	250	Noflam 500
Tab long-acting 750 mg – 1% DV Jun-15 to 2018	18.00	90	Naprosyn SR 750
Tab long-acting 1 g – 1% DV Jun-15 to 2018	21.00	90	Naprosyn SR 1000
PARECOXIB			
Inj 40 mg vial	100.00	10	Dynastat
SULINDAC			
Tab 100 mg			
Tab 200 mg			
TENOXCAM			
Tab 20 mg – 1% DV Jan-15 to 2016	3.05	20	Reutenox
Inj 20 mg vial	9.95	1	AFT

Topical Products for Joint and Muscular Pain

CAPSAICIN – Restricted see terms below

📌 Crm 0.025% 9.95 45 g **Zostrix**

➡ **Restricted**

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Agents for Parkinsonism and Related Disorders

Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – **Restricted** see terms below

⚡ Tab 50 mg	400.00	56	Rilutek
-------------------	--------	----	---------

➡ **Restricted**

Initiation

Neurologist or respiratory specialist

Re-assessment required after 6 months

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
 - 5.1 The patient is ambulatory; or
 - 5.2 The patient is able to use upper limbs; or
 - 5.3 The patient is able to swallow.

Continuation

Re-assessment required after 18 months

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
 - 3.1 The patient is ambulatory; or
 - 3.2 The patient is able to use upper limb; or
 - 3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg – 1% DV Sep-13 to 2016	118.00	112	Motetis
--	--------	-----	---------

Anticholinergics

BENZTROPINE MESYLATE

Tab 2 mg	7.99	60	Benztrop
Inj 1 mg per ml, 2 ml ampoule	95.00	5	Cogentin

ORPHENADRINE HYDROCHLORIDE

Tab 50 mg

PROCYCLIDINE HYDROCHLORIDE

Tab 5 mg

Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

Cap 100 mg – 1% DV Oct-14 to 2017	38.24	60	Symmetrel
---	-------	----	-----------

APOMORPHINE HYDROCHLORIDE

Inj 10 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 2 ml ampoule	119.00	5	Apomine

BROMOCRIPTINE

Tab 2.5 mg

Cap 5 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ENTACAPONE			
Tab 200 mg – 1% DV Sep-15 to 2018	28.00	100	Entapone
LEVODOPA WITH BENSERAZIDE			
Tab dispersible 50 mg with benserazide 12.5 mg	10.00	100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg	8.00	100	Madopar 62.5
Cap 100 mg with benserazide 25 mg	12.50	100	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg	17.00	100	Madopar HBS
Cap 200 mg with benserazide 50 mg	25.00	100	Madopar 250
LEVODOPA WITH CARBIDOPA			
Tab 100 mg with carbidopa 25 mg	20.00	100	Sinemet <i>e.g. Kinson</i>
Tab long-acting 200 mg with carbidopa 50 mg	47.50	100	Sinemet CR
Tab 250 mg with carbidopa 25 mg	40.00	100	Sinemet <i>e.g. Sindopa</i>
LISURIDE HYDROGEN MALEATE			
Tab 200 mcg	25.00	30	Dopergin
PRAMIPEXOLE HYDROCHLORIDE			
Tab 0.25 mg – 1% DV Oct-14 to 2016	7.20	100	Ramipex
Tab 1 mg – 1% DV Oct-14 to 2016	24.39	100	Ramipex
ROPINIROLE HYDROCHLORIDE			
Tab 0.25 mg – 1% DV Mar-14 to 2016	2.36	100	Apo-Ropinirole
Tab 1 mg – 1% DV Mar-14 to 2016	5.32	100	Apo-Ropinirole
Tab 2 mg – 1% DV Mar-14 to 2016	7.72	100	Apo-Ropinirole
Tab 5 mg – 1% DV Mar-14 to 2016	14.48	100	Apo-Ropinirole
SELEGILINE HYDROCHLORIDE			
Tab 5 mg			
TOLCAPONE			
Tab 100 mg	126.20	100	Tasmar

Anaesthetics

General Anaesthetics

DESFLURANE			
Soln for inhalation 100%, 240 ml bottle	1,230.00	6	Suprane
DEXMEDETOMIDINE			
Inj 100 mcg per ml, 2 ml vial – 1% DV Oct-14 to 2017	479.85	5	Precedex
ETOMIDATE			
Inj 2 mg per ml, 10 ml ampoule			
ISOFLURANE			
Soln for inhalation 100%, 250 ml bottle	1,020.00	6	Aerrane
KETAMINE			
Inj 1 mg per ml, 100 ml bag – 1% DV Sep-14 to 2017	27.00	1	Biomed
Inj 4 mg per ml, 50 ml syringe – 1% DV Sep-14 to 2017	25.00	1	Biomed
Inj 10 mg per ml, 10 ml syringe – 1% DV Sep-14 to 2017	14.00	1	Biomed
Inj 100 mg per ml, 2 ml vial			
METHOHEXITAL SODIUM			
Inj 10 mg per ml, 50 ml vial			

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PROPOFOL			
Inj 10 mg per ml, 20 ml ampoule	7.60	5	Fresofol 1%
Inj 10 mg per ml, 20 ml vial	7.60	5	Provide MCT-LCT 1%
	42.00		Diprivan
Inj 10 mg per ml, 50 ml syringe	47.00	1	Diprivan
Inj 10 mg per ml, 50 ml vial	4.00	1	Fresofol 1%
	25.00		Provide MCT-LCT 1%
			Diprivan
Inj 10 mg per ml, 100 ml vial	7.60	1	Fresofol 1%
	30.00		Provide MCT-LCT 1%
			Diprivan
SEVOFLURANE			
Soln for inhalation 100%, 250 ml bottle	1,230.00	6	Baxter
THIOPENTAL [THIOPENTONE] SODIUM			
Inj 500 mg ampoule			
Local Anaesthetics			
ARTICAINE HYDROCHLORIDE			
Inj 1%			
ARTICAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge			
Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge			
BENZOCAINE			
Gel 20%			
BUPIVACAINE HYDROCHLORIDE			
Inj 5 mg per ml, 4 ml ampoule – 1% DV Jul-14 to 2017	50.00	5	Marcaïn Isobaric
Inj 2.5 mg per ml, 20 ml ampoule			
Inj 2.5 mg per ml, 20 ml ampoule sterile pack – 1% DV Sep-15 to 2018	29.20	5	Marcaïn
Inj 5 mg per ml, 10 ml ampoule sterile pack – 1% DV Sep-15 to 2018	20.25	5	Marcaïn
Inj 5 mg per ml, 20 ml ampoule			
Inj 5 mg per ml, 20 ml ampoule sterile pack – 1% DV Sep-15 to 2018	20.70	5	Marcaïn
Inj 1.25 mg per ml, 100 ml bag			
Inj 1.25 mg per ml, 200 ml bag			
Inj 2.5 mg per ml, 100 ml bag – 1% DV Jul-14 to 2017	150.00	5	Marcaïn
Inj 2.5 mg per ml, 200 ml bag			
Inj 1.25 mg per ml, 500 ml bag			
BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV Sep-14 to 2017	135.00	5	Marcaïn with Adrenaline
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Sep-14 to 2017	115.00	5	Marcaïn with Adrenaline

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag	210.00	10	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag	210.00	10	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe	72.00	10	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe	92.00	10	Biomed
BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE			
Inj 0.5% with glucose 8%, 4 ml ampoule	38.00	5	Marcaïn Heavy
COCAINE HYDROCHLORIDE			
Paste 5%			
Soln 15%, 2 ml syringe			
Soln 4%, 2 ml syringe	25.46	1	Biomed
COCAINE HYDROCHLORIDE WITH ADRENALINE			
Paste 15% with adrenaline 0.06%			
Paste 25% with adrenaline 0.06%			
ETHYL CHLORIDE			
Spray 100%			
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE			
Gel 2% – 1% DV Sep-15 to 2018	3.40	20 ml	Orion
Soln 4%			
Spray 10% – 1% DV Sep-13 to 2016	75.00	50 ml	Xylocaine
Oral (viscous) soln 2% – 1% DV Sep-14 to 2017	55.00	200 ml	Xylocaine Viscous
Inj 1%, 20 ml ampoule, sterile pack			
Inj 2%, 20 ml ampoule, sterile pack			
Inj 1%, 5 ml ampoule	8.75	25	Lidocaine-Clarís
Inj 1%, 20 ml ampoule	2.40	1	Lidocaine-Clarís
Inj 2%, 5 ml ampoule	6.90	25	Lidocaine-Clarís
Inj 2%, 20 ml ampoule	2.40	1	Lidocaine-Clarís
Gel 2%, 10 ml urethral syringe	43.26	10	Pfizer
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE			
Inj 1% with adrenaline 1:100,000, 5 ml ampoule	27.00	10	Xylocaine
Inj 1% with adrenaline 1:200,000, 20 ml vial	50.00	5	Xylocaine
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge			
Inj 2% with adrenaline 1:200,000, 20 ml vial	60.00	5	Xylocaine
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE			
Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – 1% DV Oct-14 to 2017	17.50	1	Topicaïne
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe	43.26	10	Pfizer
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE			
Nasal spray 5% with phenylephrine hydrochloride 0.5%			

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE			
Crn 2.5% with prilocaine 2.5%	45.00	30 g	EMLA
Patch 25 mcg with prilocaine 25 mcg	115.00	20	EMLA
Crn 2.5% with prilocaine 2.5%, 5 g	45.00	5	EMLA
LIDOCAINE [LIGNOCAINE]			
Crn 4%	27.00	30 g	LMX4
Crn 4% (5 g tubes)	27.00	5	LMX4
MEPIVACAINE HYDROCHLORIDE			
Inj 3%, 1.8 ml dental cartridge – 1% DV Oct-14 to 2017	43.60	50	Scandonest 3%
Inj 3%, 2.2 ml dental cartridge – 1% DV Oct-14 to 2017	43.60	50	Scandonest 3%
PRILOCAINE HYDROCHLORIDE			
Inj 0.5%, 50 ml vial	100.00	5	Citanest
Inj 2%, 5 ml ampoule	55.00	10	Citanest
PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN			
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge			
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge			
ROPIVACAINE HYDROCHLORIDE			
Inj 2 mg per ml, 10 ml ampoule – 1% DV Aug-15 to 2017	9.05	5	Ropivacaine Kabi
Inj 2 mg per ml, 20 ml ampoule – 1% DV Aug-15 to 2017	9.50	5	Ropivacaine Kabi
Inj 2 mg per ml, 100 ml bag – 1% DV Jul-15 to 2017	60.00	5	Naropin
Inj 2 mg per ml, 200 ml bag – 1% DV Jul-15 to 2017	79.50	5	Naropin
Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Aug-15 to 2017	10.20	5	Ropivacaine Kabi
Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Aug-15 to 2017	12.50	5	Ropivacaine Kabi
Inj 10 mg per ml, 10 ml ampoule – 1% DV Aug-15 to 2017	10.90	5	Ropivacaine Kabi
Inj 10 mg per ml, 20 ml ampoule – 1% DV Aug-15 to 2017	16.30	5	Ropivacaine Kabi
ROPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag	198.50	5	Naropin
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag	270.00	5	Naropin
TETRACAINE [AMETHOCAINE] HYDROCHLORIDE			
Gel 4%			

Analgesics

Non-Opioid Analgesics

ASPIRIN

Tab EC 300 mg

Tab dispersible 300 mg

CAPSAICIN – **Restricted** see terms below

☞ Crn 0.075% 12.50 45 g Zostrix HP

☞ **Restricted**

For post-herpetic neuralgia or diabetic peripheral neuropathy

METHOXYFLURANE – **Restricted** see terms below

☞ Soln for inhalation 99.9%, 3 ml bottle

☞ **Restricted**

- Both:
- 1 Patient is undergoing a painful procedure with an expected duration of less than one hour; and
 - 2 Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NEFOPAM HYDROCHLORIDE			
Tab 30 mg			
PARACETAMOL – Some items restricted see terms below			
Tab soluble 500 mg – 1% DV Oct-15 to 2017	1.60	20	Paragesic Soluble
Tab 500 mg			
Oral liq 120 mg per 5 ml – 20% DV Oct-14 to 2017	4.15	1,000 ml	Paracare
Oral liq 250 mg per 5 ml – 20% DV Sep-14 to 2017	4.35	1,000 ml	Paracare Double Strength
⚡ Inj 10 mg per ml, 50 ml vial – 1% DV Sep-14 to 2017	12.90	12	Perfalgan
⚡ Inj 10 mg per ml, 100 ml vial – 1% DV Sep-14 to 2017	12.90	12	Perfalgan
Suppos 25 mg	56.35	20	Biomed
Suppos 50 mg	56.35	20	Biomed
Suppos 125 mg	7.49	20	Panadol
Suppos 250 mg	14.40	20	Panadol
Suppos 500 mg	20.70	50	Paracare

➡ **Restricted**

Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.

SUCROSE

Oral liq 25%

Opioid Analgesics

ALFENTANIL

Inj 0.5 mg per ml, 2 ml ampoule – **1% DV Jan-15 to 2017** 39.07 10 **Hameln**

CODEINE PHOSPHATE

Tab 15 mg – **1% DV Jul-13 to 2016** 4.75 100 **PSM**
 Tab 30 mg – **1% DV Jul-13 to 2016** 5.80 100 **PSM**
 Tab 60 mg – **1% DV Jul-13 to 2016** 12.50 100 **PSM**

DIHYDROCODEINE TARTRATE

Tab long-acting 60 mg – **1% DV Sep-13 to 2016** 13.64 60 **DHC Continus**

FENTANYL

Inj 10 mcg per ml, 10 ml syringe
 Inj 50 mcg per ml, 2 ml ampoule – **1% DV Sep-15 to 2018** 3.95 10 **Boucher and Muir**
 Inj 10 mcg per ml, 50 ml bag 210.00 10 Biomed
 Inj 10 mcg per ml, 50 ml syringe 165.00 10 Biomed
 Inj 50 mcg per ml, 10 ml ampoule – **1% DV Sep-15 to 2018** 10.45 10 **Boucher and Muir**
 Inj 10 mcg per ml, 100 ml bag 210.00 10 Biomed
 Inj 20 mcg per ml, 50 ml syringe 185.00 10 Biomed
 Inj 20 mcg per ml, 100 ml bag
 Patch 12.5 mcg per hour – **1% DV Aug-15 to 2016** 2.92 5 **Fentanyl Sandoz**
 Patch 25 mcg per hour – **1% DV Aug-15 to 2016** 3.66 5 **Fentanyl Sandoz**
 Patch 50 mcg per hour – **1% DV Aug-15 to 2016** 6.64 5 **Fentanyl Sandoz**
 Patch 75 mcg per hour – **1% DV Aug-15 to 2016** 9.18 5 **Fentanyl Sandoz**
 Patch 100 mcg per hour – **1% DV Aug-15 to 2016** 11.29 5 **Fentanyl Sandoz**

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
METHADONE HYDROCHLORIDE			
Tab 5 mg – 1% DV Sep-15 to 2018	1.85	10	Methatabs
Oral liq 2 mg per ml – 1% DV Sep-15 to 2018	5.55	200 ml	Biodone
Oral liq 5 mg per ml – 1% DV Sep-15 to 2018	5.00	200 ml	Biodone Forte
Oral liq 10 mg per ml – 1% DV Sep-15 to 2018	6.55	200 ml	Biodone Extra Forte
Inj 10 mg per ml, 1 ml vial	61.00	10	AFT
MORPHINE HYDROCHLORIDE			
Oral liq 1 mg per ml – 1% DV Oct-15 to 2018	8.84	200 ml	RA-Morph
Oral liq 2 mg per ml – 1% DV Oct-15 to 2018	14.00	200 ml	RA-Morph
Oral liq 5 mg per ml – 1% DV Oct-15 to 2018	18.00	200 ml	RA-Morph
Oral liq 10 mg per ml – 1% DV Oct-15 to 2018	26.00	200 ml	RA-Morph
MORPHINE SULPHATE			
Tab long-acting 10 mg – 1% DV Sep-13 to 2016	1.95	10	Arrow-Morphine LA
Tab immediate-release 10 mg – 1% DV Apr-15 to 2017	2.80	10	Sevredol
Tab immediate-release 20 mg – 1% DV Apr-15 to 2017	5.52	10	Sevredol
Tab long-acting 30 mg – 1% DV Sep-13 to 2016	2.98	10	Arrow-Morphine LA
Tab long-acting 60 mg – 1% DV Sep-13 to 2016	5.75	10	Arrow-Morphine LA
Tab long-acting 100 mg – 1% DV Sep-13 to 2016	6.45	10	Arrow-Morphine LA
Cap long-acting 10 mg – 1% DV Feb-14 to 2016	1.70	10	m-Eslon
Cap long-acting 30 mg – 1% DV Feb-14 to 2016	2.50	10	m-Eslon
Cap long-acting 60 mg – 1% DV Feb-14 to 2016	5.40	10	m-Eslon
Cap long-acting 100 mg – 1% DV Feb-14 to 2016	6.38	10	m-Eslon
Inj 1 mg per ml, 100 ml bag – 1% DV Oct-14 to 2017	185.00	10	Biomed
Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-14 to 2017	45.00	10	Biomed
Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-14 to 2017	87.50	10	Biomed
Inj 1 mg per ml, 2 ml syringe			
Inj 2 mg per ml, 30 ml syringe	135.00	10	Biomed
Inj 5 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	12.48	5	DBL Morphine Sulphate
Inj 10 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	9.09	5	DBL Morphine Sulphate
Inj 10 mg per ml, 100 mg cassette			
Inj 10 mg per ml, 100 ml bag			
Inj 15 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	9.77	5	DBL Morphine Sulphate
Inj 30 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	12.43	5	DBL Morphine Sulphate
Inj 200 mcg in 0.4 ml syringe			
Inj 300 mcg in 0.3 ml syringe			
MORPHINE TARTRATE			
Inj 80 mg per ml, 1.5 ml ampoule – 1% DV Sep-13 to 2016	35.60	5	Hospira
Inj 80 mg per ml, 5 ml ampoule – 1% DV Sep-13 to 2016	107.67	5	Hospira

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
OXYCODONE HYDROCHLORIDE			
Tab controlled-release 5 mg	7.51	20	OxyContin
Tab controlled-release 10 mg	6.75	20	Oxycodone ControlledRelease Tablets(BNM)
Tab controlled-release 20 mg	11.50	20	Oxycodone ControlledRelease Tablets(BNM)
Tab controlled-release 40 mg	18.50	20	Oxycodone ControlledRelease Tablets(BNM)
Tab controlled-release 80 mg	34.00	20	Oxycodone ControlledRelease Tablets(BNM)
Cap immediate-release 5 mg – 1% DV Oct-15 to 2018	1.98	20	OxyNorm
Cap immediate-release 10 mg – 1% DV Oct-15 to 2018	3.91	20	OxyNorm
Cap immediate-release 20 mg – 1% DV Oct-15 to 2018	6.84	20	OxyNorm
Oral liq 5 mg per 5 ml	11.20	250 ml	OxyNorm
Inj 1 mg per ml, 100 ml bag			
Inj 10 mg per ml, 1 ml ampoule	10.08	5	Oxycodone Orion
Inj 10 mg per ml, 2 ml ampoule	19.87	5	Oxycodone Orion
Inj 50 mg per ml, 1 ml ampoule	60.00	5	OxyNorm
PARACETAMOL WITH CODEINE			
Tab paracetamol 500 mg with codeine phosphate 8 mg	2.11	100	Paracetamol + Codeine (Relieve)
PETHIDINE HYDROCHLORIDE			
Tab 50 mg	3.95	10	PSM
Tab 100 mg	5.80	10	PSM
Inj 5 mg per ml, 10 ml syringe			
Inj 5 mg per ml, 100 ml bag			
Inj 10 mg per ml, 100 ml bag			
Inj 10 mg per ml, 50 ml syringe			
Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017	5.51	5	DBL Pethidine Hydrochloride
Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017	5.83	5	DBL Pethidine Hydrochloride
REMIFENTANIL HYDROCHLORIDE			
Inj 1 mg vial – 1% DV Nov-14 to 2017	10.00	5	Ultiva
Inj 2 mg vial – 1% DV Nov-14 to 2017	18.00	5	Ultiva
TRAMADOL HYDROCHLORIDE			
Tab sustained-release 100 mg – 1% DV Oct-14 to 2017	2.00	20	Tramal SR 100
Tab sustained-release 150 mg – 1% DV Oct-14 to 2017	3.00	20	Tramal SR 150
Tab sustained-release 200 mg – 1% DV Oct-14 to 2017	4.00	20	Tramal SR 200
Cap 50 mg – 1% DV Oct-14 to 2017	2.50	100	Arrow-Tramadol
Oral drops 100 mg per ml			
Inj 10 mg per ml, 100 ml bag			
Inj 50 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	4.50	5	Tramal 50
Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-14 to 2017	4.50	5	Tramal 100

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antidepressants			
Cyclic and Related Agents			
AMITRIPTYLINE			
Tab 10 mg – 1% DV Sep-14 to 2017	1.68	100	Arrow-Amitriptyline
Tab 25 mg – 1% DV Jan-15 to 2017	1.68	100	Arrow-Amitriptyline
Tab 50 mg – 1% DV Jan-15 to 2017	2.82	100	Arrow-Amitriptyline
CLOMIPRAMINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Sep-15 to 2018	12.60	100	Apo-Clomipramine
Tab 25 mg – 1% DV Sep-15 to 2018	8.68	100	Apo-Clomipramine
DOTHIEPIN HYDROCHLORIDE			
Tab 75 mg	10.50	100	Dopress
Cap 25 mg	6.17	100	Dopress
DOXEPIH HYDROCHLORIDE			
Cap 10 mg			
Cap 25 mg			
Cap 50 mg			
IMIPRAMINE HYDROCHLORIDE			
Tab 10 mg	5.48	50	Tofranil
	6.58	60	Tofranil
Tab 25 mg	8.80	50	Tofranil
MAPROTILINE HYDROCHLORIDE			
Tab 25 mg			
Tab 75 mg			
MIANSERIN HYDROCHLORIDE – Restricted see terms below			
⚡ Tab 30 mg			
➡ Restricted			
For continuation only			
NORTRIPTYLINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Jun-13 to 2016	4.00	100	Norpress
Tab 25 mg – 1% DV Jun-13 to 2016	9.00	180	Norpress
Monoamine-Oxidase Inhibitors - Non-Selective			
PHENELZINE SULPHATE			
Tab 15 mg			
TRANLYCYPROMINE SULPHATE			
Tab 10 mg			
Monoamine-Oxidase Type A Inhibitors			
MOCLOBEMIDE			
Tab 150 mg – 1% DV Oct-15 to 2018	85.10	500	Apo-Moclobemide
Tab 300 mg – 1% DV Oct-15 to 2018	30.70	100	Apo-Moclobemide
Other Antidepressants			
MIRTAZAPINE – Restricted see terms on the next page			
⚡ Tab 30 mg	8.78	30	Avanza
⚡ Tab 45 mg	13.95	30	Avanza

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Initiation

Re-assessment required after two years

- Both:
- 1 The patient has a severe major depressive episode; and
 - 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

Continuation

Re-assessment required after two years

The patient has a high risk of relapse (prescriber determined)

VENLAFAXINE – **Some items restricted** see terms below

Tab modified release 37.5 mg	5.06	28	Arrow-Venlafaxine XR
Tab modified release 75 mg	6.44	28	Arrow-Venlafaxine XR
Tab modified release 150 mg	8.86	28	Arrow-Venlafaxine XR
Tab modified release 225 mg	14.34	28	Arrow-Venlafaxine XR
⚡ Cap modified release 37.5 mg	5.69	28	Efexor XR
⚡ Cap modified release 75 mg	11.40	28	Efexor XR
⚡ Cap modified release 150 mg	13.98	28	Efexor XR

➔ **Restricted**

Initiation

Re-assessment required after two years

- Both:
- 1 The patient has 'treatment-resistant' depression; and
 - 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Continuation

Re-assessment required after two years

The patient has a high risk of relapse (prescriber determined)

Selective Serotonin Reuptake Inhibitors

CITALOPRAM HYDROBROMIDE			
Tab 20 mg	2.34	84	Arrow-Citalopram
ESCITALOPRAM			
Tab 10 mg – 1% DV Jul-15 to 2016	1.40	28	Air Flow Products
Tab 20 mg – 1% DV Jul-15 to 2016	2.40	28	Air Flow Products
FLUOXETINE HYDROCHLORIDE			
Tab dispersible 20 mg, scored – 1% DV Apr-14 to 2016	2.50	30	Arrow-Fluoxetine
Cap 20 mg – 1% DV Apr-14 to 2016	1.74	90	Arrow-Fluoxetine
PAROXETINE HYDROCHLORIDE			
Tab 20 mg	4.32	90	Loxamine

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SERTRALINE			
Tab 50 mg – 1% DV Sep-13 to 2016	3.64	90	Arrow-Sertraline
Tab 100 mg – 1% DV Sep-13 to 2016	6.28	90	Arrow-Sertraline

Antiepilepsy Drugs

Agents for the Control of Status Epilepticus

CLONAZEPAM			
Inj 1 mg per ml, 1 ml ampoule	19.00	5	Rivotril
DIAZEPAM			
Inj 5 mg per ml, 2 ml ampoule	11.83	5	Hospira
Rectal tubes 5 mg	25.05	5	Stesolid
Rectal tubes 10 mg	30.50	5	Stesolid
LORAZEPAM			
Inj 2 mg vial			
Inj 4 mg per ml, 1 ml vial			
PARALDEHYDE			
Inj 5 ml ampoule			
PHENYTOIN SODIUM			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-15 to 2018	88.63	5	Hospira
Inj 50 mg per ml, 5 ml ampoule – 1% DV Oct-15 to 2018	133.92	5	Hospira

Control of Epilepsy

CARBAMAZEPINE			
Tab 200 mg	14.53	100	Tegretol
Tab long-acting 200 mg	16.98	100	Tegretol CR
Tab 400 mg	34.58	100	Tegretol
Tab long-acting 400 mg	39.17	100	Tegretol CR
Oral liq 20 mg per ml	26.37	250 ml	Tegretol
CLOBAZAM			
Tab 10 mg			
CLONAZEPAM			
Oral drops 2.5 mg per ml			
ETHOSUXIMIDE			
Cap 250 mg			
Oral liq 50 mg per ml			
GABAPENTIN – Restricted see terms on the next page			
⚡ Tab 600 mg			
⚡ Cap 100 mg	7.16	100	Arrow-Gabapentin Nupentin
⚡ Cap 300 mg	11.00	100	Arrow-Gabapentin Nupentin
⚡ Cap 400 mg	13.75	100	Arrow-Gabapentin Nupentin

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

- 1 For preoperative and/or postoperative use for up to a total of 8 days' use; or
- 2 For the pain management of burns patients with monthly review.

Initiation - epilepsy

Re-assessment required after 15 months

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Continuation - epilepsy

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Initiation - Neuropathic pain or Chronic Kidney Disease-associated pruritus

Re-assessment required after 3 months

Either:

- 1 The patient has been diagnosed with neuropathic pain; or
- 2 Both:
 - 2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus* where no other cause for pruritus can be identified (e.g. scabies, allergy); and
 - 2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.

Continuation - Neuropathic pain or Chronic Kidney Disease-associated pruritus

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Notes: Indications marked with * are Unapproved Indications. Dosage adjustment of gabapentin is recommended for patients with renal impairment.

LACOSAMIDE – **Restricted** see terms below

⚡ Tab 50 mg	25.04	14	Vimpat
⚡ Tab 100 mg	50.06	14	Vimpat
	200.24	56	Vimpat
⚡ Tab 150 mg	75.10	14	Vimpat
	300.40	56	Vimpat
⚡ Tab 200 mg	400.55	56	Vimpat
⚡ Inj 10 mg per ml, 20 ml vial			

➔ **Restricted**

Initiation

Re-assessment required after 15 months

Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

continued...

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.			
Continuation			
Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).			
Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.			
LAMOTRIGINE			
Tab dispersible 2 mg	6.74	30	Lamictal
Tab dispersible 5 mg	9.64	30	Lamictal
	15.00	56	Arrow-Lamotrigine
Tab dispersible 25 mg	19.38	56	Logem
	20.40		Arrow-Lamotrigine
			Mogine
	29.09		Lamictal
Tab dispersible 50 mg	32.97	56	Logem
	34.70		Arrow-Lamotrigine
			Mogine
	47.89		Lamictal
Tab dispersible 100 mg	56.91	56	Logem
	59.90		Arrow-Lamotrigine
			Mogine
	79.16		Lamictal
LEVETIRACETAM			
Tab 250 mg	24.03	60	Levetiracetam-Rex
Tab 500 mg	28.71	60	Levetiracetam-Rex
Tab 750 mg	45.23	60	Levetiracetam-Rex
Inj 100 mg per ml, 5 ml vial			
PHENOBARBITONE			
Tab 15 mg	28.00	500	PSM
Tab 30 mg	29.00	500	PSM
PHENYTOIN			
Tab 50 mg			
PHENYTOIN SODIUM			
Cap 30 mg			
Cap 100 mg			
Oral liq 6 mg per ml			
PRIMIDONE			
Tab 250 mg			
SODIUM VALPROATE			
Tab 100 mg			
Tab EC 200 mg			
Tab EC 500 mg			
Oral liq 40 mg per ml			
Inj 100 mg per ml, 4 ml vial – 1% DV Sep-15 to 2018	16.60	1	Epilim IV

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
STIRIPENTOL – Restricted see terms below			
☞ Cap 250 mg	509.29	60	Diacomit
☞ Powder for oral liq 250 mg sachet	509.29	60	Diacomit

☞ **Restricted**

Paediatric neurologist

Initiation

Re-assessment required after 6 months

- Both:
- 1 Patient has confirmed diagnosis of Dravet syndrome; and
 - 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Continuation

Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

Tab 25 mg	11.07	60	Arrow-Topiramate Topiramate Actavis Topamax
Tab 50 mg	18.81	60	Arrow-Topiramate Topiramate Actavis Topamax
Tab 100 mg	31.99	60	Arrow-Topiramate Topiramate Actavis Topamax
Tab 200 mg	55.19	60	Arrow-Topiramate Topiramate Actavis Topamax
Cap sprinkle 15 mg	20.84	60	Topamax
Cap sprinkle 25 mg	26.04	60	Topamax

VIGABATRIN – Restricted see terms below

☞ Tab 500 mg

☞ **Restricted**

- Both:
- 1 Either:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
 - 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes:

"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antimigraine Preparations			
Acute Migraine Treatment			
DIHYDROERGOTAMINE MESYLATE			
Inj 1 mg per ml, 1 ml ampoule			
ERGOTAMINE TARTRATE WITH CAFFEINE			
Tab 1 mg with caffeine 100 mg			
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL			
Tab 5 mg with paracetamol 500 mg			
RIZATRIPTAN			
Tab orodispersible 10 mg – 1% DV Sep-14 to 2017	8.10	30	Rizamelt
SUMATRIPTAN			
Tab 50 mg – 1% DV Sep-13 to 2016	29.80	100	Arrow-Sumatriptan
Tab 100 mg – 1% DV Sep-13 to 2016	54.80	100	Arrow-Sumatriptan
Inj 12 mg per ml, 0.5 ml cartridge – 1% DV Sep-13 to 2016	13.80	2	Arrow-Sumatriptan
Prophylaxis of Migraine			
PIZOTIFEN			
Tab 500 mcg – 1% DV Sep-15 to 2018	23.21	100	Sandomigran
Antinausea and Vertigo Agents			
APREPITANT – Restricted see terms below			
☞ Cap 2 × 80 mg and 1 × 125 mg – 1% DV Sep-14 to 2017	100.00	3	Emend Tri-Pack
☞ Restricted			
Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.			
BETHAHISTINE DIHYDROCHLORIDE			
Tab 16 mg – 1% DV Jun-14 to 2017	4.95	84	Vergo 16
CYCLIZINE HYDROCHLORIDE			
Tab 50 mg	0.59	10	Nausicalm
CYCLIZINE LACTATE			
Inj 50 mg per ml, 1 ml ampoule	14.95	5	Nausicalm
DOMPERIDONE			
Tab 10 mg	3.25	100	Prokinex
DROPERIDOL			
Inj 2.5 mg per ml, 1 ml ampoule			
GRANISETRON			
Tab 1 mg – 1% DV Jan-15 to 2017	5.98	50	Granirex
HYOSCINE HYDROBROMIDE			
Inj 400 mcg per ml, 1 ml ampoule	46.50	5	Hospira
☞ Patch 1.5 mg – 1% DV Dec-13 to 2016	11.95	2	Scopoderm TTS

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Any of the following:

- 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
- 2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or
- 3 For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated.

METOCLOPRAMIDE HYDROCHLORIDE

Tab 10 mg – 1% DV Sep-14 to 2017	1.82	100	Metamide
Oral liq 5 mg per 5 ml			
Inj 5 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017	4.50	10	Pfizer

ONDANSETRON

Tab 4 mg – 1% DV Jan-14 to 2016	5.51	50	Onrex
Tab dispersible 4 mg – 1% DV Oct-14 to 2017	1.00	10	Dr Reddy's Ondansetron
Tab 8 mg – 1% DV Jan-14 to 2016	6.19	50	Onrex
Tab dispersible 8 mg – 1% DV Oct-14 to 2017	1.50	10	Ondansetron ODT-DRLA
Inj 2 mg per ml, 2 ml ampoule – 1% DV Sep-13 to 2016	1.82	5	Ondanaccord
Inj 2 mg per ml, 4 ml ampoule – 1% DV Sep-13 to 2016	2.18	5	Ondanaccord

PROCHLORPERAZINE

Tab buccal 3 mg			
Tab 5 mg – 1% DV Jun-14 to 2017	9.75	500	Antinaus
Inj 12.5 mg per ml, 1 ml ampoule			
Suppos 25 mg			

PROMETHAZINE THEOCLATE – Restricted: For continuation only

➔ Tab 25 mg

TROPISETRON

Inj 1 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018	8.95	1	Tropisetron-AFT
Inj 1 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	13.95	1	Tropisetron-AFT

Antipsychotic Agents

General

AMISULPRIDE

Tab 100 mg – 1% DV Jul-13 to 2016	6.22	30	Solian
Tab 200 mg – 1% DV Jul-13 to 2016	21.92	60	Solian
Tab 400 mg – 1% DV Jul-13 to 2016	44.52	60	Solian
Oral liq 100 mg per ml – 1% DV Jul-13 to 2016	52.50	60 ml	Solian

ARIPIRAZOLE – Restricted see terms on the next page

⚡ Tab 10 mg	123.54	30	Abilify
⚡ Tab 15 mg	175.28	30	Abilify
⚡ Tab 20 mg	213.42	30	Abilify
⚡ Tab 30 mg	260.07	30	Abilify

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➡Restricted			
Initiation - schizophrenia or related psychoses			
Both:			
1 Patient is suffering from schizophrenia or related psychoses; and			
2 Either:			
2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or			
2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.			
Initiation . Autism spectrum disorder*			
Psychiatrist or paediatrician			
All of the following:			
1 The patient has been diagnosed with an autism spectrum disorder* and has symptoms of severe irritability; and			
2 An effective dose of risperidone has been trialled and has been discontinued because of unacceptable side effects or inadequate response; and			
3 The patient is aged less than 18 years.			
Note: Indications marked with * are Unapproved Indications			
CHLORPROMAZINE HYDROCHLORIDE			
Tab 10 mg			
Tab 25 mg			
Tab 100 mg			
Oral liq 10 mg per ml			
Inj 25 mg per ml, 2 ml ampoule			
CLOZAPINE			
Tab 25 mg	5.69	50	Clozaril
	11.36	100	Clozaril
	6.69	50	Clopine
	13.37	100	Clopine
Tab 50 mg	8.67	50	Clopine
	17.33	100	Clopine
Tab 100 mg	14.73	50	Clozaril
	29.45	100	Clozaril
	17.33	50	Clopine
	34.65	100	Clopine
Tab 200 mg	34.65	50	Clopine
	69.30	100	Clopine
Oral liq 50 mg per ml	17.33	100 ml	Clopine
HALOPERIDOL			
Tab 500 mcg – 1% DV Oct-13 to 2016	6.23	100	Serenace
Tab 1.5 mg – 1% DV Oct-13 to 2016	9.43	100	Serenace
Tab 5 mg – 1% DV Oct-13 to 2016	29.72	100	Serenace
Oral liq 2 mg per ml – 1% DV Oct-13 to 2016	23.84	100 ml	Serenace
Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-13 to 2016	21.55	10	Serenace
LEVOMEPRMAZINE			
Tab 25 mg			
Tab 100 mg			
Inj 25 mg per ml, 1 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LITHIUM CARBONATE			
Tab long-acting 400 mg			
Tab 250 mg – 1% DV Sep-15 to 2018	34.30	500	Lithicarb FC
Tab 400 mg – 1% DV Sep-15 to 2018	12.83	100	Lithicarb FC
Cap 250 mg – 1% DV Sep-14 to 2017	9.42	100	Douglas
OLANZAPINE			
Tab 2.5 mg – 1% DV Sep-14 to 2017	0.75	28	Zypine
Tab 5 mg – 1% DV Sep-14 to 2017	1.65	28	Zypine
Tab orodispersible 5 mg – 1% DV Sep-14 to 2017	1.75	28	Zypine ODT
Tab 10 mg – 1% DV Sep-14 to 2017	2.55	28	Zypine
Tab orodispersible 10 mg – 1% DV Sep-14 to 2017	3.05	28	Zypine ODT
Inj 10 mg vial			
PERICYAZINE			
Tab 2.5 mg			
Tab 10 mg			
QUETIAPINE			
Tab 25 mg – 1% DV Sep-14 to 2017	2.10	90	Quetapel
Tab 100 mg – 1% DV Sep-14 to 2017	4.20	90	Quetapel
Tab 200 mg – 1% DV Sep-14 to 2017	7.20	90	Quetapel
Tab 300 mg – 1% DV Sep-14 to 2017	12.00	90	Quetapel
RISPERIDONE – Some items restricted see terms below			
Tab 0.5 mg – 1% DV Feb-15 to 2017	1.90	60	Actavis
⚡ Tab orodispersible 0.5 mg	21.42	28	Risperdal Quicklet
Tab 1 mg – 1% DV Feb-15 to 30 Sep 2017	2.10	60	Actavis
⚡ Tab orodispersible 1 mg	42.84	28	Risperdal Quicklet
Tab 2 mg – 1% DV Feb-15 to 2017	2.34	60	Actavis
⚡ Tab orodispersible 2 mg	85.71	28	Risperdal Quicklet
Tab 3 mg – 1% DV Feb-15 to 2017	2.55	60	Actavis
Tab 4 mg – 1% DV Feb-15 to 2017	3.50	60	Actavis
Oral liq 1 mg per ml – 1% DV Sep-14 to 2017	9.75	30 ml	Risperon
➡ Restricted			
Acute situations			
Both:			
1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and			
2 The patient is under direct supervision for administration of medicine.			
Chronic situations			
Both:			
1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and			
2 The patient is under direct supervision for administration of medicine.			
TRIFLUOPERAZINE HYDROCHLORIDE			
Tab 1 mg			
Tab 2 mg			
Tab 5 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ZIPRASIDONE – Some items restricted see terms below			
⚡ Cap 20 mg	87.88	60	Zeldox
⚡ Cap 40 mg	164.78	60	Zeldox
⚡ Cap 60 mg	247.17	60	Zeldox
⚡ Cap 80 mg	329.56	60	Zeldox
Inj 20 mg			
Inj 100 mg			

➡Restricted

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

ZUCLOPENTHIXOL ACETATE

Inj 50 mg per ml, 1 ml ampoule

Inj 50 mg per ml, 2 ml ampoule

ZUCLOPENTHIXOL HYDROCHLORIDE

Tab 10 mg31.45 100 Clopixol

Depot Injections

FLUPENTHIXOL DECANOATE

Inj 20 mg per ml, 1 ml ampoule13.14 5 Fluanxol

Inj 20 mg per ml, 2 ml ampoule20.90 5 Fluanxol

Inj 100 mg per ml, 1 ml ampoule40.87 5 Fluanxol

FLUPHENAZINE DECANOATE

Inj 12.5 mg per 0.5 ml ampoule17.60 5 Modecate

Inj 25 mg per ml, 1 ml ampoule27.90 5 Modecate

Inj 100 mg per ml, 1 ml ampoule154.50 5 Modecate

HALOPERIDOL DECANOATE

Inj 50 mg per ml, 1 ml ampoule28.39 5 Haldol

Inj 100 mg per ml, 1 ml ampoule55.90 5 Haldol Concentrate

OLANZAPINE – Restricted

 see terms below

⚡ Inj 210 mg vial	280.00	1	Zyprexa Relprevv
⚡ Inj 300 mg vial	460.00	1	Zyprexa Relprevv
⚡ Inj 405 mg vial	560.00	1	Zyprexa Relprevv

➡Restricted

Initiation

Re-assessment required after 12 months

- Either:
- 1 The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
 - 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Continuation

Re-assessment required after 12 months

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE – Restricted see terms below

⚡ Inj 25 mg syringe	194.25	1	Invega Sustenna
⚡ Inj 50 mg syringe	271.95	1	Invega Sustenna
⚡ Inj 75 mg syringe	357.42	1	Invega Sustenna
⚡ Inj 100 mg syringe	435.12	1	Invega Sustenna
⚡ Inj 150 mg syringe	435.12	1	Invega Sustenna

➡Restricted

Initiation

Re-assessment required after 12 months

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PIPOTHIAZINE PALMITATE – Restricted: For continuation only

- ➡ Inj 50 mg per ml, 1 ml ampoule
- ➡ Inj 50 mg per ml, 2 ml ampoule

RISPERIDONE – Restricted see terms below

⚡ Inj 25 mg vial	135.98	1	Risperdal Consta
⚡ Inj 37.5 mg vial	178.71	1	Risperdal Consta
⚡ Inj 50 mg vial	217.56	1	Risperdal Consta

➡Restricted

Initiation

Re-assessment required after 12 months

Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE

Inj 200 mg per ml, 1 ml ampoule	19.80	5	Clopixol
---------------------------------------	-------	---	----------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anxiolytics			
ALPRAZOLAM			
Tab 1 mg			
Tab 250 mcg			
Tab 500 mcg			
BUSPIRONE HYDROCHLORIDE			
Tab 5 mg	28.00	100	Pacific Buspirone
Tab 10 mg	17.00	100	Pacific Buspirone
CLONAZEPAM			
Tab 500 mcg	7.53	100	Paxam
Tab 2 mg	14.37	100	Paxam
DIAZEPAM			
Tab 2 mg	11.44	500	Arrow-Diazepam
Tab 5 mg	13.71	500	Arrow-Diazepam
LORAZEPAM			
Tab 1 mg – 1% DV Jun-15 to 2018	10.79	250	Ativan
Tab 2.5 mg – 1% DV Jun-15 to 2018	13.88	100	Ativan
OXAZEPAM			
Tab 10 mg – 1% DV Dec-14 to 2017	6.17	100	Ox-Pam
Tab 15 mg – 1% DV Dec-14 to 2017	8.53	100	Ox-Pam

Multiple Sclerosis Treatments

FINGOLIMOD – **Restricted** see terms below

☞ Cap 0.5 mg 2,650.00 28 Gilenya

☞ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

NATALIZUMAB – **Restricted** see terms below

☞ Inj 20 mg per ml, 15 ml vial 1,750.00 1 Tysabri

☞ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier.

Other Multiple Sclerosis Treatments

☞ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

GLATIRAMER ACETATE – **Restricted** see terms above

☞ Inj 20 mg per ml, 1 ml syringe

INTERFERON BETA-1-ALPHA – **Restricted** see terms above

☞ Inj 6 million iu in 0.5 ml pen injector	1,170.00	4	Avonex Pen
☞ Inj 6 million iu in 0.5 ml syringe	1,170.00	4	Avonex
☞ Inj 6 million iu vial	1,170.00	4	Avonex

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

INTERFERON BETA-1-BETA – **Restricted** see terms on the preceding page

⬆ Inj 8 million iu per ml, 1 ml vial

Sedatives and Hypnotics

CHLORAL HYDRATE

Oral liq 100 mg per ml

Oral liq 200 mg per ml

LORMETAZEPAM – **Restricted**: For continuation only

➡ Tab 1 mg

MELATONIN – **Restricted** see terms below

⬇ Tab modified-release 2 mg

e.g. Circadin

⬇ Tab 1 mg

⬇ Tab 2 mg

⬇ Tab 3 mg

⬇ Cap 2 mg

⬇ Cap 3 mg

➡ **Restricted**

For in hospital use only. For the treatment of insomnia where benzodiazepines and zopiclone are contraindicated.

MIDAZOLAM

Tab 7.5 mg 40.00 100 Hypnovel

Oral liq 2 mg per ml

Inj 1 mg per ml, 5 ml ampoule 10.00 10 Pfizer

10.75 Hypnovel

Inj 5 mg per ml, 3 ml ampoule 11.90 5 Hypnovel

Pfizer

NITRAZEPAM

Tab 5 mg – 1% DV Dec-14 to 2017 5.22 100 **Nitrados**

PHENOBARBITONE

Inj 200 mg per ml, 1 ml ampoule

TEMAZEPAM

Tab 10 mg – 1% DV Sep-14 to 2017 1.27 25 **Normison**

TRIAZOLAM – **Restricted**: For continuation only

➡ Tab 125 mcg

➡ Tab 250 mcg

ZOPICLONE

Tab 7.5 mg 1.90 30 Apo-Zopiclone

Stimulants / ADHD Treatments

ATOMOXETINE – **Restricted** see terms on the next page

⬇ Cap 10 mg 107.03 28 Strattera

⬇ Cap 18 mg 107.03 28 Strattera

⬇ Cap 25 mg 107.03 28 Strattera

⬇ Cap 40 mg 107.03 28 Strattera

⬇ Cap 60 mg 107.03 28 Strattera

⬇ Cap 80 mg 139.11 28 Strattera

⬇ Cap 100 mg 139.11 28 Strattera

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔Restricted

All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
 - 3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

CAFFEINE

Tab 100 mg

DEXAMFETAMINE SULFATE – **Restricted** see terms below

⚡ Tab 5 mg	16.50	100	PSM
------------------	-------	-----	-----

➔Restricted

ADHD

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

Narcolepsy

Neurologist or respiratory specialist

Patient suffers from narcolepsy

METHYLPHENIDATE HYDROCHLORIDE – **Restricted** see terms on the next page

⚡ Tab extended-release 18 mg	58.96	30	Concerta
⚡ Tab extended-release 27 mg	65.44	30	Concerta
⚡ Tab extended-release 36 mg	71.93	30	Concerta
⚡ Tab extended-release 54 mg	86.24	30	Concerta
⚡ Tab immediate-release 5 mg	3.20	30	Rubifen
⚡ Tab immediate-release 10 mg	3.00	30	Ritalin
			Rubifen
⚡ Tab immediate-release 20 mg	7.85	30	Rubifen
⚡ Tab sustained-release 20 mg	10.95	30	Rubifen SR
	50.00	100	Ritalin SR
⚡ Cap modified-release 10 mg	15.60	30	Ritalin LA
⚡ Cap modified-release 20 mg	20.40	30	Ritalin LA
⚡ Cap modified-release 30 mg	25.52	30	Ritalin LA
⚡ Cap modified-release 40 mg	30.60	30	Ritalin LA

Price (ex man. excl. GST)	Brand or Generic
\$	Per Manufacturer

➔ **Restricted**

ADHD (immediate-release and sustained-release formulations)

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

Narcolepsy (immediate-release and sustained-release formulations)

Neurologist or respiratory specialist

Patient suffers from narcolepsy

Extended-release and modified-release formulations

Paediatrician or psychiatrist

Both:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Either:
 - 2.1 Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

MODAFINIL – **Restricted** see terms below

⚡ Tab 100 mg

➔ **Restricted**

Neurologist or respiratory specialist

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
 - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 3 Either:
 - 3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
 - 3.2 Methylphenidate and dexamphetamine are contraindicated.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

Tab 5 mg – 1% DV Feb-15 to 2017	5.48	90	Donepezil-Rex
Tab 10 mg – 1% DV Feb-15 to 2017	10.51	90	Donepezil-Rex

RIVASTIGMINE – Restricted see terms below

⚡ Patch 4.6 mg per 24 hour	90.00	30	Exelon
⚡ Patch 9.5 mg per 24 hour	90.00	30	Exelon

➔ **Restricted**

Initiation

Re-assessment required after 6 months

Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Continuation

Re-assessment required after 12 months

Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Treatments for Substance Dependence			
BUPRENORPHINE WITH NALOXONE – Restricted see terms below			
⚡ Tab 2 mg with naloxone 0.5 mg	57.40	28	Suboxone
⚡ Tab 8 mg with naloxone 2 mg	166.00	28	Suboxone
➡Restricted			
Detoxification			
All of the following:			
1 Patient is opioid dependent; and			
2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and			
3 Prescriber works in an opioid treatment service approved by the Ministry of Health.			
Maintenance treatment			
All of the following:			
1 Patient is opioid dependent; and			
2 Patient will not be receiving methadone; and			
3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and			
4 Prescriber works in an opioid treatment service approved by the Ministry of Health.			
BUPROPION HYDROCHLORIDE			
Tab modified-release 150 mg – 1% DV Oct-13 to 2016	4.97	30	Zyban
DISULFIRAM			
Tab 200 mg	24.30	100	Antabuse
NALTREXONE HYDROCHLORIDE – Restricted see terms below			
⚡ Tab 50 mg – 1% DV Sep-13 to 2016	76.00	30	Naltraccord
➡Restricted			
Alcohol dependence			
Both:			
1 Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and			
2 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.			
Constipation			
For the treatment of opioid-induced constipation			
NICOTINE – Some items restricted see terms on the next page			
Gum 2 mg – 1% DV Apr-14 to 2017	22.26	384	Habitrol (Classic) Habitrol (Fruit) Habitrol (Mint)
Gum 4 mg – 1% DV Apr-14 to 2017	25.67	384	Habitrol (Classic) Habitrol (Fruit) Habitrol (Mint)
Patch 7 mg per 24 hours – 1% DV Apr-14 to 2017	10.57	28	Habitrol
Patch 14 mg per 24 hours – 1% DV Apr-14 to 2017	11.31	28	Habitrol
Patch 21 mg per 24 hours – 1% DV Apr-14 to 2017	11.95	28	Habitrol
⚡ Oral spray 1 mg per dose			<i>e.g. Nicorette QuickMist Mouth Spray</i>
Lozenge 1 mg – 1% DV Apr-14 to 2017	12.91	216	Habitrol
Lozenge 2 mg – 1% DV Apr-14 to 2017	14.14	216	Habitrol
⚡ Soln for inhalation 15 mg cartridge			<i>e.g. Nicorette Inhalator</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Any of the following:			
1 For perioperative use in patients who have a 'nil by mouth' instruction; or			
2 For use within mental health inpatient units; or			
3 For acute use in agitated patients who are unable to leave the hospital facilities.			
VARENICLINE – Restricted see terms below			
⚡ Tab 0.5 mg × 11 and 1 mg × 14	60.48	25	Champix
⚡ Tab 1 mg	67.74	28	Champix
	135.48	56	Champix

➔Restricted

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 3 months' funded varenicline in a 12 month period.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Chemotherapeutic Agents			
Alkylating Agents			
BUSULFAN			
Tab 2 mg	59.50	100	Myleran
Inj 6 mg per ml, 10 ml ampoule			
CARMUSTINE			
Inj 100 mg vial – 1% DV Sep-15 to 2018	532.00	1	BiCNU
CHLORAMBUCIL			
Tab 2 mg			
CYCLOPHOSPHAMIDE			
Tab 50 mg	79.00	50	Endoxan
	158.00	100	Procytox
Inj 1 g vial – 1% DV Oct-15 to 2018	35.03	1	Endoxan
Inj 2 g vial – 1% DV Oct-15 to 2018	70.06	1	Endoxan
IFOSFAMIDE			
Inj 1 g vial	96.00	1	Holoxan
Inj 2 g vial	180.00	1	Holoxan
LOMUSTINE			
Cap 10 mg	132.59	20	Ceenu
Cap 40 mg	399.15	20	Ceenu
MELPHALAN			
Tab 2 mg			
Inj 50 mg vial			
THIOTEPA			
Inj 15 mg vial			
Anthracyclines and Other Cytotoxic Antibiotics			
BLEOMYCIN SULPHATE			
Inj 15,000 iu (10 mg) vial – 1% DV Oct-15 to 2018	150.48	1	DBL Bleomycin Sulfate
DACTINOMYCIN [ACTINOMYCIN D]			
Inj 0.5 mg vial	145.00	1	Cosmegen
DAUNORUBICIN			
Inj 2 mg per ml, 10 ml vial – 1% DV Aug-13 to 2016	118.72	1	Pfizer
DOXORUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial			
Inj 2 mg per ml, 25 ml vial	17.00	1	Arrow-Doxorubicin
Inj 50 mg vial			
Inj 2 mg per ml, 50 ml vial			
Inj 2 mg per ml, 100 ml vial	65.00	1	Arrow-Doxorubicin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
EPIRUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial	25.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial	39.38	1	DBL Epirubicin Hydrochloride
Inj 2 mg per ml, 50 ml vial	58.20	1	DBL Epirubicin Hydrochloride
Inj 2 mg per ml, 100 ml vial	94.50	1	DBL Epirubicin Hydrochloride
IDARUBICIN HYDROCHLORIDE			
Inj 5 mg vial	100.00	1	Zavedos
Inj 10 mg vial	200.00	1	Zavedos
MITOMYCIN C			
Inj 5 mg vial – 1% DV Oct-13 to 2016	79.75	1	Arrow
MITOZANTRONE			
Inj 2 mg per ml, 5 ml vial	110.00	1	Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml vial – 1% DV Sep-15 to 2018	97.50	1	Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml vial	413.21	1	Onkotrone
<i>(Mitozantrone Ebewe Inj 2 mg per ml, 5 ml vial to be delisted 1 September 2015)</i>			
<i>(Onkotrone Inj 2 mg per ml, 12.5 ml vial to be delisted 1 September 2015)</i>			

Antimetabolites

AZACITIDINE – **Restricted** see terms below

⚡ Inj 100 mg vial605.00 1 Vidaza

➡ **Restricted**

Initiation

Haematologist

Re-assessment required after 12 months

All of the following:

- 1 Any of the following:
 - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
 - 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
 - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
- 2 The patient has performance status (WHO/ECOG) grade 0-2; and
- 3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
- 4 The patient has an estimated life expectancy of at least 3 months.

Notes: Indication marked with a * is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

Continuation

Haematologist

Re-assessment required after 12 months

Both:

- 1 No evidence of disease progression, and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CAPECITABINE			
Tab 150 mg – 1% DV Sep-14 to 2016	30.00	60	Capecitabine Winthrop
Tab 500 mg – 1% DV Sep-14 to 2016	120.00	120	Capecitabine Winthrop
CLADRIBINE			
Inj 2 mg per ml, 5 ml vial			
Inj 1 mg per ml, 10 ml vial	5,249.72	7	Leustatin
CYTARABINE			
Inj 20 mg per ml, 5 ml vial – 1% DV Nov-13 to 2016	55.00	5	Pfizer
Inj 20 mg per ml, 25 ml vial	18.15	1	Pfizer
Inj 100 mg per ml, 10 ml vial – 1% DV Nov-13 to 2016	8.83	1	Pfizer
Inj 100 mg per ml, 20 ml vial – 1% DV Nov-13 to 2016	17.65	1	Pfizer
FLUDARABINE PHOSPHATE			
Tab 10 mg – 1% DV Sep-15 to 2018	412.00	20	Fludara Oral
Inj 50 mg vial	525.00	5	Fludarabine Ebewe
FLUOROURACIL			
Inj 25 mg per ml, 100 ml vial	13.55	1	Hospira
Inj 50 mg per ml, 10 ml vial	26.25	5	Fluorouracil Ebewe
Inj 50 mg per ml, 20 ml vial – 1% DV Oct-15 to 2018	10.00	1	Fluorouracil Ebewe
Inj 50 mg per ml, 50 ml vial – 1% DV Oct-15 to 2018	17.00	1	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml vial – 1% DV Oct-15 to 2018	30.00	1	Fluorouracil Ebewe
<i>(Hospira Inj 25 mg per ml, 100 ml vial to be delisted 1 October 2015)</i>			
<i>(Fluorouracil Ebewe Inj 50 mg per ml, 10 ml vial to be delisted 1 October 2015)</i>			
GEMCITABINE			
Inj 10 mg per ml, 20 ml vial – 1% DV Oct-14 to 2017	8.36	1	Gemcitabine Ebewe
Inj 10 mg per ml, 100 ml vial – 1% DV Oct-14 to 2017	15.89	1	Gemcitabine Ebewe
MERCAPTOPYRINE			
Tab 50 mg – 1% DV Oct-13 to 2016	49.41	25	Puri-nethol
METHOTREXATE			
Tab 2.5 mg – 1% DV Sep-15 to 2018	3.18	30	Trexate
Tab 10 mg – 1% DV Sep-15 to 2018	21.00	50	Trexate
Inj 2.5 mg per ml, 2 ml vial			
Inj 7.5 mg prefilled syringe – 1% DV Jan-14 to 2016	17.19	1	Methotrexate Sandoz
Inj 10 mg prefilled syringe – 1% DV Jan-14 to 2016	17.25	1	Methotrexate Sandoz
Inj 15 mg prefilled syringe – 1% DV Jan-14 to 2016	17.38	1	Methotrexate Sandoz
Inj 20 mg prefilled syringe – 1% DV Jan-14 to 2016	17.50	1	Methotrexate Sandoz
Inj 25 mg prefilled syringe – 1% DV Jan-14 to 2016	17.63	1	Methotrexate Sandoz
Inj 30 mg prefilled syringe – 1% DV Jan-14 to 2016	17.75	1	Methotrexate Sandoz
Inj 25 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016	20.20	5	Hospira
Inj 25 mg per ml, 20 ml vial – 1% DV Sep-13 to 2016	27.78	1	Hospira
Inj 100 mg per ml, 10 ml vial	25.00	1	Methotrexate Ebewe
Inj 100 mg per ml, 50 ml vial – 1% DV Oct-14 to 2017	99.99	1	Methotrexate Ebewe
THIOGUANINE			
Tab 40 mg			

Other Cytotoxic Agents

AMSACRINE

- Inj 50 mg per ml, 1.5 ml ampoule
- Inj 75 mg

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ANAGRELIDE HYDROCHLORIDE			
Cap 0.5 mg			
ARSENIC TRIOXIDE			
Inj 1 mg per ml, 10 ml vial	4,817.00	10	AFT
BORTEZOMIB – Restricted see terms below			
⚡ Inj 1 mg vial	540.70	1	Velcade
⚡ Inj 3.5 mg vial	1,892.50	1	Velcade
↪ Restricted			
Initiation - treatment naive multiple myeloma/amyloidosis			
Both:			
1 Either:			
1.1 The patient has treatment-naive symptomatic multiple myeloma; or			
1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and			
2 Maximum of 9 treatment cycles.			
Note: Indications marked with * are Unapproved Indications.			
Initiation - relapsed/refractory multiple myeloma/amyloidosis			
All of the following:			
1 Either:			
1.1 The patient has relapsed or refractory multiple myeloma; or			
1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and			
2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and			
3 The patient has not had prior publicly funded treatment with bortezomib; and			
4 Maximum of 4 treatment cycles.			
Note: Indications marked with * are Unapproved Indications.			
Continuation - relapsed/refractory multiple myeloma/amyloidosis			
Both:			
1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and			
2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).			
Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:			
1 A known therapeutic chemotherapy regimen and supportive treatments; or			
2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.			
Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.			
COLASPASE [L-ASPARAGINASE]			
Inj 10,000 iu vial	102.32	1	Leunase
DACARBAZINE			
Inj 200 mg vial – 1% DV Oct-13 to 2016	51.84	1	Hospira
ETOPOSIDE			
Cap 50 mg	340.73	20	Vepesid
Cap 100 mg	340.73	10	Vepesid
Inj 20 mg per ml, 5 ml vial	25.00	1	Hospira
ETOPOSIDE (AS PHOSPHATE)			
Inj 100 mg vial	40.00	1	Etopophos
HYDROXYUREA			
Cap 500 mg	31.76	100	Hydrea
IRINOTECAN HYDROCHLORIDE			
Inj 20 mg per ml, 2 ml vial – 1% DV Sep-15 to 2018	11.50	1	Irinotecan Actavis 40
Inj 20 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018	17.80	1	Irinotecan Actavis 100

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LENALIDOMIDE – Restricted see terms below			
☞ Cap 10 mg	6,207.00	21	Revlimid
☞ Cap 25 mg	7,627.00	21	Revlimid
☞ Restricted			
Initiation			
Haematologist			
<i>Re-assessment required after 6 months</i>			
All of the following:			
1 Patient has relapsed or refractory multiple myeloma with progressive disease; and			
2 Either:			
2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or			
2.2 Both:			
2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and			
2.2.2 The patient has experienced severe (grade ≥ 3), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and			
3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.			
Continuation			
Haematologist			
<i>Re-assessment required after 6 months</i>			
Both:			
1 No evidence of disease progression; and			
2 The treatment remains appropriate and patient is benefitting from treatment.			
Notes: Indication marked with * is an Unapproved Indication (refer to Interpretations and Definitions). A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.			
PEGASPARGASE – Restricted see terms below			
☞ Inj 750 iu per ml, 5 ml vial	3,005.00	1	Oncaspar
☞ Restricted			
Newly diagnosed ALL			
<i>Limited to 12 months' treatment</i>			
All of the following:			
1 The patient has newly diagnosed acute lymphoblastic leukaemia; and			
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and			
3 Treatment is with curative intent.			
Relapsed ALL			
<i>Limited to 12 months' treatment</i>			
All of the following:			
1 The patient has relapsed acute lymphoblastic leukaemia; and			
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and			
3 Treatment is with curative intent.			
PENTOSTATIN [DEOXYCOFORMYCIN]			
Inj 10 mg vial			
PROCARBAZINE HYDROCHLORIDE			
Cap 50 mg	498.00	50	Natulan
TEMOZOLOMIDE – Restricted see terms on the next page			
☞ Cap 5 mg – 1% DV Sep-13 to 2016.....	8.00	5	Temaccord
☞ Cap 20 mg – 1% DV Sep-13 to 2016.....	36.00	5	Temaccord
☞ Cap 100 mg – 1% DV Sep-13 to 2016.....	175.00	5	Temaccord
☞ Cap 250 mg – 1% DV Sep-13 to 2016.....	410.00	5	Temaccord

☞ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
All of the following:			
1 Either:			
1.1 Patient has newly diagnosed glioblastoma multiforme; or			
1.2 Patient has newly diagnosed anaplastic astrocytoma*; and			
2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and			
3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m ² .			
Notes: Indication marked with a * is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.			
THALIDOMIDE – Restricted see terms below			
⚡ Cap 50 mg	378.00	28	Thalomid
⚡ Cap 100 mg	756.00	28	Thalomid
➔Restricted			
Initiation			
Any of the following:			
1 The patient has multiple myeloma; or			
2 The patient has systemic AL amyloidosis*; or			
3 The patient has erythema nodosum leprosum.			
Continuation			
Patient has obtained a response from treatment during the initial approval period.			
Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.			
Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.			
Indication marked with * is an Unapproved Indication			
TRETINOIN			
Cap 10 mg	479.50	100	Vesanoid
Platinum Compounds			
CARBOPLATIN			
Inj 10 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018	15.07	1	DBL Carboplatin
	20.00		Carboplatin Ebewe
Inj 10 mg per ml, 15 ml vial – 1% DV Sep-15 to 2018	14.05	1	DBL Carboplatin
	19.50		Carbaccord
Inj 10 mg per ml, 45 ml vial – 1% DV Sep-15 to 2018	32.59	1	DBL Carboplatin
	48.50		Carbaccord
Inj 10 mg per ml, 100 ml vial	105.00	1	Carboplatin Ebewe
<i>(Carboplatin Ebewe Inj 10 mg per ml, 5 ml vial to be delisted 1 September 2015)</i>			
<i>(Carbaccord Inj 10 mg per ml, 15 ml vial to be delisted 1 September 2015)</i>			
<i>(Carbaccord Inj 10 mg per ml, 45 ml vial to be delisted 1 September 2015)</i>			
<i>(Carboplatin Ebewe Inj 10 mg per ml, 100 ml vial to be delisted 1 September 2015)</i>			
CISPLATIN			
Inj 1 mg per ml, 50 ml vial	15.00	1	Cisplatin Ebewe
Inj 1 mg per ml, 100 ml vial	21.00	1	Cisplatin Ebewe
OXALIPLATIN			
Inj 50 mg vial	15.32	1	Oxaliplatin Actavis 50
Inj 100 mg vial	25.01	1	Oxaliplatin Actavis 100
Products with Hospital Supply Status (HSS) are in bold			
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Protein-Tyrosine Kinase Inhibitors			
DASATINIB – Restricted see terms below			
☞ Tab 20 mg	3,774.06	60	Sprycel
☞ Tab 50 mg	6,214.20	60	Sprycel
☞ Tab 70 mg	7,692.58	60	Sprycel
☞ Tab 100 mg	6,214.20	30	Sprycel

☞Restricted

For use in patients with approval from the CML/GIST Co-ordinator

ERLOTINIB – **Restricted** see terms below

☞ Tab 100 mg – 1% DV Jun-15 to 2018	1,000.00	30	Tarceva
☞ Tab 150 mg – 1% DV Jun-15 to 2018	1,500.00	30	Tarceva

☞Restricted
Initiation

Re-assessment required after 3 months

Either:

- 1 All of the following:
 - 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
 - 1.3 Any of the following:
 - 1.3.1 Patient is treatment naive; or
 - 1.3.2 Both:
 - 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
 - 1.3.2.2 Patient has not received prior treatment with gefitinib; or
 - 1.3.3 Both:
 - 1.3.3.1 The patient has discontinued gefitinib within 6 weeks of starting treatment due to intolerance; and
 - 1.3.3.2 The cancer did not progress while on gefitinib; and
 - 1.4 Erlotinib is to be given for a maximum of 3 months, or
- 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Continuation

Re-assessment required after 6 months

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB – **Restricted** see terms below

☞ Tab 250 mg	1,700.00	30	Iressa
--------------------	----------	----	--------

☞Restricted
Initiation

Re-assessment required after 3 months

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Either:
 - 2.1 Patient is treatment naive; or
 - 2.2 Both:
 - 2.2.1 The patient has discontinued erlotinib within 6 weeks of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Continuation

Re-assessment required after 6 months

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

☞ Tab 100 mg2,400.00 60 Glivec

☞Restricted

Initiation

Re-assessment required after 12 months

- Both:
- 1 Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
 - 2 Maximum dose of 400 mg/day.

Continuation

Re-assessment required after 12 months

Adequate clinical response to treatment with imatinib (prescriber determined).

Cap 100 mg – 1% DV Jul-14 to 2017298.90 60 **Imatinib-AFT**
Cap 400 mg597.80 30 Imatinib-AFT

LAPATINIB – **Restricted** see terms below

☞ Tab 250 mg1,899.00 70 Tykerb

☞Restricted

Initiation

Re-assessment required after 12 months

- Either:
- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
 - 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and
 - 2.4 Lapatinib not to be given in combination with trastuzumab; and
 - 2.5 Lapatinib to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months

- All of the following:
- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
 - 3 Lapatinib not to be given in combination with trastuzumab; and
 - 4 Lapatinib to be discontinued at disease progression.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NILOTINIB – Restricted see terms below			
☛ Cap 150 mg	4,680.00	120	Tasigna
☛ Cap 200 mg	6,532.00	120	Tasigna

☛Restricted
Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
- 2 Either:
 - 2.1 Patient has documented CML treatment failure* with imatinib; or
 - 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Continuation

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

PAZOPANIB – Restricted see terms below

☛ Tab 200 mg	1,334.70	30	Votrient
☛ Tab 400 mg	2,669.40	30	Votrient

☛Restricted
Initiation

Re-assessment required after 3 months

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 The patient has intermediate or poor prognosis defined as any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of ≤ 70; or
 - 5.6 ≥ 2 sites of organ metastasis.

Continuation

Re-assessment required after 3 months

Both:

continued...

Price (ex man. excl. GST)	Brand or Generic Manufacturer
\$ Per	

continued. . .

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB – **Restricted** see terms below

⚡ Cap 12.5 mg	2,315.38	28	Sutent
⚡ Cap 25 mg	4,630.77	28	Sutent
⚡ Cap 50 mg	9,261.54	28	Sutent

➔ **Restricted**

Re-assessment required after 3 months

Initiation - RCC

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 The patient has intermediate or poor prognosis defined as any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of ≤ 70; or
 - 5.6 ≥ 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Continuation - RCC

Re-assessment required after 3 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Initiation - GIST

Re-assessment required after 3 months

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation - GIST

Re-assessment required after 6 months

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

continued. . .

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

1 Any of the following:

- 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
- 1.2 The patient has had a partial response (a decrease in size of $\geq 10\%$ or decrease in tumour density in Hounsfield Units (HU) of $\geq 15\%$ on CT and no new lesions and no obvious progression of non-measurable disease); or
- 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and

2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of $\geq 10\%$ and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Taxanes

DOCETAXEL

Inj 10 mg per ml, 2 ml vial – 1% DV Dec-14 to 2017	13.70	1	DBL Docetaxel
Inj 10 mg per ml, 8 ml vial – 1% DV Dec-14 to 2017	29.99	1	DBL Docetaxel

PACLITAXEL

Inj 6 mg per ml, 5 ml vial – 1% DV Sep-14 to 2017	45.00	5	Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial – 1% DV Sep-14 to 2017	19.02	1	Paclitaxel Ebewe
Inj 6 mg per ml, 25 ml vial – 1% DV Sep-14 to 2017	26.69	1	Paclitaxel Ebewe
Inj 6 mg per ml, 50 ml vial – 1% DV Sep-14 to 2017	36.53	1	Paclitaxel Ebewe
Inj 6 mg per ml, 100 ml vial – 1% DV Sep-14 to 2017	73.06	1	Paclitaxel Ebewe

Treatment of Cytotoxic-Induced Side Effects

CALCIUM FOLINATE

Tab 15 mg	82.45	10	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule – 1% DV Oct-14 to 2017	18.25	5	Calcium Folate Ebewe
Inj 10 mg per ml, 10 ml vial – 1% DV Oct-14 to 2017	7.33	1	Calcium Folate Ebewe
Inj 10 mg per ml, 30 ml vial – 1% DV Oct-14 to 2017	22.51	1	Calcium Folate Ebewe
Inj 10 mg per ml, 100 ml vial – 1% DV Oct-14 to 2017	67.51	1	Calcium Folate Ebewe

MESNA

Tab 400 mg – 1% DV Oct-13 to 2016	227.50	50	Uromitexan
Tab 600 mg – 1% DV Oct-13 to 2016	339.50	50	Uromitexan
Inj 100 mg per ml, 4 ml ampoule – 1% DV Oct-13 to 2016	148.05	15	Uromitexan
Inj 100 mg per ml, 10 ml ampoule – 1% DV Oct-13 to 2016	339.90	15	Uromitexan

Vinca Alkaloids

VINBLASTINE SULPHATE

Inj 1 mg per ml, 10 ml vial	186.46	5	Hospira
-----------------------------------	--------	---	---------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
VINCRIStINE SULPHATE			
Inj 1 mg per ml, 1 ml vial – 1% DV Sep-13 to 2016	64.80	5	Hospira
Inj 1 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016	69.60	5	Hospira
VINOReLBINE			
Inj 10 mg per ml, 1 ml vial – 1% DV Sep-15 to 2018	8.00	1	Navelbine
Inj 10 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018	40.00	1	Navelbine
Endocrine Therapy			
ABIRATERONE ACETATE – Restricted see terms below			
⚡ Tab 250 mg	4,276.19	120	Zytiga
➡ Restricted			
Initiation			
Medical oncologist, radiation oncologist or urologist			
<i>Re-assessment required after 5 months</i>			
All of the following:			
1 Patient has prostate cancer; and			
2 Patient has metastases; and			
3 Patient's disease is castration resistant; and			
4 Either:			
4.1 All of the following:			
4.1.1 Patient is symptomatic; and			
4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and			
4.1.3 Patient has ECOG performance score of 0-1; and			
4.1.4 Patient has not had prior treatment with taxane chemotherapy; or			
4.2 All of the following:			
4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and			
4.2.2 Patient has ECOG performance score of 0-2; and			
4.2.3 Patient has not had prior treatment with abiraterone.			
Continuation			
Medical oncologist, radiation oncologist or urologist			
<i>Re-assessment required after 5 months</i>			
All of the following:			
1 Significant decrease in serum PSA from baseline; and			
2 No evidence of clinical disease progression; and			
3 No initiation of taxane chemotherapy with abiraterone; and			
4 The treatment remains appropriate and the patient is benefiting from treatment.			
BICALUTAMIDE			
Tab 50 mg – 1% DV Sep-14 to 2017	4.90	28	Bicalaccord
FLUTAMIDE			
Tab 250 mg	55.00	100	Flutamin
MEGESTROL ACETATE			
Tab 160 mg – 1% DV Oct-15 to 2018	54.30	30	Apo-Megestrol
OCTREOTIDE – Some items restricted see terms on the next page			
Inj 50 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017	13.50	5	DBL
Inj 100 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017	22.40	5	DBL
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017	89.40	5	DBL
⚡ Inj 10 mg vial	1,772.50	1	Sandostatin LAR
⚡ Inj 20 mg vial	2,358.75	1	Sandostatin LAR
⚡ Inj 30 mg vial	2,951.25	1	Sandostatin LAR

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➡Restricted			
Note: restriction applies only to the long-acting formulations of octreotide			
Malignant bowel obstruction			
All of the following:			
1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and			
2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and			
3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.			
Note: Indications marked with * are Unapproved Indications			
Initiation - acromegaly			
<i>Re-assessment required after 3 months</i>			
Both:			
1 The patient has acromegaly; and			
2 Any of the following:			
2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or			
2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or			
2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.			
Continuation - acromegaly			
Both:			
1 IGF1 levels have decreased since starting octreotide; and			
2 The treatment remains appropriate and the patient is benefiting from treatment.			
Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.			
Other indications			
Any of the following:			
1 VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or			
2 Both:			
2.1 Gastrinoma; and			
2.2 Either:			
2.2.1 Patient has failed surgery; or			
2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or			
3 Both:			
3.1 Insulinomas; and			
3.2 Surgery is contraindicated or has failed; or			
4 For pre-operative control of hypoglycaemia and for maintenance therapy; or			
5 Both:			
5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and			
5.2 Disabling symptoms not controlled by maximal medical therapy.			
TAMOXIFEN CITRATE			
Tab 10 mg	17.50	100	Genox
Tab 20 mg	2.63	30	Genox
	8.75	100	Genox
Aromatase Inhibitors			
ANASTROZOLE			
Tab 1 mg	26.55	30	Aremed DP-Anastrozole

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
EXEMESTANE			
Tab 25 mg – 1% DV Sep-14 to 2017	14.50	30	Aromasin
LETROZOLE			
Tab 2.5 mg	4.85	30	Letraccord

Immunosuppressants

Calcineurin Inhibitors

CICLOSPORIN			
Cap 25 mg	44.63	50	Neoral
Cap 50 mg	88.91	50	Neoral
Cap 100 mg	177.81	50	Neoral
Oral liq 100 mg per ml	198.13	50 ml	Neoral
Inj 50 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	276.30	10	Sandimmun
TACROLIMUS – Restricted see terms below			
⚡ Cap 0.5 mg – 1% DV Nov-14 to 31 Oct 2018	85.60	100	Tacrolimus Sandoz
⚡ Cap 1 mg – 1% DV Nov-14 to 31 Oct 2018	171.20	100	Tacrolimus Sandoz
⚡ Cap 5 mg – 1% DV Nov-14 to 31 Oct 2018	428.00	50	Tacrolimus Sandoz
⚡ Inj 5 mg per ml, 1 ml ampoule			

➡ Restricted

Initiation - organ transplant recipients

For use in organ transplant recipients

Steroid-resistant nephrotic syndrome*

Either:

- The patient is a child with steroid-resistant nephrotic syndrome* (SRNS) where ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; or
- All of the following:
 - The patient is an adult with SRNS; and
 - Ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; and
 - Cyclophosphamide or mycophenolate have been trialled and discontinued because of unacceptable side effects or inadequate clinical response, or these treatments are contraindicated.

Note: Indications marked with * are Unapproved Indications

Fusion Proteins

ETANERCEPT – Restricted see terms below

⚡ Inj 25 mg vial	949.96	4	Enbrel
⚡ Inj 50 mg autoinjector	1,899.92	4	Enbrel
⚡ Inj 50 mg syringe	1,899.92	4	Enbrel

➡ Restricted

Initiation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 4 months

Either:

- Both:
 - The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
 - Either:
 - The patient has experienced intolerable side effects from adalimumab; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or

2 All of the following:

2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and

2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Continuation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or

2 All of the following:

2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and

2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Any of the following:

continued...

continued...

- 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
- 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
- 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
- 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - plaque psoriasis, prior TNF use

Dermatologist

Re-assessment required after 4 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 - 1.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
- 2 Patient must be reassessed for continuation after 3 doses.

Initiation - plaque psoriasis, treatment-naïve

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis

Dermatologist

Re-assessment required after 6 months

Both:

1 Either:

1.1 Both:

1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

1.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

1.2.2 Either:

1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or

1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Indication - pyoderma gangrenosum

Dermatologist

All of the following:

1 Patient has pyoderma gangrenosum*; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and

3 A maximum of 4 doses.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part V (Miscellaneous Provisions) rule 5.5).

Renewal - pyoderma gangrenosum

Dermatologist

All of the following:

1 Patient has shown clinical improvement; and

2 Patient continues to require treatment; and

3 A maximum of 4 doses

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

1.1 Either:

1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Paediatric rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Monoclonal Antibodies

ABCIXIMAB – **Restricted** see terms below

⚡ Inj 2 mg per ml, 5 ml vial	579.53	1	ReoPro
------------------------------------	--------	---	--------

➡Restricted

Either:

- 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
- 2 For use in patients undergoing intra-cranial intervention.

ADALIMUMAB – **Restricted** see terms below

⚡ Inj 20 mg per 0.4 ml syringe	1,799.92	2	Humira
⚡ Inj 40 mg per 0.8 ml pen	1,799.92	2	HumiraPen
⚡ Inj 40 mg per 0.8 ml syringe	1,799.92	2	Humira

➡Restricted

Initiation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 4 months

Either:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.1.2 Either:
 - 1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or
 - 2 All of the following:
 - 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Continuation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 4 months

All of the following

1 Patient has confirmed Crohn's disease; and

2 Either:

2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or

2.2 Patient has one or more rectovaginal fistula(e); and

3 A Baseline Fistula Assessment (a copy of which is available at www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

Continuation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 6 months

Either:

1 The number of open draining fistulae have decreased from baseline by at least 50%; or

2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation - Crohn's disease

Gastroenterologist

Re-assessment required after 3 months

All of the following:

1 Patient has severe active Crohn's disease; and

2 Any of the following:

2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or

2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or

2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or

2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

Continuation - Crohn's disease

Gastroenterologist

Re-assessment required after 3 months

Both:

- 1 Either:
 - 1.1 Either:
 - 1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 1.1.2 CDAI score is 150 or less; or
 - 1.2 Both:
 - 1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Adalimumab to be administered at doses no greater than 50 mg every 7 days.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- Both:
 - The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - Either:
 - The patient has experienced intolerable side effects from etanercept; or
 - The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- All of the following:
 - Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - Either:
 - Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - Any of the following:
 - Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - plaque psoriasis, prior TNF use

Dermatologist

Re-assessment required after 4 months

Both:

- 1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from etanercept; or
 - 2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; and

Initiation - plaque psoriasis, treatment-naïve

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis

Dermatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
- 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Indication - pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part V (Miscellaneous Provisions) rule 5.5).

Renewal - pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BASILIXIMAB – Restricted see terms below			
☞ Inj 20 mg vial	3,200.00	1	Simulect
☞ Restricted			
For use in solid organ transplants			
BEVACIZUMAB – Restricted see terms below			
☞ Inj 25 mg per ml, 16 ml vial			
☞ Inj 25 mg per ml, 4 ml vial			
☞ Restricted			
Either:			
1 Ocular neovascularisation; or			
2 Exudative ocular angiopathy.			
INFLIXIMAB – Restricted see terms below			
☞ Inj 100 mg – 10% DV Mar-15 to 29 Feb 2020	806.00	1	Remicade

☞ **Restricted**

Graft vs host disease

Patient has steroid-refractory acute graft vs. host disease of the gut

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 3-4 months

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 3 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 3-4 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation - severe ocular inflammation

Re-assessment required after 3 doses

Both:

- 1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2 Either:
 - 2.1 Patient has failed to achieve control of severe vision-threatening ocular inflammation following high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids; or
 - 2.2 Patient developed new inflammatory symptoms while receiving high dose steroids.

Initiation - chronic ocular inflammation

Re-assessment required after 3 doses

Both:

- 1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2 Patient has tried at least two other immunomodulatory agents.

Continuation - ocular inflammation

Both:

- 1 Patient had a good clinical response to initial treatment; and
- 2 Either:
 - 2.1 A withdrawal of infliximab has been trialled and patient has relapsed after trial withdrawal; or
 - 2.2 Patient has Behcet's disease.

Pulmonary sarcoidosis

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initiation - Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 One of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 One of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

- 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - fistulising Crohn's disease

Gastroenterologist

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 Patient must be reassessed for continuation after 4 months of therapy.

Continuation - fistulising Crohn's disease

Gastroenterologist

All of the following:

- 1 Either:
 - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - acute severe fulminant ulcerative colitis

Gastroenterologist

All of the following:

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful; and
- 3 Patient must be reassessed for continuation after 6 weeks of therapy.

Continuation - severe fulminant ulcerative colitis

Gastroenterologist

All of the following:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - severe ulcerative colitis

Gastroenterologist

All of the following:

- 1 Patient has histologically confirmed ulcerative colitis; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is ≥ 4 ; or
 - 2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is ≥ 65 ; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - severe ulcerative colitis

Gastroenterologist

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the SCCAI score has reduced by ≥ 2 points from the SCCAI score when the patient was initiated on infliximab; or
 - 2.2 Patient is under 18 years and the PUCAI score has reduced by ≥ 30 points from the PUCAI score when the patient was initiated on infliximab; and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - plaque psoriasis, prior TNF use

Dermatologist

Re-assessment required after 3 doses

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
 - 2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis.

Initiation - plaque psoriasis, treatment-naïve

Dermatologist

Re-assessment required after 3 doses

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, thotrexate, cyclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis

Dermatologist

Re-assessment required after 3 doses

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

OMALIZUMAB – **Restricted** see terms below

⌚ Inj 150 mg vial	500.00	1	Xolair
-------------------------	--------	---	--------

➡ Restricted

Initiation

Respiratory physician

Re-assessment required after 6 months

All of the following:

- 1 Patient is over the age of 6; and
- 2 Patient has a diagnosis of severe, life threatening asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven compliance with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or eformoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; and
- 7 At least four admissions to hospital for a severe asthma exacerbation over the previous 24 months with at least one of those being in the previous 12 months; and
- 8 An Asthma Control Questionnaire (ACQ-5) score of at least 3.0 as assessed in the previous month.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Continuation

Respiratory physician

Re-assessment required after 6 months

All of the following:

- 1 Hospital admissions have been reduced as a result of treatment; and
- 2 A reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 1.0 from baseline; and
- 3 A reduction in the maintenance oral corticosteroid dose of at least 50% from baseline.

RANIBIZUMAB – Restricted see terms below

⚡ Inj 10 mg per ml, 0.23 ml vial

⚡ Inj 10 mg per ml, 0.3 ml vial

➡ **Restricted**

Initiation

Re-assessment required after 3 doses

Both:

- 1 Either
 - 1.1 Age-related macular degeneration; or
 - 1.2 Choroidal neovascular membrane; and
- 2 Any of the following:
 - 2.1 The patient has had a severe ophthalmic inflammatory response following bevacizumab; or
 - 2.2 The patient has had a myocardial infarction or stroke within the last three months; or
 - 2.3 The patient has failed to respond to bevacizumab following three intraocular injections; or
 - 2.4 The patient is of child-bearing potential and has not completed a family.

Continuation

Both:

- 1 Documented benefit after three doses must be demonstrated to continue; and
- 2 In the case of but previous non-response to bevacizumab, a retreat of bevacizumab is required to confirm non-response before continuing with ranibizumab.

RITUXIMAB – Restricted see terms below

⚡ Inj 10 mg per ml, 10 ml vial 1,075.50 2 Mabthera

⚡ Inj 10 mg per ml, 50 ml vial 2,688.30 1 Mabthera

➡ **Restricted**

Initiation - haemophilia with inhibitors

Haematologist

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Continuation - haemophilia with inhibitors

Haematologist

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initiation - post-transplant

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued. . .

Note: Indications marked with * are Unapproved Indications.

Continuation - post-transplant

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications

Initiation - indolent, low-grade lymphomas

Either:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Continuation - indolent, low-grade lymphomas

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initiation - aggressive CD20 positive NHL

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Continuation - aggressive CD20 positive NHL

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Chronic lymphocytic leukaemia

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and

continued. . .

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and

- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2 .

Initiation - rheumatoid arthritis - prior TNF inhibitor use

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Both:
 - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation - rheumatoid arthritis - TNF inhibitors contraindicated

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued...

6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

7 Either:

7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

8 Either:

8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Rheumatologist

Re-assessment required after 2 doses

All of the following:

1 Either:

1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

Re-assessment required after 2 doses

All of the following:

1 Either:

1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation - severe cold haemagglutinin disease (CHAD)

Haematologist

Limited to 4 weeks' treatment

Both:

1 Patient has cold haemagglutinin disease*; and

continued...

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per	

continued...

- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with * are Unapproved Indications.

Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

Limited to 4 weeks' treatment

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Limited to 4 weeks' treatment

Both:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to >5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with * are Unapproved Indications.

Continuation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Limited to 4 weeks' treatment

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – immune thrombocytopenic purpura (ITP)

Haematologist

Limited to 4 weeks' treatment

Both:

- 1 Either:
 - 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of \leq 20,000 platelets per microlitre; or
 - 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

continued. . .

Note: Indications marked with * are Unapproved Indications.

Continuation – immune thrombocytopenic purpura (ITP)

Haematologist

Limited to 4 weeks' treatment

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Limited to 4 weeks' treatment

Either:

- 1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
- 2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are Unapproved Indications.

Continuation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Limited to 4 weeks' treatment

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – pure red cell aplasia (PRCA)

Haematologist

Limited to 6 weeks' treatment

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are Unapproved Indications.

Continuation – pure red cell aplasia (PRCA)

Haematologist

Limited to 6 weeks' treatment

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are Unapproved Indications.

Initiation – ANCA associated vasculitis

Limited to 4 weeks' treatment

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Either:
 - 2.1 Patient does not have MPO-ANCA positive vasculitis*; or
 - 2.2 Mycophenolate mofetil has not been effective in those patients who have MPO-ANCA positive vasculitis*; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 4 Any of the following:

continued. . .

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 4.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve complete absence of disease after at least 3 months; or
- 4.2 Patient has previously had a cumulative dose of cyclophosphamide >15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose >15 g; or
- 4.3 Cyclophosphamide and methotrexate are contraindicated; or
- 4.4 Patient is a female of child-bearing potential; or
- 4.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are Unapproved Indications.

Continuation – ANCA associated vasculitis

Limited to 4 weeks' treatment

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are Unapproved Indications.

Initiation – treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are Unapproved Indications.

Continuation – treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are Unapproved Indications.

Antibody-mediated renal transplant rejection

Nephrologist

Patient has been diagnosed with antibody-mediated renal transplant rejection*.

Note: Indications marked with * are Unapproved Indications.

ABO-incompatible renal transplant

Nephrologist

Patient is to undergo an ABO-incompatible renal transplant*.

Note: Indications marked with * are Unapproved Indications.

TOCILIZUMAB – **Restricted** see terms on the next page

⚡ Inj 20 mg per ml, 4 ml vial	220.00	1	Actemra
⚡ Inj 20 mg per ml, 10 ml vial	550.00	1	Actemra
⚡ Inj 20 mg per ml, 20 ml vial	1,100.00	1	Actemra

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

➔ **Restricted**

Initiation -Rheumatoid Arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 All of the following:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
 - 1.3 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the HML rules; and
 - 1.4 Either:
 - 1.4.1 The patient has experienced intolerable side effects from rituximab; or
 - 1.4.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Tocilizumab is to be used as monotherapy; and
 - 2.3 Either:
 - 2.3.1 Treatment with methotrexate is contraindicated; or
 - 2.3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
 - 2.4 Either:
 - 2.4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or
 - 2.4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
 - 2.5 Either:
 - 2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.6 Either:
 - 2.6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - Rheumatoid Arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Initiation - systemic juvenile idiopathic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Continuation - systemic juvenile idiopathic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – **Restricted** see terms below

¶ Inj 150 mg vial	1,350.00	1	Herceptin
¶ Inj 440 mg vial	3,875.00	1	Herceptin

➡Restricted

Early breast cancer

Limited to 12 months' treatment

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
 - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

Initiation - metastatic breast cancer (trastuzumab-naïve patients)

Re-assessment required after 12 months

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Trastuzumab not to be given in combination with lapatinib; and
 - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on lapatinib; and
 - 2.4 Trastuzumab not to be given in combination with lapatinib; and
 - 2.5 Trastuzumab to be discontinued at disease progression.

Initiation - metastatic breast cancer (patients previously treated with trastuzumab)

Re-assessment required after 12 months

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
 - 3.1 All of the following:
 - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
 - 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.1.3 Trastuzumab to be discontinued at disease progression; or
 - 3.2 All of the following:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; and
 - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
 - 3.2.4 Trastuzumab to be discontinued at disease progression; or
 - 3.3 All of the following:
 - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.3.3 Trastuzumab to be discontinued at disease progression.

Continuation - metastatic breast cancer

Re-assessment required after 12 months

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE)

Inj 50 mg per ml, 5 ml ampoule	2,351.25	5	ATGAM
--------------------------------------	----------	---	-------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ANTITHYMOCYTE GLOBULIN (RABBIT)			
Inj 25 mg vial			
AZATHIOPRINE			
Tab 25 mg	8.28	60	Azamun
Tab 50 mg – 1% DV Jun-14 to 2016	13.22	100	Azamun
Inj 50 mg vial	126.00	1	Imuran
BACILLUS CALMETTE-GUERIN (BCG) – Restricted see terms below			
☞ Inj 2-8 × 10 ⁸ CFU vial – 1% DV Sep-13 to 2016	149.37	1	OncoTICE
☞ Inj 40 mg per ml, vial	149.37	3	SII-Onco-BCG
☞ Restricted			
For use in bladder cancer			
EVEROLIMUS – Restricted see terms below			
☞ Tab 5 mg	4,555.76	30	Afinitor
☞ Tab 10 mg	6,512.29	30	Afinitor
☞ Restricted			
Initiation			
Neurologist or oncologist			
<i>Re-assessment required after 3 months</i>			
Both:			
1 Patient has tuberous sclerosis; and			
2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.			
Continuation			
Neurologist or oncologist			
<i>Re-assessment required after 12 months</i>			
All of the following:			
1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and			
2 The treatment remains appropriate and the patient is benefiting from treatment; and			
3 Everolimus to be discontinued at progression of SEGAs.			
Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.			
MYCOPHENOLATE MOFETIL			
Tab 500 mg – 1% DV Nov-13 to 2016	25.00	50	CellCept
Cap 250 mg – 1% DV Nov-13 to 2016	25.00	100	CellCept
Powder for oral liq 1 g per 5 ml – 1% DV Nov-13 to 2016	187.25	165 ml	CellCept
Inj 500 mg vial – 1% DV Nov-13 to 2016	133.33	4	CellCept
PICIBANIL			
Inj 100 mg vial			
SIROLIMUS – Restricted see terms below			
☞ Tab 1 mg	813.00	100	Rapamune
☞ Tab 2 mg	1,626.00	100	Rapamune
☞ Oral liq 1 mg per ml	487.80	60 ml	Rapamune
☞ Restricted			
For rescue therapy for an organ transplant recipient			
Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:			
• GFR < 30 ml/min; or			
• Rapidly progressive transplant vasculopathy; or			
• Rapidly progressive obstructive bronchiolitis; or			

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antiallergy Preparations			
Allergy Desensitisation			
BEE VENOM – Restricted see terms below			
☞ Inj 120 mcg vial with diluent, 6 vial			
☞ Inj 550 mcg vial with diluent			
(Any Inj 120 mcg vial with diluent, 6 vial to be delisted 1 October 2015)			
☞ Restricted			
Both:			
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensitising agent.			
PAPER WASP VENOM – Restricted see terms below			
☞ Inj 550 mcg vial with diluent			
☞ Restricted			
Both:			
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensitising agent.			
YELLOW JACKET WASP VENOM – Restricted see terms below			
☞ Inj 550 mcg vial with diluent			
☞ Restricted			
Both:			
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensitising agent.			
Allergy Prophylactics			
BECLOMETHASONE DIPROPIONATE			
Nasal spray 50 mcg per dose	4.85	200 dose	Alanase
Nasal spray 100 mcg per dose	5.75	200 dose	Alanase
BUDESONIDE			
Nasal spray 50 mcg per dose	4.85	200 dose	Butacort Aqueous
Nasal spray 100 mcg per dose	5.75	200 dose	Butacort Aqueous
FLUTICASONE PROPIONATE			
Nasal spray 50 mcg per dose – 1% DV Sep-15 to 2018.....	2.18	120 dose	Flixonase Hayfever & Allergy
IPRATROPIUM BROMIDE			
Aqueous nasal spray 0.03% – 1% DV Jan-15 to 2017	3.95	15 ml	Univent
SODIUM CROMOGLYCATE			
Nasal spray 4%			
Antihistamines			
CETIRIZINE HYDROCHLORIDE			
Tab 10 mg	1.59	100	Zetop
Oral liq 1 mg per ml – 1% DV Feb-15 to 2017	2.99	200 ml	Histaclear
CHLORPHENIRAMINE MALEATE			
Oral liq 0.4 mg per ml			
Inj 10 mg per ml, 1 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CYPROHEPTADINE HYDROCHLORIDE			
Tab 4 mg			
FEXOFENADINE HYDROCHLORIDE			
Tab 60 mg			
Tab 120 mg			
Tab 180 mg			
LORATADINE			
Tab 10 mg – 1% DV Dec-13 to 2016	1.30	100	Lorafix
Oral liq 1 mg per ml – 1% DV Nov-14 to 2016	4.25	200 ml	LoraPaed
PROMETHAZINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Sep-15 to 2018	1.78	50	Allersoothe
Tab 25 mg – 1% DV Sep-15 to 2018	1.99	50	Allersoothe
Oral liq 1 mg per ml – 1% DV Sep-15 to 2018	2.59	100 ml	Allersoothe
Inj 25 mg per ml, 2 ml ampoule	11.99	5	Hospira
TRIMEPRAZINE TARTRATE			
Oral liq 6 mg per ml			

Anticholinergic Agents

IPRATROPIUM BROMIDE			
Aerosol inhaler 20 mcg per dose			
Nebuliser soln 250 mcg per ml, 1 ml ampoule – 1% DV Sep-13 to 2016	3.26	20	Univent
Nebuliser soln 250 mcg per ml, 2 ml ampoule – 1% DV Sep-13 to 2016	3.37	20	Univent

Anticholinergic Agents with Beta-Adrenoceptor Agonists

SALBUTAMOL WITH IPRATROPIUM BROMIDE			
Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose			
Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 1% DV Sep-15 to 2018	3.59	20	Duolin

Long-Acting Muscarinic Agents

➔ Restricted

Initiation

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialled a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and
- 3 Either the patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:
 - 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or
 - 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and
- 4 Actual FEV₁ as a % of predicted, must be below 60%.
- 5 Either:
 - 5.1 Patient is not a smoker (for reporting purposes only); or
 - 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunization.

GLYCOPYRRONIUM – Restricted see terms above

Note: glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium.

 Powder for inhalation 50 mcg per dose	61.00	30 dose	Seebri Breezhaler
---	-------	---------	--------------------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TIOTROPIUM BROMIDE – Restricted see terms on the preceding page			
Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised glycopyrronium.			
† Powder for inhalation 18 mcg per dose	70.00	30 dose	Spiriva

Beta-Adrenoceptor Agonists

SALBUTAMOL

Oral liq 400 mcg per ml – 1% DV Jan-14 to 2016.....	2.06	150 ml	Ventolin
Inj 500 mcg per ml, 1 ml ampoule			
Inj 1 mg per ml, 5 ml ampoule			
Aerosol inhaler, 100 mcg per dose	4.00	200 dose	Salamol
	6.00		Ventolin
Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Sep-15 to 2018	3.19	20	Asthalin
Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Sep-15 to 2018	3.29	20	Asthalin

TERBUTALINE SULPHATE

Powder for inhalation 250 mcg per dose			
Inj 0.5 mg per ml, 1 ml ampoule			

Cough Suppressants

PHOLCODINE

Oral liq 1 mg per ml			
----------------------	--	--	--

Decongestants

OXYMETAZOLINE HYDROCHLORIDE

Aqueous nasal spray 0.25 mg per ml			
Aqueous nasal spray 0.5 mg per ml			

PSEUDOEPHEDRINE HYDROCHLORIDE

Tab 60 mg			
-----------	--	--	--

SODIUM CHLORIDE

Aqueous nasal spray 7.4 mg per ml			
-----------------------------------	--	--	--

SODIUM CHLORIDE WITH SODIUM BICARBONATE

Soln for nasal irrigation			
---------------------------	--	--	--

XYLOMETAZOLINE HYDROCHLORIDE

Aqueous nasal spray 0.05%			
Aqueous nasal spray 0.1%			
Nasal drops 0.05%			
Nasal drops 0.1%			

Inhaled Corticosteroids

BECLOMETHASONE DIPROPIONATE

Aerosol inhaler 50 mcg per dose	8.54	200 dose	Beclazone 50
	9.30		Qvar
Aerosol inhaler 100 mcg per dose	12.50	200 dose	Beclazone 100
	15.50		Qvar
Aerosol inhaler 250 mcg per dose	22.67	200 dose	Beclazone 250

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BUDESONIDE			
Nebuliser soln 250 mcg per ml, 2 ml ampoule			
Nebuliser soln 500 mcg per ml, 2 ml ampoule			
Powder for inhalation 100 mcg per dose			
Powder for inhalation 200 mcg per dose			
Powder for inhalation 400 mcg per dose			
FLUTICASON			
Aerosol inhaler 50 mcg per dose	7.50	120 dose	Flixotide
Powder for inhalation 50 mcg per dose	8.67	60 dose	Flixotide Accuhaler
Powder for inhalation 100 mcg per dose	13.87	60 dose	Flixotide Accuhaler
Aerosol inhaler 125 mcg per dose	13.60	120 dose	Flixotide
Aerosol inhaler 250 mcg per dose	27.20	120 dose	Flixotide
Powder for inhalation 250 mcg per dose	24.51	60 dose	Flixotide Accuhaler
Leukotriene Receptor Antagonists			
MONTELUKAST – Restricted see terms below			
⚡ Tab 4 mg	18.48	28	Singulair
⚡ Tab 5 mg	18.48	28	Singulair
⚡ Tab 10 mg	18.48	28	Singulair
➡Restricted			
Pre-school wheeze			
Both:			
1 To be used for the treatment of intermittent severe wheezing (possibly viral); and			
2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.			
Exercise-induced asthma			
All of the following:			
1 Patient has been trialed with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and			
2 Patient continues to receive optimal inhaled corticosteroid therapy; and			
3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.			
Aspirin desensitisation			
Clinical immunologist or allergist			
All of the following:			
1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and			
2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and			
3 Nasal polyposis, confirmed radiologically or surgically; and			
4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.			
Long-Acting Beta-Adrenoceptor Agonists			
EFORMOTEROL FUMARATE			
Powder for inhalation 6 mcg per dose			
Powder for inhalation 12 mcg per dose			
INDACATEROL			
Powder for inhalation 150 mcg per dose	61.00	30 dose	Onbrez Breezhaler
Powder for inhalation 300 mcg per dose	61.00	30 dose	Onbrez Breezhaler
SALMETEROL			
Aerosol inhaler 25 mcg per dose	26.46	120 dose	Serevent
Powder for inhalation 50 mcg per dose	26.46	60 dose	Serevent Accuhaler

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists			
BUDESONIDE WITH EFORMOTEROL – Restricted see terms below ⚡ Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg ⚡ Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg ⚡ Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg ⚡ Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg ⚡ Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg			
➡Restricted Either: <ol style="list-style-type: none"> All of the following: <ol style="list-style-type: none"> Patient is a child under the age of 12; and Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or All of the following: <ol style="list-style-type: none"> Patient is over the age of 12; and Has been treated with inhaled corticosteroids of at least 800 mcg per day beclomethasone or budesonide, or 500 mcg per day fluticasone; and The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product. 			
FLUTICASONE WITH SALMETEROL Aerosol inhaler 50 mcg with salmeterol 25 mcg37.48 120 dose Seretide Powder for inhalation 100 mcg with salmeterol 50 mcg37.48 60 dose Seretide Accuhaler Aerosol inhaler 125 mcg with salmeterol 25 mcg49.69 120 dose Seretide Powder for inhalation 250 mcg with salmeterol 50 mcg49.69 60 dose Seretide Accuhaler			
Mast Cell Stabilisers			
NEDOCROMIL Aerosol inhaler 2 mg per dose			
SODIUM CROMOGLYCATE Powder for inhalation 20 mg per dose Aerosol inhaler 5 mg per dose			
Methylxanthines			
AMINOPHYLLINE Inj 25 mg per ml, 10 ml ampoule – 1% DV Oct-14 to 2017118.25 5 DBL Aminophylline			
CAFFEINE CITRATE Oral liq 20 mg per ml (caffeine 10 mg per ml)14.85 25 ml Biomed Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule55.75 5 Biomed			
THEOPHYLLINE Tab long-acting 250 mg Oral liq 80 mg per 15 ml			
Mucolytics and Expectorants			
DORNASE ALFA – Restricted see terms on the next page ⚡ Nebuliser soln 2.5 mg per 2.5 ml ampoule250.00 6 Pulmozyme			

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ Restricted

Any of the following:

- 1 Cystic fibrosis and the patient has been approved by the Cystic Fibrosis Panel; and/or
- 2 Significant mucus production and meets the following criteria
- 3 Treatment for up to four weeks for patients meeting the following:
 - 3.1 Patient is an in-patient; and
 - 3.2 The mucus production cannot be cleared by first line chest techniques; or
- 4 Treatment for up to three days for patients diagnosed with empyema.

SODIUM CHLORIDE

Nebuliser soln 7%, 90 ml bottle	23.50	90 ml	Biomed
---------------------------------------	-------	-------	--------

Pulmonary Surfactants

BERACTANT

Soln 200 mg per 8 ml vial	550.00	1	Survanta
---------------------------------	--------	---	----------

PORACTANT ALFA

Soln 120 mg per 1.5 ml vial	425.00	1	Curosurf
Soln 240 mg per 3 ml vial	695.00	1	Curosurf

Respiratory Stimulants

DOXAPRAM

Inj 20 mg per ml, 5 ml vial

Sclerosing Agents

TALC

Powder

Soln (slurry) 100 mg per ml, 50 ml

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
CHLORAMPHENICOL			
Eye oint 1%	2.76	4 g	Chlorsig
Ear drops 0.5%			
Eye drops 0.5% – 1% DV Sep-15 to 2018	0.98	10 ml	Chlorafast
Eye drops 0.5%, single dose			
CIPROFLOXACIN			
Eye drops 0.3%			
FRAMYCETIN SULPHATE			
Ear/eye drops 0.5%			
FUSIDIC ACID			
Eye drops 1%	4.50	5 g	Fucithalmic
GENTAMICIN SULPHATE			
Eye drops 0.3%	11.40	5 ml	Genoptic
PROPAMIDINE ISETHIONATE			
Eye drops 0.1%			
SULPHACETAMIDE SODIUM			
Eye drops 10%			
TOBRAMYCIN			
Eye oint 0.3% – 1% DV Sep-14 to 2017	10.45	3.5 g	Tobrex
Eye drops 0.3% – 1% DV Sep-14 to 2017	11.48	5 ml	Tobrex
Antifungals			
NATAMYCIN			
Eye drops 5%			
Antivirals			
ACICLOVIR			
Eye oint 3%			
GANCICLOVIR			
Eye gel 0.15%			<i>e.g. Virgan</i>
Combination Preparations			
CIPROFLOXACIN WITH HYDROCORTISONE			
Ear drops ciprofloxacin 0.2% with 1% hydrocortisone – 1% DV Mar-15 to 2017	16.30	10 ml	Ciproxin HC Otic
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE			
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g – 1% DV Sep-14 to 2017	5.39	3.5 g	Maxitrol
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml – 1% DV Sep-14 to 2017	4.50	5 ml	Maxitrol
DEXAMETHASONE WITH TOBRAMYCIN			
Eye drops 0.1% with tobramycin 0.3% – 1% DV Mar-15 to 2017	12.64	5 ml	Tobradex
FLUMETASONE PIVALATE WITH CLIOQUINOL			
Ear drops 0.02% with clioquinol 1%			
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN			
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	5.16	7.5 ml	Kenacomb

Anti-Inflammatory Preparations

Corticosteroids

DEXAMETHASONE			
Eye oint 0.1% – 1% DV Oct-14 to 2017	5.86	3.5 g	Maxidex
Eye drops 0.1% – 1% DV Oct-14 to 2017	4.50	5 ml	Maxidex
FLUOROMETHOLONE			
Eye drops 0.1% – 1% DV Sep-15 to 2018	3.09	5 ml	FML
	3.80		Flucon

(Flucon Eye drops 0.1% to be delisted 1 September 2015)

PREDNISOLONE ACETATE

Eye drops 0.12%
Eye drops 1%

PREDNISOLONE SODIUM PHOSPHATE

Eye drops 0.5%, single dose

Non-Steroidal Anti-Inflammatory Drugs

DICLOFENAC SODIUM			
Eye drops 0.1% – 1% DV Sep-14 to 2017	13.80	5 ml	Voltaren Ophtha
KETOROLAC TROMETAMOL			
Eye drops 0.5%			

Decongestants and Antiallergics

Antiallergic Preparations

LEVOCABASTINE			
Eye drops 0.05%			
LODOXAMIDE			
Eye drops 0.1% – 1% DV Sep-14 to 2017	8.71	10 ml	Lomide
OLOPATADINE			
Eye drops 0.1%			
SODIUM CROMOGLYCATE			
Eye drops 2%			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Decongestants			
NAPHAZOLINE HYDROCHLORIDE			
Eye drops 0.1% – 1% DV Sep-14 to 2017	4.15	15 ml	Naphcon Forte
Diagnostic and Surgical Preparations			
Diagnostic Dyes			
FLUORESCEIN SODIUM			
Eye drops 2%, single dose			
Inj 10%, 5 ml vial	125.00	12	Fluorescite
Ophthalmic strips 1 mg			
FLUORESCEIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE			
Eye drops 0.25% with lignocaine hydrochloride 4%, single dose			
LISSAMINE GREEN			
Ophthalmic strips 1.5 mg			
ROSE BENGAL SODIUM			
Ophthalmic strips 1%			
Irrigation Solutions			
CALCIUM CHLORIDE WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE, SODIUM CHLORIDE AND SODIUM CITRATE			
Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml			<i>e.g. Balanced Salt Solution</i>
Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml			<i>e.g. Balanced Salt Solution</i>
Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml			<i>e.g. Balanced Salt Solution</i>
Ocular Anaesthetics			
OXYBUPROCAINE HYDROCHLORIDE			
Eye drops 0.4%, single dose			
PROXYMETACAINE HYDROCHLORIDE			
Eye drops 0.5%			
TETRACAINE [AMETHOCAINE] HYDROCHLORIDE			
Eye drops 0.5%, single dose			
Eye drops 1%, single dose			
Viscoelastic Substances			
HYPROMELLOSE			
Inj 2%, 1 ml syringe			
Inj 2%, 2 ml syringe			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM HYALURONATE [HYALURONIC ACID]			
Inj 14 mg per ml, 0.85 ml syringe	50.00	1	Healon GV
Inj 14 mg per ml, 0.55 ml syringe	50.00	1	Healon GV
Inj 23 mg per ml, 0.6 ml syringe			
Inj 10 mg per ml, 0.85 ml syringe	30.00	1	Provisc
SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE			
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe	64.00	1	Duovisc
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe	74.00	1	Duovisc
Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe			

Other

DISODIUM EDETATE			
Inj 150 mg per ml, 20 ml ampoule			
Inj 150 mg per ml, 20 ml vial			
Inj 150 mg per ml, 100 ml vial			
RIBOFLAVIN 5-PHOSPHATE			
Soln trans epithelial riboflavin			
Inj 0.1%			
Inj 0.1% plus 20% dextran T500			

Glaucoma Preparations

Beta Blockers

BETAXOLOL			
Eye drops 0.25% – 1% DV Sep-14 to 2017	11.80	5 ml	Betoptic S
Eye drops 0.5% – 1% DV Sep-14 to 2017	7.50	5 ml	Betoptic
LEVOBUNOLOL HYDROCHLORIDE			
Eye drops 0.5%	7.00	5 ml	Betagan
TIMOLOL			
Eye drops 0.25% – 1% DV Sep-14 to 2017	1.45	5 ml	Arrow-Timolol
Eye drops 0.25%, gel forming – 1% DV Mar-14 to 2016	3.30	2.5 ml	Timoptol XE
Eye drops 0.5% – 1% DV Sep-14 to 2017	1.45	5 ml	Arrow-Timolol
Eye drops 0.5%, gel forming – 1% DV Mar-14 to 2016	3.78	2.5 ml	Timoptol XE

Carbonic Anhydrase Inhibitors

ACETAZOLAMIDE			
Tab 250 mg – 1% DV Sep-14 to 2017	17.03	100	Diamox
Inj 500 mg			
BRINZOLAMIDE			
Eye drops 1%			
DORZOLAMIDE			
Eye drops 2%			
DORZOLAMIDE WITH TIMOLOL			
Eye drops 2% with timolol 0.5%	15.50	5 ml	Cosopt

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Miotics			
ACETYLCHOLINE CHLORIDE			
Inj 20 mg vial with diluent			
PILOCARPINE HYDROCHLORIDE			
Eye drops 1% – 1% DV Sep-14 to 2017	4.26	15 ml	Isopto Carpine
Eye drops 2% – 1% DV Sep-14 to 2017	5.35	15 ml	Isopto Carpine
Eye drops 2%, single dose			
Eye drops 4% – 1% DV Sep-14 to 2017	7.99	15 ml	Isopto Carpine
Prostaglandin Analogues			
BIMATOPROST			
Eye drops 0.03%			
LATANOPROST			
Eye drops 0.005% – 1% DV Sep-15 to 2018	1.50	2.5 ml	Hysite
TRAVOPROST			
Eye drops 0.004%			
Sympathomimetics			
APRACLOPIDINE			
Eye drops 0.5% – 1% DV Mar-15 to 2017	19.77	5 ml	Iopidine
BRIMONIDINE TARTRATE			
Eye drops 0.2% – 1% DV Sep-14 to 2017	4.32	5 ml	Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL			
Eye drops 0.2% with timolol 0.5%			
Mydriatics and Cycloplegics			
Anticholinergic Agents			
ATROPINE SULPHATE			
Eye drops 0.5%			
Eye drops 1%, single dose			
Eye drops 1% – 1% DV Jul-14 to 2017	17.36	15 ml	Atropt
CYCLOPENTOLATE HYDROCHLORIDE			
Eye drops 0.5%, single dose			
Eye drops 1% – 1% DV Sep-14 to 2017	8.76	15 ml	Cyclogyl
Eye drops 1%, single dose			
TROPICAMIDE			
Eye drops 0.5% – 1% DV Oct-14 to 2017	7.15	15 ml	Mydriacyl
Eye drops 0.5%, single dose			
Eye drops 1% – 1% DV Oct-14 to 2017	8.66	15 ml	Mydriacyl
Eye drops 1%, single dose			
Sympathomimetics			
PHENYLEPHRINE HYDROCHLORIDE			
Eye drops 2.5%, single dose			
Eye drops 10%, single dose			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Ocular Lubricants			
CARBOMER			
Ophthalmic gel 0.3%, single dose	8.25	30	Poly Gel
Ophthalmic gel 0.2%			
CARMELLOSE SODIUM			
Eye drops 0.5%			
Eye drops 0.5%, single dose			
Eye drops 1%			
Eye drops 1%, single dose			
HYPROMELLOSE			
Eye drops 0.5%	3.92	15 ml	Methopt
HYPROMELLOSE WITH DEXTRAN			
Eye drops 0.3% with dextran 0.1%	2.30	15 ml	Poly-Tears
Eye drops 0.3% with dextran 0.1%, single dose			
MACROGOL 400 AND PROPYLENE GLYCOL			
Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose	4.30	24	Systane Unit Dose
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN			
Eye oint 42.5% with soft white paraffin 57.3%			
PARAFFIN LIQUID WITH WOOL FAT			
Eye oint 3% with wool fat 3% – 1% DV Jul-14 to 2017	3.63	3.5 g	Poly-Visc
POLYVINYL ALCOHOL			
Eye drops 1.4%	2.95	15 ml	Vistil
	3.62		Liquifilm Tears
Eye drops 3%	3.80	15 ml	Vistil Forte
	3.88		Liquifilm Forte
POLYVINYL ALCOHOL WITH POVIDONE			
Eye drops 1.4% with povidone 0.6%, single dose			
RETINOL PALMITATE			
Oint 138 mcg per g	3.80	5 g	VitA-POS
SODIUM HYALURONATE [HYALURONIC ACID]			
Eye drops 1 mg per ml	22.00	10 ml	Hylo-Fresh

Other Otological Preparations

ACETIC ACID WITH PROPYLENE GLYCOL			
Ear drops 2.3% with propylene glycol 2.8%			
DOCUSATE SODIUM			
Ear drops 0.5%			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Agents Used in the Treatment of Poisonings			
Antidotes			
ACETYLCYSTEINE			
Tab eff 200 mg			
Inj 200 mg per ml, 10 ml ampoule – 1% DV Sep-15 to 2018.....	78.34	10	DBL Acetylcysteine
	178.00		Martindale
			Acetylcysteine
Inj 200 mg per ml, 30 ml vial	219.00	4	Acetadote
<i>(Martindale Acetylcysteine Inj 200 mg per ml, 10 ml ampoule to be delisted 1 September 2015)</i>			
<i>(Acetadote Inj 200 mg per ml, 30 ml vial to be delisted 1 September 2015)</i>			
DIGOXIN IMMUNE FAB			
Inj 38 mg vial			
Inj 40 mg vial			
ETHANOL			
Liq 96%			
ETHANOL WITH GLUCOSE			
Inj 10% with glucose 5%, 500 ml bottle			
ETHANOL, DEHYDRATED			
Inj 100%, 5 ml ampoule			
Inj 96%			
FLUMAZENIL			
Inj 0.1 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018.....	85.05	5	Anexate
HYDROXOCOBALAMIN			
Inj 5 g vial			
Inj 2.5 g vial			
NALOXONE HYDROCHLORIDE			
Inj 400 mcg per ml, 1 ml ampoule	48.84	5	Hospira
PRALDOXIME IODIDE			
Inj 25 mg per ml, 20 ml ampoule			
SODIUM NITRITE			
Inj 30 mg per ml, 10 ml ampoule			
SODIUM THIOSULFATE			
Inj 500 mg per ml, 20 ml ampoule			
Inj 250 mg per ml, 10 ml vial			
Inj 500 mg per ml, 10 ml vial			
SOYA OIL			
Inj 20%, 500 ml bag			
Inj 20%, 500 ml bottle			
Antitoxins			
BOTULISM ANTITOXIN			
Inj 250 ml vial			
DIPHThERIA ANTITOXIN			
Inj 10,000 iu vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antivenoms			
RED BACK SPIDER ANTIVENOM			
Inj 500 u vial			
SNAKE ANTIVENOM			
Inj 50 ml vial			
Removal and Elimination			
CHARCOAL			
Oral liq 200 mg per ml	43.50	250 ml	Carbasorb-X
DEFERASIROX – Restricted see terms below			
⚡ Tab 125 mg dispersible	276.00	28	Exjade
⚡ Tab 250 mg dispersible	552.00	28	Exjade
⚡ Tab 500 mg dispersible	1,105.00	28	Exjade
➡ Restricted			
Initiation			
Haematologist			
<i>Re-assessment required after 2 years</i>			
All of the following:			
1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and			
2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and			
3 Any of the following:			
3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or			
3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or			
3.3 Treatment with deferiprone has resulted in arthritis; or			
3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per μL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per μL)			
Continuation			
Haematologist			
<i>Re-assessment required after 2 years</i>			
Either:			
1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or			
2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.			
DEFERIPRONE – Restricted see terms below			
⚡ Tab 500 mg	533.17	100	Ferriprox
⚡ Oral liq 100 mg per ml	266.59	250 ml	Ferriprox
➡ Restricted			
Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.			
DEFERRIOXAMINE MESILATE			
Inj 500 mg vial	109.89	10	Hospira
DICOBALT EDETATE			
Inj 15 mg per ml, 20 ml ampoule			
DIMERCAPROL			
Inj 50 mg per ml, 2 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DIMERCAPTOSUCCINIC ACID Cap 100 mg			
SODIUM CALCIUM EDETATE Inj 200 mg per ml, 2.5 ml ampoule Inj 200 mg per ml, 5 ml ampoule			
Antiseptics and Disinfectants			
CHLORHEXIDINE Soln 4% Soln 5%	1.86 15.50	50 ml 500 ml	healthE healthE
CHLORHEXIDINE WITH CETRIMIDE Crm 0.1% with cetrimide 0.5% Foaming soln 0.5% with cetrimide 0.5%			
CHLORHEXIDINE WITH ETHANOL Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml Soln 2% with ethanol 70%, non-staining (pink) 100 ml Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml Soln 0.5% with ethanol 70%, staining (red) 100 ml Soln 2% with ethanol 70%, staining (red) 100 ml Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml Soln 0.5% with ethanol 70%, staining (red) 500 ml Soln 2% with ethanol 70%, staining (red) 500 ml	2.65 3.54 1.55 2.90 3.86 5.45 5.90 9.56	1 1 1 1 1 1 1 1	healthE healthE healthE healthE healthE healthE healthE healthE
IODINE WITH ETHANOL Soln 1% with ethanol 70%, 100 ml	9.30	1	healthE
ISOPROPYL ALCOHOL Soln 70%, 500 ml	5.00 5.65	1	PSM healthE
POVIDONE-IODINE Vaginal tab 200 mg ➡ Restricted Rectal administration pre-prostate biopsy.			
Oint 10% Soln 10% Soln 5% Soln 7.5% Pad 10% Swab set 10%	3.27 2.95 6.20	25 g 100 ml 500 ml	Betadine Riodine Riodine Betadine
POVIDONE-IODINE WITH ETHANOL Soln 10% with ethanol 30% Soln 10% with ethanol 70%	10.00	500 ml	Betadine Skin Prep
SODIUM HYPOCHLORITE Soln			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Contrast Media			
Iodinated X-ray Contrast Media			
DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE			
Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle	22.50	100 ml	Gastrografin
Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle	80.00	1	Urografin
DIATRIZOATE SODIUM			
Oral liq 370 mg per ml, 10 ml sachet	156.12	50	Ioscan
IODISED OIL			
Inj 38% w/w (480 mg per ml), 10 ml ampoule	143.00	1	Lipiodol Ultra Fluid
IODIXANOL			
Inj 270 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	220.00	10	Visipaque
Inj 270 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017	430.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	220.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017	430.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 200 ml bottle – 5% DV Sep-14 to 2017	850.00	10	Visipaque
IOHEXOL			
Inj 240 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	75.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 20 ml bottle – 5% DV Sep-14 to 2017	57.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	75.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017	150.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 20 ml bottle – 5% DV Sep-14 to 2017	59.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	75.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 75 ml bottle – 5% DV Sep-14 to 2017	114.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017	150.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 200 ml bottle – 5% DV Sep-14 to 2017	290.00	10	Omnipaque

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Non-iodinated X-ray Contrast Media			
BARIUM SULPHATE			
Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet	507.50	50	E-Z-Cat Dry
Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle	17.39	148 g	Varibar - Thin Liquid
Oral liq 600 mg per g (60% w/w), tube	36.51	454 g	E-Z-Paste
Oral liq 400 mg per ml (40% w/v), bottle	38.40	240 ml	Varibar - Nectar
.....	145.04	230 ml	Varibar - Pudding
.....	155.35	250 ml	Varibar - Honey
Enema 1,250 mg per ml (125% w/v), 500 ml bag	282.30	12	Liquibar
Oral liq 22 mg per g (2.2% w/w), 250 ml bottle	175.00	24	CT Plus+
Oral liq 22 mg per g (2.2% w/w), 450 ml bottle	220.00	24	CT Plus+
Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle	441.12	24	VoLumen
Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle	140.94	24	Readi-CAT 2
Powder for oral soln 97.65% w/w, 300 g bottle	237.76	24	X-Opaque-HD
Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle	52.35	3	Tagitol V
Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle	91.77	1	Liquibar
BARIUM SULPHATE WITH SODIUM BICARBONATE			
Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet	102.93	50	E-Z-Gas II
CITRIC ACID WITH SODIUM BICARBONATE			
Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet			<i>e.g. E-Z-GAS II</i>
Paramagnetic Contrast Media			
GADOBENIC ACID			
Inj 334 mg per ml, 10 ml vial	324.74	10	Multihance
Inj 334 mg per ml, 20 ml vial	636.28	10	Multihance
GADOBUTROL			
Inj 1 mmol per ml, 15 ml vial			
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe	180.00	5	Gadovist
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe	700.00	10	Gadovist
GADODIAMIDE			
Inj 287 mg per ml, 10 ml prefilled syringe	200.00	10	Omniscan
Inj 287 mg per ml, 10 ml vial	170.00	10	Omniscan
Inj 287 mg per ml, 5 ml vial	120.00	10	Omniscan
Inj 287 mg per ml, 15 ml prefilled syringe	320.00	10	Omniscan
GADOTERIC ACID			
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe	24.50	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle	34.50	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe	41.00	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe	55.00	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle	23.20	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle	46.30	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle	12.30	1	Dotarem

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GADOXETATE DISODIUM			
Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe	300.00	1	Primovist
MEGLUMINE GADOPENTETATE			
Inj 469 mg per ml, 10 ml prefilled syringe	95.00	5	Magnevist
Inj 469 mg per ml, 10 ml vial	185.00	10	Magnevist
MEGLUMINE IOTROXATE			
Inj 105 mg per ml, 100 ml bottle	150.00	100 ml	Biliscopin
Ultrasound Contrast Media			
PERFLUTREN			
Inj 1.1 mg per ml, 1.5 ml vial – 5% DV Sep-14 to 2017	180.00	1	Definity
	720.00	4	Definity
Diagnostic Agents			
ARGININE			
Inj 50 mg per ml, 500 ml bottle			
Inj 100 mg per ml, 300 ml bottle			
HISTAMINE ACID PHOSPHATE			
Nebuliser soln 0.6%, 10 ml vial			
Nebuliser soln 2.5%, 10 ml vial			
Nebuliser soln 5%, 10 ml vial			
MANNITOL			
Powder for inhalation			<i>e.g. Aridol</i>
METHACHOLINE CHLORIDE			
Powder 100 mg			
SECRETIN PENTAHYDROCHLORIDE			
Inj 100 u ampoule			
SINCALIDE			
Inj 5 mcg per vial			
TUBERCULIN, PURIFIED PROTEIN DERIVATIVE			
Inj 5 TU per 0.1 ml, 1 ml vial			
Diagnostic Dyes			
BONNEY'S BLUE DYE			
Soln			
INDIGO CARMINE			
Inj 4 mg per ml, 5 ml ampoule			
Inj 8 mg per ml, 5 ml ampoule			
INDOCYANINE GREEN			
Inj 25 mg vial			
METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE]			
Inj 10 mg per ml, 10 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule			
PATENT BLUE V			
Inj 2.5%, 2 ml ampoule	440.00	5	Obex Medical

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Irrigation Solutions			
CHLORHEXIDINE			
Irrigation soln 0.02%, bottle	2.92	100 ml	Baxter
Irrigation soln 0.05%, bottle	3.02	100 ml	Baxter
	3.63	500 ml	Baxter
Irrigation soln 0.1%, bottle	3.10	100 ml	Baxter
Irrigation soln 0.5%, bottle	4.69	500 ml	Baxter
Irrigation soln 0.02%, 500 ml bottle			
Irrigation soln 0.1%, 30 ml ampoule			
CHLORHEXIDINE WITH CETRIMIDE			
Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule			
Irrigation soln 0.015% with cetrimide 0.15%, bottle	3.21	100 ml	Baxter
	3.47	500 ml	Baxter
	4.17	1,000 ml	Baxter
Irrigation soln 0.05% with cetrimide 0.5%, bottle	4.20	100 ml	Baxter
	3.87	500 ml	Baxter
Irrigation soln 0.1% with cetrimide 1%, bottle	4.38	100 ml	Baxter
	5.81	500 ml	Baxter
GLYCINE			
Irrigation soln 1.5%, bottle	11.38	2,000 ml	Baxter
	14.44	3,000 ml	Baxter
SODIUM CHLORIDE			
Irrigation soln 0.9%, 30 ml ampoule	19.50	30 ml	Pfizer
Irrigation soln 0.9%, bottle	2.49	100 ml	Baxter
	2.88	500 ml	Baxter
	2.96	1,000 ml	Baxter
	10.00	2,000 ml	Baxter
	12.67	3,000 ml	Baxter
WATER			
Irrigation soln, bottle	2.68	100 ml	Baxter
	2.61	500 ml	Baxter
	2.75	1,000 ml	Baxter
	9.71	2,000 ml	Baxter
	15.80	3,000 ml	Baxter
Surgical Preparations			
BISMUTH SUBNITRATE AND IODOFORM PARAFFIN			
Paste			
DIMETHYL SULFOXIDE			
Soln 50%			
Soln 99%			
PHENOL			
Inj 6%, 10 ml ampoule			
PHENOL WITH IOXAGLIC ACID			
Inj 12%, 10 ml ampoule			
TROMETAMOL			
Inj 36 mg per ml, 500 ml bottle			

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

Cardioplegia Solutions

ELECTROLYTES

Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 mmol/l potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium chloride, 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 mmol/l tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chloride, 1,000 ml bag

e.g. Custodiol-HTK

Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag

*e.g. Cardioplegia
Enriched Paed.
Soln.*

Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag

*e.g. Cardioplegia
Enriched Solution*

Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag

*e.g. Cardioplegia Base
Solution*

Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag

*e.g. Cardioplegia
Solution AHB7832*

Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag

*e.g. Cardioplegia
Electrolyte Solution*

MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE

Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle

MONOSODIUM L-ASPARTATE

Inj 14 mmol per 10 ml, 10 ml

Cold Storage Solutions

SODIUM WITH POTASSIUM

Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Extemporaneously Compounded Preparations		
ACETIC ACID Liq		
ALUM Powder BP		
ARACHIS OIL [PEANUT OIL] Liq		
ASCORBIC ACID Powder		
BENZOIN Tincture compound BP		
BISMUTH SUBGALLATE Powder		
BORIC ACID Powder		
CARBOXYMETHYLCELLULOSE Soln 1.5%		
CETRIMIDE Soln 40%		
CHLORHEXIDINE GLUCONATE Soln 20 %		
CHLOROFORM Liq BP		
CITRIC ACID Powder BP		
CLOVE OIL Liq		
COAL TAR Soln BP		
CODEINE PHOSPHATE Powder		
COLLODION FLEXIBLE Liq		
COMPOUND HYDROXYBENZOATE Soln		
CYSTEAMINE HYDROCHLORIDE Powder		
DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule		
DITHRANOL Powder		

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GLUCOSE [DEXTROSE] Powder			
GLYCERIN WITH SODIUM SACCHARIN Suspension	35.50	473 ml	Ora-Sweet SF
GLYCERIN WITH SUCROSE Suspension	35.50	473 ml	Ora-Sweet
GLYCEROL Liq	19.80	2,000 ml	ABM
HYDROCORTISONE Powder – 1% DV Dec-14 to 2017	59.50	25 g	ABM
LACTOSE Powder			
MAGNESIUM HYDROXIDE Paste			
MENTHOL Crystals			
METHADONE HYDROCHLORIDE Powder			
METHYL HYDROXYBENZOATE Powder			
METHYLCELLULOSE Powder			
Suspension	35.50	473 ml	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension	35.50	473 ml	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension	35.50	473 ml	Ora-Blend
OLIVE OIL Liq			
PARAFFIN Liq			
PHENOBARBITONE SODIUM Powder			
PHENOL Liq			
PILOCARPINE NITRATE Powder			
POLYHEXAMETHYLENE BIGUANIDE Liq			
POVIDONE K30 Powder			
PROPYLENE GLYCOL Liq	12.00	500 ml	ABM

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SALICYLIC ACID Powder			
SILVER NITRATE Crystals			
SODIUM BICARBONATE Powder BP			
SODIUM CITRATE Powder			
SODIUM METABISULFITE Powder			
STARCH Powder			
SULPHUR Precipitated Sublimed			
SYRUP Liq (pharmaceutical grade)	21.75	2,000 ml	Midwest
THEOBROMA OIL Oint			
TRI-SODIUM CITRATE Crystals			
TRICHLORACETIC ACID Grans			
UREA Powder BP			
WOOL FAT Oint, anhydrous			
XANTHAN Gum 1%			
ZINC OXIDE Powder			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Food Modules		
Carbohydrate		
➡Restricted		
Use as an additive		
Any of the following:		
1 Cystic fibrosis; or		
2 Chronic kidney disease; or		
3 Cancer in children; or		
4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or		
5 Faltering growth in an infant/child; or		
6 Bronchopulmonary dysplasia; or		
7 Premature and post premature infant; or		
8 Inborn errors of metabolism.		
Use as a module		
For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.		
Notes: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.		
CARBOHYDRATE SUPPLEMENT – Restricted see terms above		
⬆ Powder 95 g carbohydrate per 100 g, 368 g can		
⬆ Powder 96 g carbohydrate per 100 g, 400 g can		e.g. Polycal
Fat		
➡Restricted		
Use as an additive		
Any of the following:		
1 Patient has inborn errors of metabolism; or		
2 Faltering growth in an infant/child; or		
3 Bronchopulmonary dysplasia; or		
4 Fat malabsorption; or		
5 Lymphangiectasia; or		
6 Short bowel syndrome; or		
7 Infants with necrotising enterocolitis; or		
8 Biliary atresia; or		
9 For use in a ketogenic diet; or		
10 Chyle leak; or		
11 Ascites; or		
12 Patient has increased energy requirements, and for whom dietary measures have not been successful.		
Use as a module		
For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.		
Notes: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.		
LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted see terms above		
⬆ Liquid 50 g fat per 100 ml, 200 ml bottle		e.g. Calogen
⬆ Liquid 50 g fat per 100 ml, 500 ml bottle		e.g. Calogen
MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted see terms above		
⬆ Liquid 50 g fat per 100 ml, 250 ml bottle		e.g. Liquigen
⬆ Liquid 95 g fat per 100 ml, 500 ml bottle		e.g. MCT Oil
WALNUT OIL – Restricted see terms above		
⬆ Liq		

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Protein

➡Restricted

Use as an additive

Either:

- 1 Protein losing enteropathy; or
- 2 High protein needs.

Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Notes: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

PROTEIN SUPPLEMENT – **Restricted** see terms above

⬆ Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can			<i>e.g. Promod</i>
⬆ Powder 6 g protein per 7 g, can	8.95	227 g	Resource Beneprotein
⬆ Powder 89 g protein, <1.5 g carbohydrate and 2 g fat per 100 g, 225 g can			<i>e.g. Protifar</i>

Other Supplements

BREAST MILK FORTIFIER

Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet	<i>e.g. FM 85</i>
Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet	<i>e.g. S26 Human Milk Fortifier</i>
Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet	<i>e.g. Nutricia Breast Milk Fortifier</i>

CARBOHYDRATE AND FAT SUPPLEMENT – **Restricted** see terms below

⬆ Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can	<i>e.g. Super Soluble Duocal</i>
--	----------------------------------

➡Restricted

Both:

- 1 Infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 Cystic fibrosis; or
 - 2.2 Cancer in children; or
 - 2.3 Faltering growth; or
 - 2.4 Bronchopulmonary dysplasia; or
 - 2.5 Premature and post premature infants.

Price (ex man. excl. GST)	Brand or Generic Manufacturer
\$	Per

Food/Fluid Thickeners

NOTE:

While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:

- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by PHARMAC; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN

Powder

*e.g. Feed Thickener
Karicare Aptamil*

GUAR GUM

Powder

e.g. Guarcol

MAIZE STARCH

Powder

*e.g. Resource Thicken
Up; Nutrilis*

MALTODEXTRIN WITH XANTHAN GUM

Powder

e.g. Instant Thick

MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID

Powder

e.g. Easy Thick

Metabolic Products

➔ Restricted

Any of the following:

- 1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinaemia or urea cycle disorders; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) – **Restricted** see terms above

⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre
per 100 g, 400 g can

e.g. GA1 Anamix Infant

⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

*e.g. XLYS Low TRY
Maxamaid*

Homocystinuria Products

AMINO ACID FORMULA (WITHOUT METHIONINE) – **Restricted** see terms above

⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre
per 100 g, 400 g can

e.g. HCU Anamix Infant

⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

e.g. XMET Maxamaid

⬆ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can

e.g. XMET Maxamum

⬆ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per
100 ml, 125 ml bottle

*e.g. HCU Anamix Junior
LQ*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Isovaleric Acidaemia Products			
AMINO ACID FORMULA (WITHOUT LEUCINE) – Restricted see terms on the preceding page			
⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			<i>e.g. IVA Anamix Infant</i>
⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			<i>e.g. XLEU Maxamaid</i>
⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			<i>e.g. XLEU Maxamum</i>
Maple Syrup Urine Disease Products			
AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – Restricted see terms on the preceding page			
⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			<i>e.g. MSUD Anamix Infant</i>
⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			<i>e.g. MSUD Maxamaid</i>
⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			<i>e.g. MSUD Maxamum</i>
⚡ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle			<i>e.g. MSUD Anamix Junior LQ</i>
Phenylketonuria Products			
AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – Restricted see terms on the preceding page			
⚡ Tab 8.33 mg			<i>e.g. Phlexy-10</i>
⚡ Powder 29 g protein, 38 g carbohydrate and 13.5 g fibre per 100 g, 29 g sachet			<i>e.g. PKU Anamix Junior</i>
⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			<i>e.g. PKU Anamix Infant</i>
⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			<i>e.g. XP Maxamaid</i>
⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			<i>e.g. XP Maxamum</i>
⚡ Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet			<i>e.g. Phlexy-10</i>
⚡ Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle			<i>e.g. PKU Lophlex LQ 10</i>
⚡ Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle			<i>e.g. PKU Lophlex LQ 20</i>
⚡ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle	13.10	125 ml	PKU Anamix Junior LQ (Berry) PKU Anamix Junior LQ (Orange) PKU Anamix Junior LQ (Unflavoured)
⚡ Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle			<i>e.g. PKU Lophlex LQ 20</i>
⚡ Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle			<i>e.g. PKU Lophlex LQ 10</i>
⚡ Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle			<i>e.g. PKU Lophlex LQ 20</i>
⚡ Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle			<i>e.g. PKU Lophlex LQ 10</i>
⚡ Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton			<i>e.g. Easiphen</i>

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

Propionic Acidaemia and Methylmalonic Acidaemia Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) – **Restricted** see terms on page 197

⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	<i>e.g. MMA/PA Anamix Infant</i>
⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can	<i>e.g. XMTVI Maxamaid</i>
⬆ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can	<i>e.g. XMTVI Maxamum</i>

Protein Free Supplements

PROTEIN FREE SUPPLEMENT – **Restricted** see terms on page 197

⬆ Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can	<i>e.g. Energivit</i>
---	-----------------------

Tyrosinaemia Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) – **Restricted** see terms on page 197

⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	<i>e.g. TYR Anamix Infant</i>
⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can	<i>e.g. XPHEN, TYR Maxamaid</i>
⬆ Powder 29 g protein, 38 g carbohydrate and 13.5 g fat per 100 g, 29 g sachet	<i>e.g. TYR Anamix Junior</i>
⬆ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle	<i>e.g. TYR Anamix Junior LQ</i>

Urea Cycle Disorders Products

AMINO ACID SUPPLEMENT – **Restricted** see terms on page 197

⬆ Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can	<i>e.g. Dialamine</i>
⬆ Powder 79 g protein per 100 g, 200 g can	<i>e.g. Essential Amino Acid Mix</i>

X-Linked Adrenoleukodystrophy Products

GLYCEROL TRIERUCATE – **Restricted** see terms on page 197

⬆ Liquid, 1,000 ml bottle

GLYCEROL TRIOLEATE – **Restricted** see terms on page 197

⬆ Liquid, 500 ml bottle

Specialised Formulas

Diabetic Products

➡ **Restricted**

Any of the following:

- 1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
- 2 For patients with pancreatic insufficiency; or
- 3 For patients who have, or are expected to, eat little or nothing for 5 days;
- 4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued...			
5 For use pre- and post-surgery; or			
6 For patients being tube-fed; or			
7 For tube-feeding as a transition from intravenous nutrition.			
LOW-GI ENTERAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
☞ Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle	7.50	1,000 ml	Glucerna Select RTH (Vanilla)
☞ Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag			e.g. <i>Nutrison Advanced Diason</i>
LOW-GI ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
☞ Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, can	2.10	237 ml	Sustagen Diabetic (Vanilla)
☞ Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml bottle	1.88	250 ml	Glucerna Select (Vanilla)
☞ Liquid 6 g protein, 9.5 g carbohydrate, 4.7 g fat and 2.6 g fibre per 100 ml, can	2.10	237 ml	Resource Diabetic (Vanilla)
☞ Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle			e.g. <i>Diasip</i>
Elemental and Semi-Elemental Products			
☞ Restricted			
Any of the following:			
1 Malabsorption; or			
2 Short bowel syndrome; or			
3 Enterocutaneous fistulas; or			
4 Eosinophilic enteritis (including oesophagitis); or			
5 Inflammatory bowel disease; or			
6 Acute pancreatitis where standard feeds are not tolerated; or			
7 Patients with multiple food allergies requiring enteral feeding.			
AMINO ACID ORAL FEED – Restricted see terms above			
☞ Powder 11.5 g protein, 61.7 g carbohydrate and 0.8 g fat per sachet	4.50	80.4 g	Vivonex TEN
AMINO ACID ORAL FEED 0.8 KCAL/ML – Restricted see terms above			
☞ Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton			e.g. <i>Elemental 028 Extra</i>
PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – Restricted see terms above			
☞ Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag			e.g. <i>Nutrison Advanced Peptisorb</i>

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PEPTIDE-BASED ORAL FEED – Restricted see terms on the preceding page			
⬆ Powder 12.5 g protein, 55.4 g carbohydrate and 3.25 g fat per sachet	4.40	79 g	Vital HN
⬆ Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can			<i>e.g. Peptamen Junior</i>
⬆ Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can			<i>e.g. MCT Pepdite; MCT Pepdite 1+</i>
⬆ Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet	7.50	76 g	Alitraq
PEPTIDE-BASED ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
⬆ Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton	4.95	237 ml	Peptamen OS 1.0 (Vanilla)

Fat Modified Products

FAT-MODIFIED FEED – **Restricted** see terms below

⬆ Powder 11.4 g protein, 68 g carbohydrate and 11.8 g fat per 100 g, 400 g can			<i>e.g. Monogen</i>
---	--	--	---------------------

➡Restricted

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Notes: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Hepatic Products

➡Restricted

For children (up to 18 years) who require a liver transplant

HEPATIC ORAL FEED – **Restricted** see terms above

⬆ Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can	78.97	400 g	Heparon Junior
--	-------	-------	----------------

High Calorie Products

➡Restricted

Any of the following:

- 1 Patient is fluid volume or rate restricted; or
- 2 Patient requires low electrolyte; or
- 3 Both:
 - 3.1 Any of the following:
 - 3.1.1 Cystic fibrosis; or
 - 3.1.2 Any condition causing malabsorption; or
 - 3.1.3 Faltering growth in an infant/child; or
 - 3.1.4 Increased nutritional requirements; and
 - 3.2 Patient has substantially increased metabolic requirements.

ENTERAL FEED 2 KCAL/ML – **Restricted** see terms above

⬆ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle	5.50	500 ml	Nutrison Concentrated
⬆ Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle	11.00	1,000 ml	TwoCal HN RTH (Vanilla)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ORAL FEED 2 KCAL/ML – Restricted see terms on the preceding page			
☞ Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle	1.90	200 ml	Two Cal HN

High Protein Products

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – **Restricted** see terms below

☞ Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bag	e.g. <i>Nutrison Protein Plus</i>		
--	-----------------------------------	--	--

☞Restricted

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
 - 2.1 Patient has liver disease; or
 - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
 - 2.3 Patient is fluid restricted; or
 - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – **Restricted** see terms below

☞ Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag	e.g. <i>Nutrison Protein Plus Multi Fibre</i>		
---	---	--	--

☞Restricted

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
 - 2.1 Patient has liver disease; or
 - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
 - 2.3 Patient is fluid restricted; or
 - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

Infant Formulas

AMINO ACID FORMULA – **Restricted** see terms on the next page

☞ Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can		e.g. <i>Neocate</i>
☞ Powder 13 g protein, 52.5 g carbohydrate and 24.5 g fat per 100 g, 400 g can		e.g. <i>Neocate LCP</i>
☞ Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can	53.00	400 g Neocate Gold (Unflavoured)
☞ Powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can		e.g. <i>Neocate Advance</i>
☞ Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can	53.00	400 g Neocate Advance (Vanilla)
☞ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can	53.00	400 g Elecare LCP (Unflavoured)
☞ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can	53.00	400 g Elecare (Unflavoured)
☞ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can	53.00	400 g Elecare (Vanilla)
☞ Powder 6 g protein, 31.5 g carbohydrate and 5.88 g fat per sachet	6.00	48.5 g Vivonex Paediatric

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
Per	

➔ Restricted

Initiation

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows' milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Note: A reasonable trial is defined as a 2-4 week trial.

Continuation

Both:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

EXTENSIVELY HYDROLYSED FORMULA – **Restricted** see terms below

- ⬇ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g,
450 g can

*e.g. Gold Pepti Junior
Karicare Aptamil*

➔ Restricted

Initiation - new patients

Any of the following:

- 1 Both:
 - 1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malabsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure.

Note: A reasonable trial is defined as a 2-4 week trial.

Initiation - step down from amino acid formula

Both:

- 1 The infant is currently receiving funded amino acid formula; and
- 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula.

Continuation

Both:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

FRUCTOSE-BASED FORMULA

- ⬇ Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g,
400 g can

e.g. Galactomin 19

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LACTOSE-FREE FORMULA			
Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can			<i>e.g. Karicare Aptamil Gold De-Lact</i>
Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can			<i>e.g. S26 Lactose Free</i>
LOW-CALCIUM FORMULA			
Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can			<i>e.g. Locasol</i>
PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms below			
☛ Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, 100 ml bottle			<i>e.g. Infatrini</i>
☛Restricted			
Both:			
1 Either:			
1.1 The patient is fluid restricted; or			
1.2 The patient has increased nutritional requirements due to faltering growth; and			
2 Patient is under 18 months old and weighs less than 8kg.			
PRETERM FORMULA – Restricted see terms below			
☛ Powder 1.9 g protein, 7.5 g carbohydrate and 3.9 g fat per 14 g, can15.25	400 g		S-26 Gold Premgro
☛ Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle0.75	100 ml		S26 LBW Gold RTF
☛ Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle			<i>e.g. Pre Nan Gold RTF</i>
☛ Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle			<i>e.g. Karicare Aptamil Gold+Preterm</i>
☛Restricted			
For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth.			
THICKENED FORMULA			
Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can			<i>e.g. Karicare Aptamil Thickened AR</i>

Ketogenic Diet Products

HIGH FAT FORMULA – Restricted see terms below			
☛ Powder 15.25 g protein, 3 g carbohydrate and 73 g fat per 100 g, can35.50	300 g		Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)
☛ Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can35.50	300 g		Ketocal 3:1 (Unflavoured)
☛Restricted			
For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.			

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Paediatric Products

➔Restricted

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 Any condition causing malabsorption; or
 - 2.3 Faltering growth in an infant/child; or
 - 2.4 Increased nutritional requirements; or
 - 2.5 The child is being transitioned from TPN or tube feeding to oral feeding; or
 - 2.6 The child has eaten, or is expected to eat, little or nothing for 3 days.

PAEDIATRIC ORAL FEED – **Restricted** see terms above

⬆ Powder 14.9 g protein, 54.3 g carbohydrate and 24.7 g fat per 100 g, can	20.00	850 g	Pediasure (Vanilla)
---	-------	-------	---------------------

PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – **Restricted** see terms above

⬆ Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag	4.00	500 ml	Nutrini Low Energy Multifibre RTH
---	------	--------	--------------------------------------

PAEDIATRIC ENTERAL FEED 1 KCAL/ML – **Restricted** see terms above

⬆ Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag	2.68	500 ml	Pediasure RTH
⬆ Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag			<i>e.g. Nutrini RTH</i>

PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – **Restricted** see terms above

⬆ Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag	6.00	500 ml	Nutrini Energy Multi Fibre
⬆ Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag			<i>e.g. Nutrini Energy RTH</i>

PAEDIATRIC ORAL FEED 1 KCAL/ML – **Restricted** see terms above

⬆ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle	1.07	200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla) Pediasure (Vanilla)
⬆ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can	1.34	250 ml	Pediasure (Vanilla)

PAEDIATRIC ORAL FEED 1.5 KCAL/ML – **Restricted** see terms above

⬆ Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortini</i>
⬆ Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortini Multifibre</i>

Renal Products

LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – **Restricted** see terms below

⬆ Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle	6.08	500 ml	Nepro HP RTH
---	------	--------	--------------

➔Restricted

For patients with acute or chronic kidney disease.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LOW ELECTROLYTE ORAL FEED – Restricted see terms below			
☞ Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can			<i>e.g. Kindergen</i>
☞ Restricted			
For children (up to 18 years) with acute or chronic kidney disease			
LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML			
☞ Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton	2.67	220 ml	Nepro HP (Strawberry) Nepro HP (Vanilla)
☞ Restricted			
For patients with acute or chronic kidney disease.			
LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted see terms below			
☞ Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton	3.31	237 ml	Novasource Renal (Vanilla)
☞ Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle			
☞ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton			<i>e.g. Renilon 7.5</i>
☞ Restricted			
For patients with acute or chronic kidney disease.			
Respiratory Products			
LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – Restricted see terms below			
☞ Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle	1.66	237 ml	Pulmocare (Vanilla)
☞ Restricted			
For patients with CORD and hypercapnia, defined as a CO ₂ value exceeding 55 mmHg			
Surgical Products			
HIGH ARGININE ORAL FEED 1.4 KCAL/ML – Restricted see terms below			
☞ Liquid 7.6 g protein, 18.9 g carbohydrate, 3.9 g fat and 1.4 g fibre per 100 ml, carton	4.00	237 ml	Impact Advanced Recovery (Chocolate) Impact Advanced Recovery (Vanilla)
☞ Restricted			
Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery			
PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – Restricted see terms below			
☞ Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle	6.80	4	preOp
☞ Restricted			
Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.			

Price (ex man. excl. GST)	Brand or Generic Manufacturer
\$	Per

Standard Feeds

➔ Restricted

Any of the following:

- For patients with malnutrition, defined as any of the following:
 - BMI < 18.5; or
 - Greater than 10% weight loss in the last 3-6 months; or
 - BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
- For patients who have, or are expected to, eat little or nothing for 5 days; or
- For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- For use pre- and post-surgery; or
- For patients being tube-fed; or
- For tube-feeding as a transition from intravenous nutrition; or
- For any other condition that meets the community Special Authority criteria.

ENTERAL FEED 1.5 KCAL/ML – **Restricted** see terms above

☛ Liquid 5.4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1,000 ml bottle			<i>e.g. Isosource Standard RTH</i>
☛ Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag	7.00	1,000 ml	Nutrison Energy
☛ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Energy Multi Fibre</i>
☛ Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can	1.75	250 ml	Ensure Plus HN
☛ Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag	7.00	1,000 ml	Ensure Plus HN RTH
☛ Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag	7.00	1,000 ml	Jevity HiCal RTH

ENTERAL FEED 1 KCAL/ML – **Restricted** see terms above

☛ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle	2.65	500 ml	Osmolite RTH
	5.29	1,000 ml	Osmolite RTH
☛ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, can	1.24	250 ml	Osmolite
☛ Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle	2.65	500 ml	Jevity RTH
	5.29	1,000 ml	Jevity RTH
☛ Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, can	1.32	237 ml	Jevity
☛ Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bag			<i>e.g. NutrisonStdRTH; NutrisonLowSodium</i>
☛ Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag			<i>e.g. Nutrison Multi Fibre</i>

ENTERAL FEED 1.2 KCAL/ML – **Restricted** see terms above

☛ Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Jevity Plus RTH</i>
---	--	--	-----------------------------

SPECIAL FOODS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ORAL FEED – Restricted see terms on the preceding page			
☯ Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can	13.00	850 g	Ensure (Chocolate) Ensure (Vanilla)
☯ Powder 21.9 g protein, 53.5 g carbohydrate and 14.5 g fat per 100 g, can	3.67	350 g	Fortisip (Vanilla)
☯ Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can	14.90	900 g	Sustagen Hospital Formula (Chocolate) Sustagen Hospital Formula (Vanilla)
Note: Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer's surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.			
ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
☯ Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton			<i>e.g. Resource Fruit Beverage</i>
ORAL FEED 1.5 KCAL/ML – Restricted see terms on the preceding page			
☯ Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can	1.33	237 ml	Ensure Plus (Chocolate) Ensure Plus (Vanilla)
☯ Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton	1.26	200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla)
☯ Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle			<i>e.g. Fortijuice</i>
☯ Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortisip</i>
☯ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortisip Multi Fibre</i>

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – **Restricted** see terms below

<p>⚡ Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe – 1% DV Jul-14 to 2017</p>	0.00	10	Infanrix IPV
--	------	----	--------------

➔Restricted

Funded for any of the following:

- 1 A single dose for children up to the age of 7 who have completed primary immunisation; or
- 2 A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
- 3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 4 Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – **Restricted** see terms below

<p>⚡ Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial – 1% DV Jul-14 to 2017</p>	0.00	10	Infanrix-hexa
--	------	----	---------------

➔Restricted

Funded for patients meeting any of the following criteria:

- 1 Up to four doses for children up to and under the age of 10 for primary immunisation; or
- 2 An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 3 Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Bacterial Vaccines

ADULT DIPHTHERIA AND TETANUS VACCINE

<p>⚡ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe – 1% DV Jul-14 to 2017</p>	0.00	5	ADT Booster
--	------	---	-------------

➔Restricted

Any of the following:

- 1 For vaccination of patients aged 45 and 65 years old; or
- 2 For vaccination of previously unimmunised or partially immunised patients; or
- 3 For revaccination following immunosuppression; or
- 4 For boosting of patients with tetanus-prone wounds; or
- 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BACILLUS CALMETTE-GUERIN VACCINE – Restricted see terms below			
☞ Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent – 1% DV Oct-14 to 2017	0.00	10	BCG Vaccine
☞ Restricted			
For infants at increased risk of tuberculosis			
Note: increased risk is defined as:			
1 Living in a house or family with a person with current or past history of TB; or			
2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or			
3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.			
Note: A list of countries with high rates of TB are available at http://www.health.govt.nz/tuberculosis (Search for Downloads) or www.bcgatlas.org/index.php			
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Restricted see terms below			
☞ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe – 1% DV Jul-14 to 2017.....	0.00	1 10	Boostrix Boostrix
☞ Restricted			
Funded for any of the following:			
1 A single vaccine for pregnant woman between gestational weeks 28 and 38; or			
2 A course of up to four vaccines is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation; or			
3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens			
Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.			
HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted see terms below			
☞ Inj 10 mcg vial with diluent syringe – 1% DV Jul-14 to 2017	0.00	1	Act-HIB
☞ Restricted			
One dose for patients meeting any of the following:			
1 For primary vaccination in children; or			
2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or			
3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.			
MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted see terms on the next page			
☞ Inj 4 mcg or each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – 1% DV Jul-14 to 2017	0.00	1	Menactra

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔Restricted

Any of the following:

- 1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
- 2 One dose for close contacts of meningococcal cases; or
- 3 A maximum of two doses for bone marrow transplant patients; or
- 4 A maximum of two doses for patients following immunosuppression*.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE – Restricted see terms below

☛ Inj 10 mcg in 0.5 ml syringe – 1% DV Jul-14 to 2017	0.00	1	Neisvac-C
		10	Neisvac-C

➔Restricted

Any of the following:

- 1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
- 2 One dose for close contacts of meningococcal cases; or
- 3 A maximum of two doses for bone marrow transplant patients; or
- 4 A maximum of two doses for patients following immunosuppression*.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted see terms below

☛ Inj 30.8 mcg in 0.5 ml syringe – 1% DV Oct-14 to 2017	0.00	1	Prevenar 13
		10	Prevenar 13

➔Restricted

Any of the following:

- 1 A primary course of up to four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or
- 2 Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV10; or
- 3 One dose is funded for high risk children (over the age of 17 months and up to the age of 18) who have previously received four doses of PCV10; or
- 4 Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients with HIV, for patients post haematopoietic stem cell transplantation HSCT, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or
- 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – Restricted see terms below

☛ Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – 1% DV Jun-15 to 2017	0.00	1	Pneumovax 23
☛ Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococcal serotype)	0.00	1	Pneumovax 23

(Pneumovax 23 Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococcal serotype) to be delisted 1 December 2015)

➔Restricted

Any of the following:

- 1 Up to three doses for patients pre- or post-splenectomy or with functional asplenia; or
- 2 Up to two doses are funded for high risk children to the age of 18; or
- 3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SALMONELLA TYPHI VACCINE – Restricted see terms below			
☞ Inj 25 mcg in 0.5 ml syringe			
☞ Restricted			
For use during typhoid fever outbreaks			
Viral Vaccines			
HEPATITIS A VACCINE – Restricted see terms below			
☞ Inj 720 ELISA units in 0.5 ml syringe – 1% DV Jul-14 to 2017	0.00	1	Havrix Junior
☞ Inj 1440 ELISA units in 1 ml syringe – 1% DV Jul-14 to 2017	0.00	1	Havrix
☞ Restricted			
Funded for patients meeting any of the following criteria:			
1 Two vaccinations for use in transplant patients; or			
2 Two vaccinations for use in children with chronic liver disease; or			
3 One dose of vaccine for close contacts of known hepatitis A cases.			
HEPATITIS B RECOMBINANT VACCINE			
☞ Inj 40 mcg per 1 ml vial – 1% DV Jul-14 to 2017	0.00	1	HBvaxPRO
☞ Restricted			
Funded for any of the following criteria:			
1 For dialysis patients; or			
2 For liver or kidney transplant patient.			
☞ Inj 5 mcg in 0.5 ml vial – 1% DV Jul-14 to 2017	0.00	1	HBvaxPRO
☞ Restricted			
Funded for patients meeting any of the following criteria:			
1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or			
2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or			
3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or			
4 For HIV positive patients; or			
5 For hepatitis C positive patients; or			
6 For patients following non-consensual sexual intercourse; or			
7 For patients following immunosuppression; or			
8 For transplant patients; or			
9 Following needle stick injury.			
☞ Inj 10 mcg in 1 ml vial – 1% DV Jul-14 to 2017	0.00	1	HBvaxPRO
☞ Restricted			
Funded for patients meeting any of the following criteria:			
1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or			
2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or			
3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or			
4 For HIV positive patients; or			
5 For hepatitis C positive patients; or			
6 For patients following non-consensual sexual intercourse; or			
7 For patients following immunosuppression; or			
8 For transplant patients; or			
9 Following needle stick injury.			
HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] – Restricted see terms on the next page			
☞ Inj 120 mcg in 0.5 ml syringe – 1% DV Jul-14 to 2017	0.00	10	Gardasil

☞ Item restricted (see ☞ above); ☞ Item restricted (see ☞ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Maximum of three doses for patient meeting any of the following criteria:			
1 Females aged under 20 years old; or			
2 Patients aged under 26 years old with confirmed HIV infection; or			
3 For use in transplant (including stem cell) patients; or			
4 An additional dose for patients under 26 years of age post chemotherapy.			
INFLUENZA VACCINE – Restricted see terms below			
☞ Inj 45 mcg in 0.5 ml syringe	90.00	10	Fluarix Influvac
➔Restricted			
Any of the following:			
1 All people 65 years of age and over; or			
2 People under 65 years of age who:			
2.1 Have any of the following cardiovascular diseases:			
2.1.1 Ischaemic heart disease; or			
2.1.2 Congestive heart failure; or			
2.1.3 Rheumatic heart disease; or			
2.1.4 Congenital heart disease; or			
2.1.5 Cerebro-vascular disease; or			
2.2 Have any of the following chronic respiratory diseases:			
2.2.1 Asthma, if on a regular preventative therapy; or			
2.2.2 Other chronic respiratory disease with impaired lung function; or			
2.3 Have diabetes; or			
2.4 Have chronic renal disease; or			
2.5 Have any cancer, excluding basal and squamous skin cancers if not invasive; or			
2.6 Have any of the following other conditions:			
2.6.1 Autoimmune disease; or			
2.6.2 Immune suppression or immune deficiency; or			
2.6.3 HIV; or			
2.6.4 Transplant recipients; or			
2.6.5 Neuromuscular and CNS diseases/ disorders; or			
2.6.6 Haemoglobinopathies; or			
2.6.7 Are children on long term aspirin; or			
2.6.8 Have a cochlear implant; or			
2.6.9 Errors of metabolism at risk of major metabolic decompensation; or			
2.6.10 Pre and post splenectomy; or			
2.6.11 Down syndrome; or			
2.7 Are pregnant; or			
2.8 Are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or			
3 Patients who are compulsorily detained long-term in a forensic unit within a DHB hospital in the 2015 season.			
Note: The following conditions are excluded from funding:			
• asthma not requiring regular preventative therapy; and			
• hypertension and/or dyslipidaemia without evidence of end-organ disease.			
MEASLES, MUMPS AND RUBELLA VACCINE – Restricted see terms on the next page			
☞ Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000 TCID50 rubella vial with diluent – 1% DV Jul-14 to 2017	0.00	10	M-M-R-II

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➡Restricted			
A maximum of two doses for any patient meeting the following criteria:			
1 For primary vaccination in children; or			
2 For revaccination following immunosuppression; or			
3 For any individual susceptible to measles, mumps or rubella; or			
4 A maximum of three doses for children who have had their first dose prior to 12 months.			
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.			
POLIOMYELITIS VACCINE – Restricted see terms below			
☞ Inj 80 D-antigen units in 0.5 ml syringe – 1% DV Jul-14 to 2017	0.00	1	IPOL
➡Restricted			
Up to three doses for patients meeting either of the following:			
1 For partially vaccinated or previously unvaccinated individuals; or			
2 For revaccination following immunosuppression.			
Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.			
RABIES VACCINE			
Inj 2.5 IU vial with diluent			
ROTAVIRUS LIVE REASSORTANT ORAL VACCINE – Restricted see terms below			
☞ Oral susp G1, G2, G3, G4, P1(8) 11.5 million CCID50 units per 2 ml, tube – 1% DV Jul-14 to 2017	0.00	10	RotaTeg
➡Restricted			
Maximum of three doses for patients meeting the following:			
1 First dose to be administered in infants aged under 15 weeks of age; and			
2 No vaccination being administered to children aged 8 months or over.			
VARICELLA VACCINE [CHICKEN POX VACCINE] – Restricted see terms below			
☞ Inj 2,000 PFU vial with diluent – 1% DV Jul-14 to 2017	0.00	1	Varilrix
➡Restricted			
Maximum of two doses for any of the following:			
1 For non-immune patients:			
1.1 With chronic liver disease who may in future be candidates for transplantation; or			
1.2 With deteriorating renal function before transplantation; or			
1.3 Prior to solid organ transplant; or			
1.4 Prior to any elective immunosuppression*.			
2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist.			
3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist.			
4 For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist.			
5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella.			
6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.			
7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella			
* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Optional Pharmaceuticals			
NOTE:			
In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a number of additional Optional Pharmaceuticals, including some wound care products and disposable laparoscopic equipment, are listed in an addendum to Part III which is available at www.pharmac.govt.nz . The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.			
BLOOD GLUCOSE DIAGNOSTIC TEST METER			
1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips	20.00	1	Caresens II
			Caresens N
			Caresens N POP
Meter	9.00	1	FreeStyle Lite
			On Call Advanced
	19.00		Accu-Chek Performa
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP			
Blood glucose test strips	10.56	50 test	CareSens
			CareSens N
	21.65		FreeStyle Lite
	28.75		Accu-Chek Performa
			Freestyle Optium
Blood glucose test strips × 50 and lancets × 5	19.10	50 test	On Call Advanced
BLOOD KETONE DIAGNOSTIC TEST METER			
Meter	40.00	1	Freestyle Optium
INSULIN PEN NEEDLES			
29 g × 12.7 mm	10.50	100	B-D Micro-Fine
31 g × 5 mm	11.75	100	B-D Micro-Fine
31 g × 6 mm	10.50	100	ABM
31 g × 8 mm	10.50	100	B-D Micro-Fine
32 g × 4 mm	10.50	100	B-D Micro-Fine
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE			
Syringe 0.3 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
Syringe 0.3 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II
Syringe 0.5 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
Syringe 0.5 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II
Syringe 1 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
Syringe 1 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II
KETONE BLOOD BETA-KETONE ELECTRODES			
Test strips	15.50	10 strip	Freestyle Optium Ketone
MASK FOR SPACER DEVICE			
Size 2	2.99	1	EZ-fit Paediatric Mask
PEAK FLOW METER			
Low Range	11.44	1	Breath-Alert
Normal Range	11.44	1	Breath-Alert

PART III - OPTIONAL PHARMACEUTICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PREGNANCY TEST - HCG URINE			
Cassette – 1% DV Sep-15 to 2017	17.60	40 test	EasyCheck
	22.80		Innovacon hCG One Step Pregnancy Test
<i>(Innovacon hCG One Step Pregnancy Test Cassette to be delisted 1 September 2015)</i>			
SODIUM NITROPRUSSIDE			
Test strip	6.00	50 strip	Accu-Chek Ketur-Test
SPACER DEVICE			
230 ml (single patient)	4.72	1	Space Chamber Plus
800 ml	8.50	1	Volumatic

- Symbols -

8-methoxypsoralen53

- A -

A-Scabies50
Abacavir sulphate83
Abacavir sulphate with
 lamivudine83
Abciximab147
Abilify117
Abiraterone acetate139
ABM Hydroxocobalamin25
Acarbose16
Accarb16
Accu-Chek Ketur-Test216
Accu-Chek Performa215
Accuretic 1037
Accuretic 2037
Acetadote184
Acetazolamide181
Acetic acid
 Extemporaneously
 Compounded
 Preparations192
 Genito-Urinary55
 Acetic acid with hydroxyquinoline,
 glycerol and ricinoleic acid55
 Acetic acid with propylene
 glycol183
Acetylcholine chloride182
Acetylcysteine184
Aciclovir
 Infections88
 Sensory178
Acid Citrate Dextrose A30
Acidex13
Acipimox44
Acitretin53
Aclasta94
Act-HIB210
Actavis119
Actemra166
Actinomycin D128
Adalimumab147
Adapalene50
Adefin XL41
Adefovir dipivoxil85
Adenosine38-39
Adenuric98
Adrenaline45
ADT Booster209
Adult diphtheria and tetanus
 vaccine209

Advantan52
Advate29
Aerlane103
Afinitor170
Agents Affecting the
 Renin-Angiotensin System37
Agents for Parkinsonism and
 Related Disorders102
Agents Used in the Treatment of
 Poisonings184
Air Flow Products111
Ajmaline39
Alanase172
Albendazole79
Alendronate sodium92-93
Alendronate sodium with
 cholecalciferol93
Alfacalcidol25
Alfentanil107
Alinia80
Alitraq201
Allersoothe173
Allopurinol97
Alpha tocopheryl acetate25
Alpha-Adrenoceptor Blockers38
Alprazolam122
Alprostadil hydrochloride46
Alteplase33
Alum192
Aluminium hydroxide13
Aluminium hydroxide with
 magnesium hydroxide and
 simethicone13
Amantadine hydrochloride102
AmBisome76
Ambrisentan47
Amethocaine106, 180
 Nervous106
 Sensory180
Amikacin69
Amiloride hydrochloride43
Amiloride hydrochloride with
 furosemide42
Amiloride hydrochloride with
 hydrochlorothiazide42
Aminophylline176
Amiodarone hydrochloride39
Amisulpride117
Amitriptyline110
Amlodipine41
Amorolfine49
Amoxicillin72
Amoxicillin Actavis72
Amoxicillin with clavulanic
 acid72
Amphotericin B
 Alimentary23
 Infections76
Amsacrine130
Amyl nitrite46
Anabolic Agents59
Anaesthetics103
Anagrelide hydrochloride131
Analgesics106
Anastrozole140
Andriol Testocaps59
Androderm59
Androgen Agonists and
 Antagonists59
Anexate184
Antabuse126
Antacids and Antiflatulents13
Anti-Infective Agents55
Anti-Infective Preparations
 Dermatological49
 Sensory178
Anti-Inflammatory
 Preparations179
Antiacne Preparations50
Antiallergy Preparations172
Antianaemics27
Antiarrhythmics38
Antibacterials69
Anticholinergic Agents173
Anticholinesterases92
Antidepressants110
Antidiarrhoeals and Intestinal
 Anti-Inflammatory Agents13
Antiepilepsy Drugs112
Antifibrinolytics, Haemostatics
 and Local Sclerosants28
Antifungals75
Antihypotensives39
Antimigraine Preparations116
Antimycobacterials78
Antinaus117
Antinausea and Vertigo
 Agents116
Antiparasitics79
Antipruritic Preparations50
Antipsychotic Agents117
Antiretrovirals81
Antirheumatoid Agents92
Antiseptics and

Disinfectants	186	Arginine		Aspirin	
Antispasmodics and Other		Alimentary	20	Blood	32
Agents Altering Gut		Various	189	Nervous	106
Motility	15	Argipressin [Vasopressin]	67	Asthalin	174
Antithrombotics	30	Aripiprazole	117	Atazanavir sulphate	84
Antithymocyte globulin		Aristocort	52	Atenolol	39
(equine)	169	Aromasin	141	Atenolol-AFT	39
Antithymocyte globulin		Arrow - Clopid	32	ATGAM	169
(rabbit)	170	Arrow-Amitriptyline	110	Ativan	122
Antiulcerants	15	Arrow-Bendrofluzide	43	Atomoxetine	123
Antivirals	85	Arrow-Brimonidine	182	Atorvastatin	43
Anxiolytics	122	Arrow-Calcium	21	Atovaquone with proguanil	
Apidra	17	Arrow-Citalopram	111	hydrochloride	79
Apidra Solostar	17	Arrow-Diazepam	122	Atracurium besylate	98
Apo-Allopurinol	97	Arrow-Doxorubicin	128	Atripia	83
Apo-Amiloride	43	Arrow-Etidronate	94	Atropine sulphate	
Apo-Amlodipine	41	Arrow-Fluoxetine	111	Cardiovascular	39
Apo-Amoxi	72	Arrow-Gabapentin	112	Sensory	182
Apo-Azithromycin	71	Arrow-Iloprost	48	Atropt	182
Apo-Ciclopirox	49	Arrow-Lamotrigine	114	Augmentin	72
Apo-Cilazapril/		Arrow-Lisinopril	37	Auranofin	92
Hydrochlorothiazide	37	Arrow-Losartan &		Ava 20 ED	55
Apo-Clarithromycin	71	Hydrochlorothiazide	38	Ava 30 ED	55
Apo-Clomipramine	110	Arrow-Morphine LA	108	Avanza	110
Apo-Diclo	100	Arrow-Norfloxacin	73	Avelox	73
Apo-Diltiazem CD	41	Arrow-Ornidazole	80	Avelox IV 400	73
Apo-Doxazosin	38	Arrow-Quinapril 10	37	Avonex	122
Apo-Folic Acid	28	Arrow-Quinapril 20	37	Avonex Pen	122
Apo-Imiquimod Cream 5%	54	Arrow-Quinapril 5	37	Azacididine	129
Apo-Megestrol	139	Arrow-Roxithromycin	72	Azactam	74
Apo-Moclobemide	110	Arrow-Sertraline	112	Azamun	170
Apo-Nadolol	40	Arrow-Simva	44	Azathioprine	170
Apo-Nicotinic Acid	44	Arrow-Sumatriptan	116	Azithromycin	71
Apo-Oxybutynin	58	Arrow-Timolol	181	Azol	62
Apo-Perindopril	37	Arrow-Tolterodine	58	AZT	83
Apo-Pindolol	40	Arrow-Topiramate	115	Aztreonam	74
Apo-Prazosin	38	Arrow-Tramadol	109		
Apo-Prednisone	60	Arrow-Venlafaxine XR	111	- B -	
Apo-Prednisone S29	60	Arsenic trioxide	131	B-D Micro-Fine	215
Apo-Propranolol	40	Artemether with lumefantrine	79	B-D Ultra Fine	215
Apo-Pyridoxine	25	Artesunate	79	B-D Ultra Fine II	215
Apo-Ropinirole	103	Articaine hydrochloride	104	Bacillus calmette-guerin	
Apo-Zopiclone	123	Articaine hydrochloride with		(BCG)	170
Apomine	102	adrenaline	104	Bacillus calmette-guerin	
Apomorphine hydrochloride	102	Asacol	14	vaccine	210
Apraclonidine	182	Asamax	14	Baclofen	98
Aprepitant	116	Ascorbic acid		Bacterial and Viral Vaccines	209
Apresoline	46	Alimentary	25	Bacterial Vaccines	209
Aprotinin	28	Extemporaneously		Baraclade	85
Aqueous cream	51	Compounded		Barium sulphate	188
Arachis oil [Peanut oil]	192	Preparations	192	Barium sulphate with sodium	
Arava	92	Aspen Adrenaline	45	bicarbonate	188
Aremed	140	Aspen Ciprofloxacin	73	Barrier Creams and	
				Emollients	50

219

Musculoskeletal System	101	Cetomacrogol	51	Ciprofloxacin	
Nervous	106	Cetomacrogol with glycerol	51	Infections	73
Captopril	37	Cetrimide	192	Sensory	178
Carbaccord	133	Champix	127	Ciprofloxacin with	
Carbamazepine	112	Charcoal	185	hydrocortisone	178
Carbasorb-X	185	Chemotherapeutic Agents	128	Ciproxin HC Otic	178
Carbimazole	67	Chicken pox vaccine	214	Cisplatin	133
Carbomer	183	Chlorafast	178	Cisplatin Ebewe	133
Carboplatin	133	Chloral hydrate	123	Citalopram hydrobromide	111
Carboplatin Ebewe	133	Chlorambucil	128	Citanest	106
Carboprost trometamol	56	Chloramphenicol		Citric acid	192
Carboxymethylcellulose		Infections	74	Citric acid with magnesium oxide	
Alimentary	23	Sensory	178	and sodium picosulfate	19
Extemporaneously		Chlorhexidine	186, 190	Citric acid with sodium	
Compounded		Chlorhexidine gluconate		bicarbonate	188
Preparations	192	Alimentary	23	Cladribine	130
Cardinol LA	40	Extemporaneously		Clarithromycin	71
Cardizem CD	41	Compounded		Clexane	31
CareSens	215	Preparations	192	Clindamycin	74
Caresens II	215	Genito-Urinary	55	Clindamycin ABM	74
CareSens N	215	Chlorhexidine with		Clobazam	112
Caresens N	215	cetrimide	186, 190	Clobetasol BNM	52
Caresens N POP	215	Chlorhexidine with ethanol	186	Clobetasol propionate	52, 54
Carmellose sodium	183	Chloroform	192	Clobetasone butyrate	52
Carmustine	128	Chloroquine phosphate	79	Clofazimine	78
Carvedilol	40	Chlorothiazide	43	Clomazol	49, 55
Caspofungin	77	Chlorpheniramine maleate	172	Clomiphene citrate	61
Catapres	42	Chlorpromazine		Clomipramine hydrochloride	110
Catapres-TTS-1	42	hydrochloride	118	Clonazepam	112, 122
Catapres-TTS-2	42	Chlorsig	178	Clonidine	42
Catapres-TTS-3	42	Chlortalidone		Clonidine BNM	42
Ceenu	128	[Chlortalidone]	43	Clonidine hydrochloride	42
Cefaclor	70	Chlortalidone	43	Clopidogrel	32
Cefalexin	70	Choice TT380 Short	55	Clopine	118
Cefalexin Sandoz	70	Choice TT380 Standard	55	Clopixol	120, 121
Cefazolin	70	Cholecalciferol	25	Clostridium botulinum type A	
Cefepime	70	Cholestyramine	44	toxin	99
Cefepime-AFT	70	Choline salicylate with		Clotrimazole	
Cefotaxime	70	cetalkonium chloride	23	Dermatological	49
Cefotaxime Sandoz	70	Cholvastin	43	Genito-Urinary	55
Cefoxitin	70	Choriogonadotropin alfa	63	Clove oil	192
Ceftaroline fosamil	71	Ciclopriox olamine	49	Clozapine	118
Ceftazidime	70	Ciclosporin	141	Clozaril	118
Ceftriaxone	70	Cidofovir	88	Co-trimoxazole	75
Ceftriaxone-AFT	70	Cilazapril	37	Coal tar	192
Cefuroxime	70	Cilazapril with		Coal tar with salicylic acid and	
Celecoxib	99	hydrochlorothiazide	37	sulphur	53
Celiprolol	40	Cilicaine	72	Coal tar with triethanolamine	
CellCept	170	Cilicaine VK	72	lauryl sulphate and	
Celol	40	Cimetidine	15	fluorescein	53
Centrally-Acting Agents	42	Cinchocaine hydrochloride with		Cocaine hydrochloride	105
Cephalexin ABM	70	hydrocortisone	14	Cocaine hydrochloride with	
Cetirizine hydrochloride	172	Cipflox	73	adrenaline	105

Codeine phosphate	hydrochloride	182	DBL Sterile Dopamine	
Extemporaneously	Cyclophosphamide	128	Concentrate	45
Compounded	Cycloserine	78	DBL Tobramycin	69
Preparations	Cyklokapron	29	DDI	83
Nervous	Cymevene	88	De-Nol	16
Cogentin	Cyproheptadine		De-Worm	79
Colaspase [L-asparaginase]	hydrochloride	173	Decongestants	174
Colchicine	Cyproterone acetate	59	Decongestants and	
Colestimethate	Cyproterone acetate with		Antiallergics	179
Colestipol hydrochloride	ethinyloestradiol	55	Decozol	23
Colgout	Cysteamine hydrochloride	192	Deferasirox	185
Colifoam	Cytarabine	130	Deferiprone	185
Colistin sulphomethate			Defibrotide	30
[Colestimethate]	- D -		Definity	189
Colistin-Link	D-Penamine	92	Demeclocycline	
Collodion flexible	Dabigatran	30	hydrochloride	73
Colofac	Dacarbazine	131	Deoxycoformycin	132
Colony-Stimulating Factors	Dactinomycin [Actinomycin		Depo-Medrol	60
Coloxyl	D]	128	Depo-Medrol with Lidocaine	60
Compound electrolytes	Daivobet	53	Depo-Provera	56
Compound electrolytes with	Daivonex	53	Depo-Testosterone	59
glucose	Dalacin C	74	Deprim	75
Compound	Dalteparin	30	Dermol	54
hydroxybenzoate	Danaparoid	30	Desferrioxamine mesilate	185
Compound sodium lactate	Danazol	62	Desflurane	103
[Hartmann's solution]	Dantrium	99	Desmopressin acetate	67
Compound sodium lactate with	Dantrolene	99	Desmopressin-PH&T	67
glucose	Dapa-Tabs	43	Dexamethasone	
Concerta	Dapsone		Hormone Preparations	60
Condyline	Contracted	78	Sensory	179
Contraceptives	Infections	78	Dexamethasone phosphate	60
Contrast Media	Daptomycin	74	Dexamethasone with framycetin	
Cordarone-X	Darunavir	84	and gramicidin	178
Corticosteroids	Dasatinib	134	Dexamethasone with neomycin	
Dermatological	Daunorubicin	128	sulphate and polymyxin B	
Hormone Preparations	DBL Acetylcysteine	184	sulphate	179
Corticotrorelin (ovine)	DBL Amikacin	69	Dexamethasone with	
Cosmegen	DBL Aminophylline	176	tobramycin	179
Cosopt	DBL Bleomycin Sulfate	128	Dexamethasone-hameln	60
Cough Suppressants	DBL Carboplatin	133	Dexametamine sulfate	124
Creon 10000	DBL Cefepime	70	Dexmedetomidine	103
Creon 25000	DBL Cefotaxime	70	Dextrose	16, 34, 192
Crotamiton	DBL Docetaxel	138	Alimentary	16
Crystaderm	DBL Epirubicin		Blood	34
CT Plus+	Hydrochloride	129	Extemporaneously	
Cubicin	DBL Ergometrine	57	Compounded	
Curam Duo	DBL Flucloxacillin	72	Preparations	192
Curosurf	DBL Leucovorin Calcium	138	Dextrose with sodium citrate and	
Cvite	DBL Meropenem	69	citric acid [Acid Citrate	
Cyclizine hydrochloride	DBL Morphine Sulphate	108	Dextrose A]	30
Cyclizine lactate	DBL Pethidine		DHC Continus	107
Cyclogyl	Hydrochloride	109	Diabetes	16
Cyclopentolate	DBL Rocuronium Bromide	99	Diacomit	115

Diagnostic Agents	189	with sodium dihydrogen phosphate	192	EasyCheck	216
Diagnostic and Surgical Preparations	180	Disopyramide phosphate	39	Econazole nitrate	49
Diamide Relief	13	Disulfiram	126	Edrophonium chloride	92
Diamox	181	Dithranol	192	Efavirenz	82
Diatrizoate meglumine with sodium amidotrizoate	187	Diuretics	42	Efavirenz with emtricitabine and tenofovir disoproxil fumarate	83
Diatrizoate sodium	187	Diurin 40	42	Efixor XR	111
Diazepam	112, 122	Dobutamine hydrochloride	45	Effient	32
Diazoxide		Docetaxel	138	Eformoterol fumarate	175
Alimentary	16	Docusate sodium Alimentary	19	Efudix	54
Cardiovascular	46	Sensory	183	Elecare (Unflavoured)	202
Dicarz	40	Docusate sodium with sennosides	19	Elecare (Vanilla)	202
Dichlorobenzyl alcohol with amylmetacresol	23	Domperidone	116	Elecare LCP (Unflavoured)	202
Diclax SR	100	Donepezil hydrochloride	125	Electrolytes	191
Diclofenac sodium Musculoskeletal System	100	Donepezil-Rex	125	Eligard	63
Sensory	179	Dopamine hydrochloride	45	Elocon	52
Dicobalt edetate	185	Dopergin	103	Eltrombopag	28
Didanosine [DDI]	83	Dopress	110	Emend Tri-Pack	116
Diflucan	76	Dornase alfa	176	EMLA	106
Diflucortolone valerate	52	Dorzolamide	181	Emtricitabine	83
Digestives Including Enzymes	18	Dorzolamide with timolol	181	Emtricitabine with tenofovir disoproxil fumarate	83
Digoxin	39	Dostinex	61	Emtriva	83
Digoxin immune Fab	184	Dotarem	188	Emulsifying ointment	51
Dihydrocodeine tartrate	107	Dothiepin hydrochloride	110	Enalapril maleate	37
Dihydroergotamine mesylate	116	Doxapram	177	Enalapril maleate with hydrochlorothiazide	37
Diltiazem hydrochloride	41	Doxazosin	38	Enbrel	141
Dilzem	41	Doxepin hydrochloride	110	Endocrine Therapy	139
Dimercaprol	185	Doxine	74	Endoxan	128
Dimercaptosuccinic acid	186	Doxorubicin hydrochloride	128	Enfuvirtide	81
Dimethicone	50	Doxycycline	74	Enoxaparin	31
Dimethyl sulfoxide	190	DP Fusidic Acid Cream	49	Ensure (Chocolate)	208
Dinoprostone	57	DP Lotn HC	52	Ensure (Vanilla)	208
Diphenamil metilsulfate	54	DP-Anastrozole	140	Ensure Plus (Banana)	208
Diphenoxylate hydrochloride with atropine sulphate	13	Dr Reddy's Omeprazole	15	Ensure Plus (Chocolate)	208
Diphtheria antitoxin	184	Dr Reddy's Ondansetron	117	Ensure Plus (Fruit of the Forest)	208
Diphtheria, tetanus and pertussis vaccine	210	Dr Reddy's Terbinafine	77	Ensure Plus (Vanilla)	208
Diphtheria, tetanus, pertussis and polio vaccine	209	Droperidol	116	Ensure Plus HN	207
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	209	Drugs Affecting Bone Metabolism	92	Ensure Plus HN RTH	207
Diprivan	104	Dulcolax	20	Entacapone	103
Dipyridamole	32	Duolin	173	Entapone	103
Disodium edetate	181	Duovisc	181	Entecavir	85
Disodium hydrogen phosphate		Duride	45	Enzymes	97
		Dynastat	101	Ephedrine	45
		Dysport	99	Epilim IV	114
		- E -		Epirubicin Ebewe	129
		E-Mycin	71	Epirubicin hydrochloride	129
		E-Z-Cat Dry	188	Epoetin alfa [Erythropoietin alfa]	27
		E-Z-Gas II	188	Exprex	27
		E-Z-Paste	188		

Eptacog alfa [Recombinant factor VIIa]	29	agent	29	Fluids and Electrolytes	33
Eptifibatide	32	Febuxostat	98	Flumazenil	184
Ergometrine maleate	57	FEIBA	29	Flumetasone pivalate with	
Ergotamine tartrate with		Felodipine	41	clioquinol	179
caffeine	116	Fenpaed	100	Fluocortolone caproate with	
Erlotinib	134	Fentanyl	107	fluocortolone pivalate and	
Ertapenem	69	Fentanyl Sandoz	107	cinchocaine	14
Erythrocin IV	71	Ferinject	22	Fluorescein sodium	180
Erythromycin (as		Ferodan	22	Fluorescein sodium with	
ethylsuccinate)	71	Ferric carboxymaltose	22	lignocaine hydrochloride	180
Erythromycin (as		Ferric subsulfate	28	Fluorescite	180
lactobionate)	71	Ferriprox	185	Fluorometholone	179
Erythromycin (as stearate)	71	Ferro-F-Tabs	22	Fluorouracil	130
Erythropoietin alfa	27	Ferro-tab	22	Fluorouracil Ebewe	130
Escitalopram	111	Ferrogad	22	Fluorouracil sodium	54
Esmolol hydrochloride	40	Ferrous fumarate	22	Fluoxetine hydrochloride	111
Etanercept	141	Ferrous fumarate with folic		Flupenthixol decanoate	120
Ethambutol hydrochloride	78	acid	22	Fluphenazine decanoate	120
Ethanol	184	Ferrous gluconate with ascorbic		Flutamide	139
Ethanol with glucose	184	acid	22	Flutamin	139
Ethanol, dehydrated	184	Ferrous sulphate	22	Fluticasone	175
Ethics Aspirin EC	32	Ferrous sulphate with ascorbic		Fluticasone propionate	172
Ethics Enalapril	37	acid	22	Fluticasone with salmeterol	176
Ethinylloestradiol	62	Ferrous sulphate with folic		FML	179
Ethinylloestradiol with		acid	22	Foban	49
desogestrel	55	Ferrum H	22	Folic acid	28
Ethinylloestradiol with		Xenofenadine hydrochloride	173	Fondaparinux sodium	31
levonorgestrel	55	Filgrastim	33	Food Modules	195
Ethinylloestradiol with		Finasteride	57	Food/Fluid Thickeners	197
norethisterone	55	Fingolimod	122	Forteo	97
Ethosuximide	112	Finpro	57	Fortisip (Vanilla)	208
Ethyl chloride	105	Flagyl	80	Fortum	70
Etidronate disodium	94	Flagyl-S	80	Fosamax	92
Etomidate	103	Flamazine	49	Fosamax Plus	93
Etopophos	131	Flecainide acetate	39	Foscarnet sodium	88
Etoposide	131	Fleet Phosphate Enema	20	Fosfomycin	74
Etoposide (as phosphate)	131	Flixonase Hayfever &		Fragmin	30
Etoricoxib	100	Allergy	172	Framycetin sulphate	178
Etravirine	82	Flixotide	175	Freeflex	35
Everolimus	170	Flixotide Accuhaler	175	FreeStyle Lite	215
Evista	96	Florinef	60	Freestyle Optium	215
Exelon	125	Fluanxol	120	Freestyle Optium Ketone	215
Exemestane	141	Fluarix	213	Fresofol 1%	104
Exjade	185	Flucloxacillin	72	Frusemide-Clarix	42
Extemporaneously Compounded		Flucloxin	72	Fucidin	74
Preparations	192	Flucon	179	Fucithalmic	178
EZ-fit Paediatric Mask	215	Fluconazole	76	Fungilin	23
Ezemibe	44	Fluconazole-Clarix	76	Furosemide (frusemide)	42
Ezetimibe	44	Flucytosine	77	Fusidic acid	
Ezetimibe with simvastatin	44	Fludara Oral	130	Dermatological	49
		Fludarabine Ebewe	130	Infections	74
		Fludarabine phosphate	130	Sensory	178
		Fludrocortisone acetate	60	Fuzeon	81
Factor eight inhibitors bypassing					

- G -

Gabapentin	112
Gadobenic acid	188
Gadobutrol	188
Gadodiamide	188
Gadoteric acid	188
Gadovist	188
Gadoxetate disodium	189
Gamma benzene hexachloride	49
Ganciclovir	
Infections	88
Sensory	178
Gardasil	212
Gastrografin	187
Gastrosoothe	15
Gefitinib	134
Gelatine, succinylated	36
Gelofusine	36
Gemcitabine	130
Gemcitabine Ebewe	130
Gemfibrozil	43
Genoptic	178
Genox	140
Gentamicin sulphate	
Infections	69
Sensory	178
Gestrinone	62
Gilenya	122
Ginet	55
Glatiramer acetate	122
Glaucoma Preparations	181
Glibenclamide	18
Gliclazide	18
Glipizide	18
Glivec	135
Glizide	18
Glucagen Hypokit	16
Glucagon hydrochloride	16
Glucerna Select (Vanilla)	200
Glucerna Select RTH (Vanilla)	200
Glucobay	16
Glucose [Dextrose]	
Alimentary	16
Blood	34
Extemporaneously Compounded Preparations	193
Glucose with potassium chloride	34
Glucose with potassium chloride and sodium chloride	34

Glucose with sodium chloride	34
Glucose with sucrose and fructose	17
Glycerin with sodium saccharin	193
Glycerin with sucrose	193
Glycerol	
Alimentary	20
Extemporaneously Compounded Preparations	193
Glycerol with paraffin	51
Glyceryl trinitrate	
Alimentary	15
Cardiovascular	45
Glycine	190
Glycopyrronium	173
Glycopyrronium bromide	15
Glypressin	68
Glytrin	45
Gonadorelin	62
Goserelin	62
Granirex	116
Granisetron	116

- H -

Habitrol	126
Habitrol (Classic)	126
Habitrol (Fruit)	126
Habitrol (Mint)	126
Haem arginate	21
Haemophilus influenzae type B vaccine	210
Haldol	120
Haldol Concentrate	120
Haloperidol	118
Haloperidol decanoate	120
Hameln	107
Hartmann's solution	33
Havrix	212
Havrix Junior	212
HBvaxPRO	212
Healon GV	181
healthE Dimethicone 5%	50
healthE Fatty Cream	51
Heparin sodium	31
Heparinised saline	31
Heparon Junior	201
Hepatitis A vaccine	212
Hepatitis B recombinant vaccine	212
Hepsera	85
Herceptin	168

Hexamine hippurate	75
Histaclear	172
Histamine acid phosphate	189
Holoxan	128
Hormone Replacement Therapy	61
HPV	212
Humalog Mix 25	17
Humalog Mix 50	17
Human papillomavirus (6, 11, 16 and 18) vaccine [HPV]	212
Humatin	69
Humira	147
HumiraPen	147
Hyaluronic acid	23, 180, 181, 183
Alimentary	23
Sensory	180, 181, 183
Hyaluronidase	97
Hybloc	40
Hydralazine hydrochloride	46
Hydrea	131
Hydrocortisone	
Dermatological	52
Extemporaneously Compounded Preparations	193
Hormone Preparations	60
Hydrocortisone acetate	
Alimentary	14
Dermatological	52
Hydrocortisone and paraffin liquid and lanolin	52
Hydrocortisone butyrate	52, 54
Hydrocortisone with miconazole	53
Hydrocortisone with natamycin and neomycin	53
Hydrocortisone with paraffin and wool fat	52
Hydrogen peroxide	49
Hydroxocobalamin	
Alimentary	25
Various	184
Hydroxychloroquine	92
Hydroxyethyl starch 130/0.4 with magnesium chloride, potassium chloride, sodium acetate and sodium chloride	36
Hydroxyethyl starch 130/0.4 with sodium chloride	36
Hydroxyurea	131

Hygroton	43
Hylo-Fresh	183
Hyoscine butylbromide	15
Hyoscine hydrobromide	116–117
Hyperuricaemia and Antigout	97
Hypnovel	123
Hypromellose	180, 183
Hypromellose with dextran	183
Hysite	182

- I -

Ibiamox	72
Ibuprofen	100
Idarubicin hydrochloride	129
Ifosfamide	128
Ikorel	46
Iloprost	48
Imatinib mesilate	135
Imatinib-AFT	135
Imiglucerase	21
Imipenem with cilastatin	69
Imipenem+Cilastatin RBX	69
Imipramine hydrochloride	110
Imiquimod	54
Immune Modulators	90
Immunosuppressants	141
Impact Advanced Recovery (Chocolate)	206
Impact Advanced Recovery (Vanilla)	206
Imuran	170
Indacaterol	175
Indapamide	43
Indigo carmine	189
Indinavir	84
Indocyanine green	189
Indomethacin	100
Infanrix IPV	209
Infanrix-hexa	209
Infliximab	154
Influenza vaccine	213
Influvac	213
Inhaled Corticosteroids	174
Innovacon hCG One Step Pregnancy Test	216
Insulin aspart	17
Insulin aspart with insulin aspart protamine	17
Insulin glargine	17
Insulin glulisine	17
Insulin isophane	17
Insulin lispro	17

Insulin lispro with insulin lispro protamine	17
Insulin neutral	17
Insulin neutral with insulin isophane	17
Insulin pen needles	215
Insulin syringes, disposable with attached needle	215
Integrilin	32
Intelligence	82
Interferon alfa-2a	90
Interferon alfa-2b	90
Interferon beta-1-alpha	122
Interferon beta-1-beta	123
Interferon gamma	90
Intra-uterine device	55
Invanz	69
Invega Sustenna	121
Iodine	67
Iodine with ethanol	186
Iodised oil	187
Iodixanol	187
Iohexol	187
Iopidine	182
Ioscan	187
IPOL	214
Ipratropium bromide	172–173
Iressa	134
Irinotecan Actavis 100	131
Irinotecan Actavis 40	131
Irinotecan hydrochloride	131
Iron polymaltose	22
Iron sucrose	22
Irrigation Solutions	190
Isentress	85
Ismo 40 Retard	45
Ismo-20	45
Isoflurane	103
Isoniazid	78
Isoniazid with rifampicin	78
Isoprenaline	46
Isopropyl alcohol	186
Isoptin	42
Isopto Carpine	182
Isosorbide mononitrate	45
Isotretinoin	50
Ispaghula (psyllium) husk	19
Isradipine	41
Itch-Soothe	50
Itraconazole	76
Itrazole	76
Ivermectin	79

- J -

Jadelle	56
Jevity	207
Jevity HiCal RTH	207
Jevity RTH	207

- K -

Kaletra	84
Kenacomb	179
Kenacort-A 10	60
Kenacort-A 40	60
Kenalog in Orabase	23
Ketamine	103
Ketocal 3:1 (Unflavoured)	204
Ketocal 4:1 (Unflavoured)	204
Ketocal 4:1 (Vanilla)	204
Ketoconazole Dermatological	49
Infections	75
Ketone blood beta-ketone electrodes	215
Ketoprofen	100
Ketorolac trometamol	179
Kivexa	83
Klacid	71
Klean Prep	19
Kogenate FS	29
Konakion MM	30
Konsyl-D	19

- L -

L-asparaginase	131
L-ornithine L-aspartate	16
Labetalol	40
Lacosamide	113
Lactose	193
Lactulose	20
Laevolac	20
Lamictal	114
Lamivudine	83, 86
Lamotrigine	114
Lansoprazole	15
Lantus	17
Lantus SoloStar	17
Lapatinib	135
Lariam	80
Latanoprost	182
Lax-Sachets	20
Lax-Tabs	20
Laxatives	19
Laxsol	19
Leflunomide	92
Lenalidomide	132
Letraccord	141

Letrozole	141	Lisinopril	37	glycol	183	
Leukotriene Receptor Antagonists	175	Lissamine green	180	Madopar 125	103	
Leunase	131	Lisuride hydrogen maleate	103	Madopar 250	103	
Leuprorelin acetate	63	Lithicarb FC	119	Madopar 62.5	103	
Leustatin	130	Lithium carbonate	119	Madopar HBS	103	
Levetiracetam	114	LMX4	106	Madopar Rapid	103	
Levetiracetam-Rex	114	Local Preparations for Anal and Rectal Disorders	14	Mafenide acetate	49	
Levobunolol hydrochloride	181	Locoid	52, 54	Magnesium hydroxide Alimentary	22	
Levocabastine	179	Locoid Crelo	52	Extemporaneously Compounded Preparations	193	
Levocarnitine	21	Locoid Lipocream	52	Magnesium oxide	22	
Levodopa with benserazide	103	Lodoxamide	179	Magnesium sulphate	22	
Levodopa with carbidopa	103	Logem	114	Magnevist	189	
Levomepromazine	118	Lomide	179	Malarone	79	
Levonorgestrel	56	Lomustine	128	Malarone Junior	79	
Levosimendan	45	Long-Acting Beta-Adrenoceptor Agonists	175	Malathion [Maldison]	50	
Levothyroxine	67	Loniten	46	Malathion with permethrin and piperonyl butoxide	50	
Lidocaine [lignocaine]	106	Loperamide hydrochloride	13	Maldison	49	
Lidocaine [Lignocaine] hydrochloride	105	Lopinavir with ritonavir	84	Mannitol Cardiovascular	42	
Lidocaine [Lignocaine] hydrochloride with adrenaline	105	Lopresor	40	Various	189	
Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride	105	Lorafix	173	Maprotiline hydrochloride	110	
Lidocaine [Lignocaine] hydrochloride with chlorhexidine	105	LoraPaed	173	Marcain	104	
Lidocaine [Lignocaine] hydrochloride with phenylephrine hydrochloride	105	Loratadine	173	Marcain Heavy	105	
Lidocaine [Lignocaine] with prilocaine	106	Lorazepam	112, 122	Marcain Isobaric	104	
Lidocaine-Claris	105	Lormetazepam	123	Marcain with Adrenaline	104	
Lignocaine	60, 106	Losartan Actavis	38	Marevan	32	
Hormone Preparations	60	Losartan potassium	38	Marine Blue Lotion SPF 50+	54	
Nervous	106	Losartan potassium with hydrochlorothiazide	38	Martindale Acetylcysteine	184	
Lincomycin	75	Lovir	88	Mask for spacer device	215	
Lindane [Gamma benzene hexachloride]	49	Loxamine	111	Mast Cell Stabilisers	176	
Linezolid	75	Lucrin Depot PDS	63	Maxidex	179	
Lioresal Intrathecal	98	Lycinate	45	Maxitrol	179	
Liothyronine sodium	67	Lyderm	50	Measles, mumps and rubella vaccine	213	
Lipazil	43	- M -			Mebendazole	79
Lipid-Modifying Agents	43	m-Amoxiclav	72	Mebeverine hydrochloride	15	
Lipiodol Ultra Fluid	187	m-Eslon	108	Medrol	60	
Liquibar	188	M-M-R-II	213	Medroxyprogesterone	62	
Liquifilm Forte	183	m-Mometasone	52	Medroxyprogesterone acetate Genito-Urinary	56	
Liquifilm Tears	183	Mabthera	160	Hormone Preparations	61	
		Macroglol 3350 with ascorbic acid, potassium chloride and sodium chloride	19	Mefenamic acid	100	
		Macroglol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	20	Mefloquine	80	
		Macroglol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate	19	Megestrol acetate	139	
		Macroglol 400 and propylene		Meglumine gadopentetate	189	
				Meglumine iotroxate	189	
				Melatonin	123	
				Meloxicam	100	
				Melphalan	128	

Menactra	210	[Methylene blue]	189	factor VIII]	29
Meningococcal (A, C, Y and W-135) conjugate vaccine	210	Methylxanthines	176	Morphine hydrochloride	108
Meningococcal C conjugate vaccine	211	Metoclopramide hydrochloride	117	Morphine sulphate	108
Menthol	193	Metoclopramide hydrochloride with paracetamol	116	Morphine tartrate	108
Mepivacaine hydrochloride	106	Metolazone	43	Motetis	102
Mercaptopurine	130	Metoprolol - AFT CR	40	Mouth and Throat	23
Meropenem	69	Metoprolol succinate	40	Moxifloxacin	73
Mesalazine	14	Metoprolol tartrate	40	Mucolytics and Expectorants	176
Mesna	138	Metronidazole	49	Multihance	188
Mestinon	92	Dermatological	49	Multiple Sclerosis Treatments	122
Metabolic Disorder Agents	20	Infections	80	Multivitamin and mineral supplement	23
Metabolic Products	197	Metyrapone	62	Multivitamins	24
Metamide	117	Mexiletine hydrochloride	39	Mupirocin	49
Metaraminol	46	Mexiletine Hydrochloride USP	39	Muscle Relaxants and Related Agents	98
Metformin	18	Miacalcic	59	Myambutol	78
Methacholine chloride	189	Mianserin hydrochloride	110	Mycobutin	78
Methadone hydrochloride Extemporaneously Compounded Preparations	193	Micolette	20	MycoNail	49
Nervous	108	Miconazole	23	Mycophenolate mofetil	170
Methatabs	108	Dermatological	49	Mydriacyl	182
Methohexital sodium	103	Genito-Urinary	55	Mydriatics and Cycloplegics	182
Methopt	183	Micreme	55	Mylan Atenolol	39
Methotrexate	130	Micreme H	53	Mylan-Bosentan	47
Methotrexate Ebewe	130	Microgynon 50 ED	55	Myleran	128
Methotrexate Sandoz	130	Midazolam	123		
Methoxsalen [8-methoxypsoralen]	53	Midodrine	39	- N -	
Methoxyflurane	106	Mifepristone	56	Nadolol	40
Methyl aminolevulinate hydrochloride	54	Milrinone	46	Naloxone hydrochloride	184
Methyl hydroxybenzoate	193	Minerals	21	Naltracord	126
Methylcellulose	193	Minidiab	18	Naltrexone hydrochloride	126
Methylcellulose with glycerin and sodium saccharin	193	Minirin	67	Naphazoline hydrochloride	180
Methylcellulose with glycerin and sucrose	193	Minocycline	74	Naphcon Forte	180
Methyldopa	42	Minoxidil	46	Naprosyn SR 1000	101
Methylene blue	189	Mirtazapine	110	Naprosyn SR 750	101
Methylphenidate hydrochloride	124	Misoprostol	15	Naproxen	101
Methylprednisolone (as sodium succinate)	60	Mitomycin C	129	Naropin	106
Methylprednisolone aceponate	52	Mitozantrone	129	Natalizumab	122
Methylprednisolone acetate	60	Mitozantrone Ebewe	129	Natamycin	178
Methylprednisolone acetate with lidocaine [lignocaine]	60	Mivacron	99	Natalan	132
Methylthioninium chloride		Mivacurium chloride	99	Nausicalm	116
		Moclobemide	110	Navelbine	139
		Modafinil	125	Nedocromil	176
		Modecate	120	Nefopam hydrochloride	107
		Mogine	114	Neisvac-C	211
		Mometasone furoate	52	Neo-B12	25
		Monosodium glutamate with sodium aspartate	191	Neocate Advance (Vanilla)	202
		Monosodium l-aspartate	191	Neocate Gold (Unflavoured)	202
		Montelukast	175	Neoral	141
		Morocetocog alfa [Recombinant		Neostigmine metilsulfate	92

glycopyrronium bromide	92	Nutrini Low Energy Multifibre		Ora-Blend	193
Neosynephrine HCL	46	RTH	205	Ora-Blend SF	193
Nepro HP (Strawberry)	206	Nutrison Concentrated	201	Ora-Plus	193
Nepro HP (Vanilla)	206	Nutrison Energy	207	Ora-Sweet	193
Nepro HP RTH	205	Nyefax Retard	41	Ora-Sweet SF	193
Neulastim	33	Nystatin		Oratane	50
Neupogen	33	Alimentary	23	Ornidazole	80
NeuroTabs	22	Dermatological	49	Orphenadrine citrate	99
Nevirapine	82	Genito-Urinary	55	Orphenadrine hydrochloride	102
Nevirapine Alphapharm	82	Infections	76	Oruvail SR	100
Nicardipine hydrochloride	41	NZ Medical & Scientific	62	Oseltamivir	89
Nicorandil	46			Osmolite	207
Nicotine	126	- O -		Osmolite RTH	207
Nicotinic acid	44	Obstetric Preparations	56	Other Cardiac Agents	45
Nifedipine	41	Octocog alfa [Recombinant factor		Other Endocrine Agents	61
Nilotinib	136	VIII]	29	Other Oestrogen	
Nilstat	23, 76	Octreotide	139	Preparations	62
Nimodipine	41	Ocular Lubricants	183	Other Otological	
Nitazoxanide	80	Oestradiol	61-62	Preparations	183
Nitrados	123	Oestradiol valerate	61	Other Progestogen	
Nitrates	45	Oestradiol with norethisterone		Preparations	62
Nitrazepam	123	acetate	61	Other Skin Preparations	54
Nitroderm TTS 10	45	Oestriol		Ox-Pam	122
Nitroderm TTS 5	45	Genito-Urinary	57	Oxaliplatin	133
Nitrofurantoin	75	Hormone Preparations	62	Oxaliplatin Actavis 100	133
Nitrolingual Pump Spray	45	Oestrogens	57	Oxaliplatin Actavis 50	133
Nitronal	45	Oestrogens (conjugated		Oxandrolone	59
Noflam 250	101	equine)	61	Oxazepam	122
Noflam 500	101	Oestrogens with		Oxpentifylline	46
Non-Steroidal Anti-Inflammatory		medroxyprogesterone		Oxybuprocaine	
Drugs	99	acetate	61	hydrochloride	180
Nonacog alfa [Recombinant		Oil in water emulsion	51	Oxybutynin	58
factor IX]	29	Oily phenol [Phenol oily]	15	Oxycodone Controlled Release	
Noradrenaline	46	Olanzapine	119-120	Tablets (BNM)	109
Norethisterone		Olive oil	193	Oxycodone hydrochloride	109
Genito-Urinary	56	Olopatadine	179	Oxycodone Orion	109
Hormone Preparations	62	Olsalazine	14	OxyContin	109
Norethisterone with		Omalizumab	159	Oxymetazoline	
mestranol	55	Omeprazole	15	hydrochloride	174
Norfloxacin	73	Omezol Relief	15	OxyNorm	109
Noriday 28	56	Omnipaque	187	Oxytocin	57
Normison	123	Omniscan	188	Oxytocin BNM	57
Norpress	110	Omnitrope	63	Oxytocin with ergometrine	
Nortriptyline hydrochloride	110	On Call Advanced	215	maleate	57
Norvir	84	Onbrez Breezhaler	175	Ozole	76
Novasource Renal (Vanilla)	206	Oncaspar	132		
Novatretin	53	OncoTICE	170	- P -	
NovoMix 30 FlexPen	17	Ondanaccord	117	Pacifen	98
NovoRapid FlexPen	17	Ondansetron	117	Pacific Buspiron	122
NovoSeven RT	29	Ondansetron ODT-DRLA	117	Paclitaxel	138
Noxafil	76	One-Alpha	25	Paclitaxel Ebewe	138
Nupentin	112	Onkotrone	129	Paliperidone	121
Nutrini Energy Multi Fibre	205	Onrex	117	Pamidronate disodium	94
		Optional Pharmaceuticals	215	Pamisol	94

Panadol	107	Pentostatin	(Berry)	198
Pancreatic enzyme	18	[Deoxycoformycin]	PKU Anamix Junior LQ	
Pancuronium bromide	99	Pentoxifylline [Oxpentifylline]	(Orange)	198
Pantoprazole	16	Peptamen OS 1.0 (Vanilla)	PKU Anamix Junior LQ	
Pantoprazole Actavis 20	16	Peptisoothe	(Unflavoured)	198
Pantoprazole Actavis 40	16	Perfalgan	Plaquenil	92
Papaverine hydrochloride	46	Perflutren	Plendil ER	41
Paper wasp venom	172	Perhexiline maleate	pms-Bosentan	47
Para-aminosalicylic Acid	78	Pericyazine	Pneumococcal (PCV13)	
Paracare	107	Perindopril	conjugate vaccine	211
Paracare Double Strength	107	Permethrin	Pneumococcal (PPV23)	
Paracetamol	107	Peteha	polysaccharide vaccine	211
Paracetamol + Codeine		Pethidine hydrochloride	Pneumovax 23	211
(Relieve)	109	Pexsig	Podophyllotoxin	54
Paracetamol with codeine	109	Phenelzine sulphate	Polidocanol	28
Paraffin		Phenindione	Poliomyelitis vaccine	214
Alimentary	19	Phenobarbitone	Poloxamer	19
Dermatological	51	Phenobarbitone sodium	Poly Gel	183
Extemporaneously		Phenol	Poly-Tears	183
Compounded		Extemporaneously	Poly-Visc	183
Preparations	193	Compounded	Polyhexamethylene	
Paraffin liquid with soft white		Preparations	biguanide	193
paraffin	183	Various	Polyvinyl alcohol	183
Paraffin liquid with wool fat	183	Phenol oily	Polyvinyl alcohol with	
Paraffin with wool fat	51	Phenol with ioxaglic acid	povidone	183
Paragesic Soluble	107	Phenoxybenzamine	Poractant alfa	177
Paraldehyde	112	hydrochloride	Posaconazole	76
Parecoxib	101	Phenoxyethylpenicillin	Postinor-1	56
Paromomycin	69	[Penicillin V]	Potassium chloride	34, 36
Paroxetine hydrochloride	111	Phentolamine mesylate	Potassium chloride with sodium	
Paser	78	Phenylephrine hydrochloride	chloride	35
Patent blue V	189	Cardiovascular	Potassium citrate	58
Paxam	122	Sensory	Potassium dihydrogen	
Pazopanib	136	Phenytoin	phosphate	35
Peak flow meter	215	Phenytoin sodium	Potassium iodate	
Peanut oil	192	Pholcodine	Alimentary	22
Pediasure (Chocolate)	205	Phosphorus	Hormone Preparations	67
Pediasure (Strawberry)	205	Phytomenadione	Potassium iodate with iodine	22
Pediasure (Vanilla)	205	Picibanil	Potassium perchlorate	67
Pediasure RTH	205	Pilocarpine hydrochloride	Potassium permanganate	53
Pegaspargase	132	Pilocarpine nitrate	Povidone K30	193
Pegasus RBV Combination		Pimafucort	Povidone-iodine	186
Pack	90	Pindolol	Povidone-iodine with	
Pegasys	90	Pinetarsol	ethanol	186
Pegfilgrastim	33	Pioglitazone	Pradaxa	30
Pegylated interferon alfa-2a	90	Piperacillin with tazobactam	Pralidoxime iodide	184
Penicillamine	92	Pipthiazine palmitate	Pramipexole hydrochloride	103
Penicillin G	72	Pituitary and Hypothalamic	Prasugrel	32
Penicillin V	72	Hormones and Analogues	Pravastatin	43
Pentacarinat	80	Pivmecillinam	Praziquantel	79
Pentagastrin	62	Pizaccord	Prazosin	38
Pentamidine isethionate	80	Pizotifen	Precedex	103
Pentasa	14	PKU Anamix Junior LQ	Prednisolone	60

Prednisolone acetate	179	Pulmonary Surfactants	177	Revlimid	132
Prednisolone sodium phosphate	179	Pulmozyme	176	Revolade	28
Prednisone	60	Puri-nethol	130	Reyataz	84
Pregnancy test - hCG urine	216	Pyrazinamide	78	Riboflavin 5-phosphate	181
preOp	206	Pyridostigmine bromide	92	Rifabutin	78
Prevenar 13	211	Pyridoxal-5-phosphate	21	Rifadin	79
Prezista	84	Pyridoxine hydrochloride	25	Rifampicin	79
Prilocaine hydrochloride	106	Pyrimethamine	80	Rifaximin	16
Prilocaine hydrochloride with felypressin	106	Pytazen SR	32	Rifinah	78
Primaquine phosphate	80	- Q -			
Primidone	114	Q 300	80	Rilutek	102
Primolut N	62	Quetapel	119	Riluzole	102
Primovist	189	Quetiapine	119	Ringer's solution	35
Probenecid	98	Quinapril	37	Riodine	186
Procaine penicillin	72	Quinapril with hydrochlorothiazide	37	Risedronate Sandoz	94
Procarbazine hydrochloride	132	Quinine dihydrochloride	80	Risedronate sodium	94
Prochlorperazine	117	Quinine sulphate	80	Risperdal Consta	121
Proctosedyl	14	Qvar	174	Risperdal Quicklet	119
Procur	59	- R -			
Procyclidine hydrochloride	102	RA-Morph	108	Risperdone	119, 121
Procytox	128	Rabies vaccine	214	Risperon	119
Prodopa	42	Raloxifene	96	Ritalin	124
Progesterone	57	Raltegravir potassium	85	Ritalin LA	124
Proglicem	16	Ramipex	103	Ritalin SR	124
Proglycem	16	Ranbaxy-Cefaclor	70	Ritonavir	84
Prodynova	61	Ranibizumab	160	Rituximab	160
Prokinex	116	Ranitidine	15	Rivaroxaban	31
Promethazine hydrochloride	173	Ranitidine Relief	15	Rivastigmine	125
Promethazine theoclate	117	Rapamune	170	Rivotril	112
Propafenone hydrochloride	39	Rasburicase	98	Rizamelt	116
Propamide isethionate	178	Readi-CAT 2	188	Rizatriptan	116
Propofol	104	Reandron 1000	59	Rocuronium bromide	99
Propranolol	40	Recombinant factor IX	29	Ropinirole hydrochloride	103
Propylene glycol	193	Recombinant factor VIIa	29	Ropivacaine hydrochloride	106
Propylthiouracil	67	Recombinant factor VIII	29	Ropivacaine hydrochloride with fentanyl	106
Prostin E2	57	Rectogesic	15	Ropivacaine Kabi	106
Prostin VR	46	Red back spider antivenom	185	Rose bengal sodium	180
Protamine sulphate	31	Redipred	60	RotaTeq	214
Protonamide	78	Relenza Rotadisk	89	Rotavirus live reassortant oral vaccine	214
Protirelin	67	Remicade	154	Roxane	13
Provera	61, 62	Remifentanyl hydrochloride	109	Roxithromycin	72
Provisc	181	ReoPro	147	Rubifen	124
Provie MCT-LCT 1%	104	Resonium A	36	Rubifen SR	124
Proxymetacaine hydrochloride	180	Resource Beneprotein	196	- S -	
Pseudoephedrine hydrochloride	174	Resource Diabetic (Vanilla)	200	S-26 Gold Premgro	204
Psoriasis and Eczema Preparations	53	Respiratory Stimulants	177	S26 LBW Gold RTF	204
PTU	67	Retinol	25	Salamol	174
Pulmocare (Vanilla)	206	Retinol Palmitate	183	Salazopyrin	14
		Retrovir	83	Salazopyrin EN	14
		Retrovir IV	83	Salbutamol	174
		Reutenox	101	Salbutamol with ipratropium bromide	173
				Salicylic acid	194

Salmeterol	175	Sodium bicarbonate	114
Salmonella typhi vaccine	212	Blood	35-36
Sandimmun	141	Extemporaneously	
Sandomigran	116	Compounded	
Sandostatin LAR	139	Preparations	194
Scalp Preparations	53	Sodium calcium edetate	186
Scandonest 3%	106	Sodium carboxymethylcellulose	
Sclerosing Agents	177	with pectin and gelatine	23
Scopoderm TTS	116	Sodium chloride	
Sebizole	49	Blood	35-36
Secretin pentahydrochloride	189	Respiratory	174, 177
Sedatives and Hypnotics	123	Various	190
Seebri Breezhaler	173	Sodium chloride with sodium	
Selegiline hydrochloride	103	bicarbonate	174
Sennosides	20	Sodium citrate	
Serenace	118	Alimentary	13
Seretide	176	Extemporaneously	
Seretide Accuhaler	176	Compounded	
Serevent	175	Preparations	194
Serevent Accuhaler	175	Sodium citrate with sodium	
Serophene	61	chloride and potassium	
Sertraline	112	chloride	31
Sevoflurane	104	Sodium citrate with sodium lauryl	
Sevredol	108	sulphoacetate	20
SII-Onco-BCG	170	Sodium citro-tartrate	58
Silagra	47	Sodium cromoglycate	
Sildenafil	47	Alimentary	14
Silver nitrate		Respiratory	172, 176
Dermatological	54	Sensory	179
Extemporaneously		Sodium dihydrogen phosphate	
Compounded		[Sodium acid phosphate]	35
Preparations	194	Sodium fluoride	21
Simethicone	13	Sodium hyaluronate [Hyaluronic acid]	
Simulect	154	Alimentary	23
Simvastatin	44	Sensory	181, 183
Sincalide	189	Sodium hyaluronate [Hyaluronic	
Sinemet	103	acid] with chondroitin	
Sinemet CR	103	sulphate	181
Singulair	175	Sodium hypochlorite	186
Sirolimus	170	Sodium metabisulfite	194
Siterone	59	Sodium nitrite	184
Slow-Lopresor	40	Sodium nitroprusside	
Snake antivenom	185	Cardiovascular	47
Sodibic	36	Part III - OPTIONAL	
Sodium acetate	35	PHARMACEUTICALS	216
Sodium acid phosphate	35	Sodium phenylbutyrate	21
Sodium alginate with magnesium		Sodium phosphate with	
alginate	13	phosphoric acid	20
Sodium alginate with sodium		Sodium polystyrene	
bicarbonate and calcium		sulphonate	36
carbonate	13	Sodium stibogluconate	80
Sodium aurothiomalate	92	Sodium tetradecyl sulphate	28
Sodium benzoate	21	Sodium thiosulfate	184
		Sodium valproate	114
		Sodium with potassium	191
		Solian	117
		Solifenacin succinate	58
		Solox	15
		Solu-Cortef	60
		Solu-Medrol	60
		Somatropin	63
		Sotacor	40
		Sotalol	40
		Soya oil	184
		Space Chamber Plus	216
		Spacer device	216
		Span-K	36
		Specialised Formulas	199
		Spiractin	43
		Spiramycin	80
		Spiriva	174
		Spironolactone	43
		Sprycel	134
		Standard Feeds	207
		Staphlex	72
		Starch	194
		Stavudine	83
		Sterculia with frangula	19
		Stesolid	112
		Stimulants / ADHD	
		Treatments	123
		Stiripentol	115
		Stocrin	82
		Strattera	123
		Streptomycin sulphate	69
		Stromectol	79
		Suboxone	126
		Sucalfate	16
		Sucrose	107
		Sugammadex	99
		Sulindac	101
		Sulphacetamide sodium	178
		Sulphadiazine	75
		Sulphadiazine silver	49
		Sulphasalazine	14
		Sulphur	194
		Sumatriptan	116
		Sunitinib	137
		Sunscreen, proprietary	54
		Suprane	103
		Surgical Preparations	190
		Survanta	177
		Sustagen Diabetic (Vanilla)	200
		Sustagen Hospital Formula	
		(Chocolate)	208
		Sustagen Hospital Formula	

(Vanilla)	208	Tetracycline	74	Travoprost	182
Sutent	137	Thalidomide	133	Treatments for Dementia	125
Suxamethonium chloride	99	Thalomid	133	Treatments for Substance	
Symmetrel	102	Theobroma oil	194	Dependence	126
Sympathomimetics	45	Theophylline	176	Tretinoin	
Synacthen	62	Thiamine hydrochloride	25	Dermatological	50
Synacthen Depot	62	Thioguanine	130	Oncology	133
Syntometrine	57	Thiopental [Thiopentone]		Trexate	130
Syrup	194	sodium	104	Tri-sodium citrate	194
Systane Unit Dose	183	Thiopentone	104	Triamcinolone acetoneide	
- T -		Thiotepa	128	Alimentary	23
Tacrolimus	141	Thrombin	28	Dermatological	52
Tacrolimus Sandoz	141	Thymol glycerin	23	Hormone Preparations	60
Tagitol V	188	Thyroid and Antithyroid		Triamcinolone acetoneide with	
Talc	177	Preparations	67	gramicidin, neomycin and	
Tambocor	39	Thyrotropin alfa	62	nystatin	179
Tambocor CR	39	Ticagrelor	32	Triamcinolone acetoneide with	
Tamoxifen citrate	140	Ticarcillin with clavulanic acid	72	neomycin sulphate, gramicidin	
Tamsulosin	58	Ticlopidine	32	and nystatin	53
Tamsulosin-Rex	58	Tigecycline	74	Triamcinolone hexacetoneide	60
Tarceva	134	Timolol	181	Triazolam	123
Tasigna	136	Timolol maleate	40	Trichloroacetic acid	194
Tasmar	103	Timoptol XE	181	Trichozole	80
Tazocin EF	72	Tiotropium bromide	174	Trientine dihydrochloride	21
Tegretol	112	TMP	75	Trifluoperazine	
Tegretol CR	112	TOBI	69	hydrochloride	119
Teicoplanin	75	Tobradex	179	Trimeprazine tartrate	173
Temaccord	132	Tobramycin		Trimethoprim	75
Temazepam	123	Infections	69	Trimethoprim with	
Temozolomide	132	Sensory	178	sulphamethoxazole	
Tenecteplase	33	Tobrex	178	[Co-trimoxazole]	75
Tenofovir disoproxil fumarate	87	Tocilizumab	166	Trisodium citrate	31
Tenoxicam	101	Tofranol	110	Trometamol	190
Terazosin	38	Tolcapone	103	Tropicamide	182
Terbinafine	77	Tolterodine tartrate	58	Tropisetron	117
Terbutaline	57	Topamax	115	Tropisetron-AFT	117
Terbutaline sulphate	174	Topicaline	105	Truvada	83
Teriparatide	97	Topical Products for Joint and		Tuberculin, purified protein	
Terlipressin	68	Muscular Pain	101	derivative	189
Testosterone	59	Topiramate	115	Two Cal HN	202
Testosterone cypionate	59	Topiramate Actavis	115	TwoCal HN RTH (Vanilla)	201
Testosterone esters	59	Tracleer	47	Tykerb	135
Testosterone undecanoate	59	Tracrium	98	Tysabri	122
Tetrabenazine	102	Tramadol hydrochloride	109	- U -	
Tetracaine [Amethocaine]		Tramal 100	109	Ultiva	109
hydrochloride		Tramal 50	109	Ultraproct	14
Nervous	106	Tramal SR 100	109	Univent	172, 173
Sensory	180	Tramal SR 150	109	Ural	58
Tetracosactide		Tramal SR 200	109	Urea	
[Tetracosactrin]	62	Trandolapril	37	Dermatological	51
Tetracosactrin	62	Tranexamic acid	29	Extemporaneously	
Tetracyclin Wolff	74	Tranylcypromine sulphate	110	Compounded	
		Trastuzumab	168		

Preparations	194
Urex Forte	42
Urografin	187
Urokinase	33
Urologicals	57
Uromitexan	138
Ursodeoxycholic acid	18
Urososan	18
Utrogestan	57

- V -

Valaciclovir	89
Valcyte	89
Valganciclovir	89
Valtrex	89
Vancomycin	75
Varenicline	127
Varibar - Honey	188
Varibar - Nectar	188
Varibar - Pudding	188
Varibar - Thin Liquid	188
Varicella vaccine [Chicken pox vaccine]	214
Varilrix	214
Vasodilators	46
Vasopressin	67
Vasopressin Agents	67
Vecuronium bromide	99
Vedafil	47
Velcade	131
Venlafaxine	111
Venofer	22
Ventavis	48
Ventolin	174
Vepesid	131
Verapamil hydrochloride	42
Vergo 16	116
Verpamil SR	42
Vesanoid	133
Vesicare	58
Vfend	77
Victrelis	88
Vidaza	129
Vigabatrin	115
Vimpat	113
Vinblastine sulphate	138
Vincristine sulphate	139
Vinorelbine	139
Viral Vaccines	212
Viramune Suspension	82

Viread	87
Visipaque	187
Vistil	183
Vistil Forte	183
VitA-POS	183
Vital HN	201
Vitamin A with vitamins D and C	24
Vitamin B complex	25
Vitamin B6 25	25
Vitamins	23
Vivonex Paediatric	202
Vivonex TEN	200
Volibris	47
Voltaren	100
Voltaren D	100
Voltaren Ophtha	179
Volulyte 6%	36
Volumatic	216
VoLumen	188
Voluven	36
Voriconazole	77
Votrient	136

- W -

Warfarin sodium	32
Wart Preparations	54
Water	
Blood	36
Various	190
Wool fat	
Dermatological	51
Extemporaneously Compounded Preparations	194

- X -

X-Opaque-HD	188
Xanthan	194
Xarelto	31
Xifaxan	16
Xolair	159
Xylocaine	105
Xylocaine Viscous	105
Xylometazoline hydrochloride	174
Xyntha	29

- Y -

Yellow jacket wasp venom	172
--------------------------------	-----

- Z -

Zanamivir	89
Zantac	15
Zapril	37
Zarator	43
Zarzio	33
Zavedos	129
Zeffix	86
Zeldox	120
Zetop	172
Ziagen	83
Zidovudine [AZT]	83
Zidovudine [AZT] with lamivudine	83
Zimybe	44
Zinacef	70
Zinc	
Alimentary	22
Dermatological	50
Zinc and castor oil	50
Zinc chloride	22
Zinc oxide	194
Zinc sulphate	22
Zinc with wool fat	51
Zincaps	22
Zinfozo	71
Zinnat	70
Ziprasidone	120
Zithromax	71
Zoladex	62
Zoledronic acid	
Hormone Preparations	59
Musculoskeletal System	94-96
Zometa	59
Zopiclone	123
Zostrix	101
Zostrix HP	106
Zovirax IV	88
Zuclopenthixol acetate	120
Zuclopenthixol decanoate	121
Zuclopenthixol hydrochloride	120
Zyban	126
Zypine	119
Zypine ODT	119
Zyprexa Relprevv	120
Zytiga	139
Zyvox	75



